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1.1 Introduction
Cellular homeostasis is the condition of the cells to maintain their internal environment for 
optimal functioning. Therefore, the cell carries out many cellular processes and cell-to-cell 
interactions by forming a molecular machinery consisting of interacting proteins.1,2 These 
protein-protein interactions (PPIs) are established by non-covalent binding of two or more 
proteins via the residues residing in these proteins, which is often driven by electrostatic 
forces or hydrophobic associations.3–5 The interacting interface of PPIs can exist between 
identical protein domains (homologous) or between structurally different domains of 
proteins (heterologous).6,7 In addition, PPIs can be transient or more permanent. Transient 
PPIs readily associate and dissociate, which play an important role in complexes involved 
in signaling pathways.8,9 In contrast, more permanent PPIs are strong complexes, such as 
antigen-antibody, enzyme-inhibitor, and large oligomeric enzyme complex structures.10 Since 
the protein complexes formed by PPIs are essential for many cellular processes, information 
about the associating partners within the molecular machinery is essential to understand 
the function of PPIs in the cell. Furthermore, improper PPIs might lead to impaired cell 
functioning and disease.11,12 Therefore, fundamental knowledge about PPIs is helpful to 
understand the mechanisms of biomolecular processes in healthy and diseased cells, and is 
necessary to develop small molecules targeting PPIs with clinical relevance.12–14
Over the years, several techniques have been developed to identify PPIs.15–19 In general, 
proteins in regulatory complexes are identified by mass spectrometry (MS)-based proteomic 
approaches (Figure 1A).20–24 The setup typically starts with the purification of a tagged-
protein and the interacting partners from a biological sample, followed by identification of the 
co-purified proteins by MS/MS (tandem MS). The method to purify a protein of interest (POI) 
and the associating partners determines the quantity and quality of the outcome by MS. In this 
chapter, we will first briefly introduce different approaches to isolate the POI from a biological 
sample, including tandem-affinity purification (TAP), chemical and photo-crosslinking, and 
enzymatic labeling (Figure 1B-E). Then, we will discuss in more detail the types of enzymatic 
labeling strategies and the most recent developments in this field. Finally, we will provide the 
aim and an outline of this thesis that introduces a novel enzymatic labeling strategy.
1.1.1	 Purifying	protein	complexes	by	tandem-affinity	purification
One of the first proteomic approaches to identify PPIs involved TAP, a methodology based on 
two sequential purification steps (Figure 1B).25 In general, a TAP fragment consists of two 
different affinity tags and a cleavage site, which are genetically incorporated in the POI. The 
first step involves the extraction of the POI and the associating partners by affinity purification 
from the biological sample. Next, the bound complexes are recovered via an enzymatic 
cleavage step, releasing the first affinity tag from the protein complex. Aspecific protein 
binders are not cleaved by the enzyme and will therefore not elute from the beads. The eluted 
proteins are further purified using a different second affinity tag. Finally, the isolated proteins 
are analyzed and identified by tandem MS.
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Figure 1 – Schematic representation of MS-based methods for identifying PPIs.
General scheme of the proteomic approach to identify PPIs (A) and overview of methods to purify PPIs, including TAP 
(B), chemical crosslinking (C), photo-crosslinking (D), and proximity-dependent labeling (PDL; E).
The TAP methodology enables purification of a POI and the associating partners and prevents 
contamination of proteins binding non-specifically to the beads used in the first purification 
step.26–28 However, affinity-based approaches from cell lysates may also lead to false positive 
and negative results due to (1) loss of spatial organization, allowing proteins that are not 
associating in living cells to interact, (2) loss of weak interactions during purification, 
and (3) structural alterations in the proteins causing a loss in specific or gain in aspecific 
binding during purification. Therefore, methods to covalently label proteins in their native environment are of great interest to validate suspected protein pairs and to discover novel 
PPIs.
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1.1.2 Stabilization of PPIs by chemical crosslinking 
Chemical crosslinking of biomolecules followed by MS analysis (XL-MS) has become 
increasingly important for identifying PPIs and the localization of their associating interface 
regions in the native environment.29–32 In chemical crosslinking, two functional groups 
within a protein or a protein complex are connected by adding a chemical reagent (Figure 
1C). The chemical reagent, or crosslinker, consists of two reactive moieties separated by a 
defined spacer. The most widely applied crosslinkers are based on N-hydroxysuccinimide 
(NHS) esters, which preferentially react with amine groups of lysine side chains or with the 
N-terminus of proteins.29–32
Protein interaction reporter (PIR) crosslinkers have been developed, which contain an affinity 
handle and an MS-cleavable linker in addition to two amine-reactive NHS esters (Figure 
2A).33–35 Chemically crosslinked proteins using PIR are first enriched by the affinity handle and 
fragmented on the beads by enzyme digestions. Subsequently, the crosslinked peptides are 
eluted from the beads and separated from the spacer arm by low-energy MS collision-induced 
dissociation (CID). Despite the enrichment of crosslinked peptides using the PIR strategy, 
isolated peptides contain also dead-end modified peptides (peptides attached with one-end 
hydrolyzed crosslinker) and intra-peptide crosslinks (amino acids crosslinked within a single 
peptide).36 These so-called dead-end modified peptides and intra-peptide crosslinks increase 
the complexity of the interpretation of the XL-MS data. Although XL-MS studies demonstrate 
the applicability in living systems, examining proteins in the native environment by XL-MS 
remains challenging due to the complexity of the peptide mixture and the difficulties in data 
analysis.37–39 
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Figure 2 – Illustration of the chemical crosslinker PIR and DAU. 
A) Structure of the PIR crosslinker. Biotin in green, the maleimide esters in grey, and the red dashed lines indicate the 
released linker by CID.33 B) Structure of 1,3-diallylurea (DAU) and the thiol-ene click reaction.40 The MS/MS labile region 
is again indicated by the red dashed lines.
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Besides the amine-reactive NHS crosslinkers, Iacobucci and coworkers have recently 
developed a novel photo-chemical CID-cleavable crosslinker, 1,3-diallylurea (DAU), which 
covalently reacts with the sulfhydryl groups of reduced cysteines (Figure 2B).40 The reaction 
of DAU involves the radical-based thiol-ene click reaction, which combines a radical initiator 
with heat or ultraviolet (UV) radiation in order to activate the sulfhydryl group of cysteines. 
The activated cysteine then reacts with alkenes, present in the DAU crosslinker, to form an 
anti-Markovnikov addition product (alkyl sulfide or thioether). The DAU crosslinker is also 
equipped with a spacer containing an ureido group to cleave the crosslinked products upon 
CID. The DAU crosslinker was applied in vitro by optimizing first the crosslinking reaction of 
cysteine residues and a tripeptide containing one cysteine (glutathione).40 In addition, they 
applied the DAU crosslinker by covalently reacting two thiol-containing cytosolic proteins.40 
This newly designed photo-chemical MS-cleavable crosslinker offers a powerful way to 
discover and characterize PPIs, though DAU still needs to be tested in a setting of living cells 
in order to identify PPIs in their native environment.
1.1.3 Stabilization of PPIs by photo-crosslinking
Next to chemical crosslinking, photo-crosslinking can be used to identify PPIs. Photo-
reactive moieties are activated upon UV radiation resulting in covalent linkage to residues 
in neighboring proteins (Figure 1D).41–43 One promising photo-crosslinking application 
employs the incorporation of photo-reactive amino acid analogs in living cells (Figure 3). 
The photo-crosslinker is activated by UV radiation resulting in a highly reactive intermediate 
(half-life of ns-µs), which will react with any nearby molecule.44 The most frequently used 
photo-crosslinkers are diazirines, arylazides, and benzophenones (Bpa), which need to be 
incorporated in the protein in living cells either residue-specifically45 or site-specifically46, as 
explained shortly below.
Protein synthesis in living cells is facilitated in the ribosomes, where the messenger RNA 
(mRNA) is translated to produce the polypeptide (middle route in Figure 3A).47,48 The 
complementary transfer RNA (tRNA) charged with the amino acid binds to the mRNA codon 
for correct peptide elongation. The appropriate amino acid is loaded onto the corresponding 
tRNA by aminoacyl tRNA synthetases (aaRS).
It appears that several unnatural amino acids (uAAs) containing a diazirine photo-crosslinker 
are accepted by naturally occurring aaRS (Figure 3B).45 Culturing cells with medium 
containing uAA while depleting the naturally occurring corresponding amino acid results in 
residue-specific incorporation of the uAA in newly synthesized proteins in the cells (left route 
in Figure 3A).45 In contrast, site-specific incorporation of an uAA requires a unique mRNA 
codon and an orthogonal tRNA/aaRS pair (right route in Figure 3A).46 In this method, cells are 
cultured in medium containing photo-reactive uAAs that are not recognized by the naturally 
occurring aaRS (Figure 3C). The use of an orthogonal aaRS allows the incorporation of such 
unnatural analogs into the accompanied tRNA. As this unique tRNA should not recognize an 
existing codon, a nonsense codon (amber stop codon) is used to incorporate the uAA at a 
specific site of the POI.
1
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1
Figure 3 – Overview of incorporating photo-reactive amino acid analogs in proteins for photo-crosslinking. 
A) Middle route represents incorporation of amino acids in proteins in general. Residue-specific (left route) or site-
specific (right route) incorporation of photo-crosslinking analogs. Structures of amino acid analogs used for residue-
specific (B) and site-specific (C) incorporation.41
Up to this point, several photo-crosslinkers containing a diazirine functionality have been site-
specifically incorporated into a POI, including the DiZHSeC analog (Figure 4A).49 Incorporation 
of the DiZHSeC resulted in covalent linkage of associating proteins upon UV exposure (Figure 
4B).49 This type of photo-crosslinking was applied in living Escherichia coli (E. coli) and 
mammalian cells to identify interacting proteins as well as to profile the interaction sites of 
two associating proteins.50–52 The main limitation of site-specific incorporation of an uAA is 
that genetic incorporation of both the amber stop codon and the orthogonal tRNA/aaRS pair 
is labor intensive.49
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Figure	4	–	General	workflow	of	the	photo-crosslinker.49 
A) Structure of DiZHSeC. B) After the uAA is genetically incorporated into the POI (indicated by green star), photo-
crosslinking is initiated upon UV radiation. The crosslinked complex is purified and proteins are identified by tandem 
MS analysis.
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1.1.4 Enzymatically labeling proteins by proximity-dependent labeling
Besides covalent chemical or photo-crosslinking of nearby proteins, PPIs can be identified by 
proximity-dependent labeling (PDL) techniques. PDL is based on the tagging of proteins in 
close vicinity of an ectopically expressed enzyme (Figure 1E).53–56 The PDL enzyme activates 
a small molecule into a reactive intermediate, which covalently reacts with the enzyme and 
the proximal proteins. Local expression of the enzyme is achieved by a genetic fusion of the 
enzyme to a POI, or a tag encoding a specific cellular region or an organelle. Subsequently, 
proteins labeled by the spatially-restricted enzyme are isolated and identified by MS. Two 
of the most used PDL techniques are based on biotin ligase (BioID) and an engineered 
ascorbate peroxidase (APEX). These systems have provided valuable information on protein 
compositions in living cells. Below, we described the characteristics of BioID and APEX in 
more detail. In addition, we discuss possible improvements and briefly compare both systems 
to other existing PDL methods.
1.2 Protein labeling by biotin ligase
One of the first PDL systems reported is based on biotin ligase derived from E. coli (BirA). This 
enzyme activates a biotin donor substrate, which is subsequently transferred onto a specific 15 
amino acid long acceptor peptide (AP tag; Figure 5A).57,58 The BirA reaction involves two steps 
(Figure 5B): i) the conjugation of biotin and ATP forming an activated 5’-AMP-biotin, which is 
retained in the BirA reactive center; ii) the binding of the AP-tag residing in the target protein 
to the BirA pocket followed by biotinylation of the AP-tag.59 In the second step, the 5’-AMP-
biotin-anhydride attacks the ε-amino group of the lysine residue in the AP-tag generating an 
amide bond between biotin and the target protein.59 Since biotin is covalently linked to the 
proteins by BirA, the biotinylated proteins can be isolated by streptavidin-conjugated resins 
under stringent conditions.
In one of the first applications, the potential interaction between two proteins was detected 
by functionalizing a POI with the BirA enzyme and introducing the AP-tag in the expected 
associating partner of the POI (Figure 5A).60 If the two modified proteins are indeed 
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interacting partners, BirA will biotinylate the AP-tag of the expected PPI upon addition of ATP 
and biotin. The potential of the BirA system was demonstrated using two well-studied protein 
pairs, namely FK506 binding protein and FKBP-rapamycin binding protein, as well as Cdc25C 
phosphatase and the 14-3-3ε phosphoserine/threonine binding protein.60 This method was 
also successfully used to study localization during protein translation by profiling ribosomes 
at the mitochondrial surface and the endoplasmic reticulum.61,62 Because the BirA system 
requires a specific peptide tag introduced in one of the interacting proteins, this method can 
only be used to validate suspected protein pairs rather than discover new PPIs.
Figure 5 – Overview of protein biotinylation by the BirA system. 
A) Schematic representation. B) Reaction mechanism of biotin catalysis by BirA. C) Schematic overview of BirA* 
proximity labeling.
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1.2.1 The development of BioID
In order to avoid site-specific labeling by BirA for identifying novel PPIs, a mutant of the BirA 
enzyme (R118G; also called BirA*) was developed to biotinylate proximal proteins without 
the need for the AP-tag (Figure 5C).63 After formation of 5’-AMP-biotin by the BirA* enzyme, 
the 5’-AMP-biotin was released from the binding pocket and reacted with lysine residues 
of proteins in close proximity of the BirA* enzyme. When the BirA* enzyme was targeted 
to a region of interest, nearby proteins were identified after a labeling period of 24 hours 
in living cells using exogenous biotin. Initially the labeling radius was roughly estimated 
to be 20-30 nm63, and this was later changed into ~ 10 nm by using the known structure 
of the nuclear pore complex (NPC) as a molecular ruler.64 The exact value of the labeling 
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radius likely depends on the protein complex to be studied. This proximity-dependent biotin 
identification (BioID) approach has been used to identify PPIs by fusion of a POI to the BirA* 
enzyme resulting in biotinylation of proteins positioned in close vicinity of the BirA* enzyme. 
Labeling is independent of a direct or indirect interaction between the adjacent proteins and 
the POI-fused BirA* enzyme (extensively reviewed by Varnaitė and MacNeil and by Li and 
coworkers).65,66
The second generation of BioID (BioID2) is based on a smaller biotin ligase derived from 
Aquifex aeolicus (A. aeolicus), lacking the DNA binding domain that is present in BirA* in order 
to minimize the effect of localization and/or function of the enzyme on the fusion POI.67 A. 
aeolicus biotin ligase was mutated at the catalytic site (R40G) to enable proximity-dependent 
biotinylation without the need for the AP-tag.67 The localization of the biotin ligases used for 
BioID and BioID2 was compared by fusing the enzymes to the mammalian protein Sun2, which 
is located at the inner membrane of the nucleus. In both cases, the biotin ligases of BioID 
and BioID2 were predominantly localized at the nuclear envelope, though the BioID2 ligase 
enabled a more appropriate targeting of Sun2 to the nuclear envelope.67 The better targeting 
of the biotin ligase used for the BioID2 system might be related to the smaller enzyme, which 
is likely less disruptive to a fusion protein than using BirA* of the BioID system. Furthermore, 
BioID2 requires tenfold less exogenous biotin than BioID (0.1 µM instead of 1 µM in cell 
culture) and exhibits enhanced biotinylation of proximal proteins.67 
Kim and coworkers introduced a linker existing of 13 GGGGS repeats between the POI and 
the BioID2 ligase, resulting in the biotinylation of proteins with an increased labeling radius.67 
Nucleoporin 43 (Nup43), a protein present in the human NPC (Figure 6A), was fused to BioID2 
with or without the molecular spacer (Figure 6B).67 Human cells stably expressing the Nup43-
BioID2 or the Nup43-linker-BioID2 construct were generated followed by biotinylation 
of proteins in close proximity of the BioID2 ligase.67 After a large-scale BioID2 pull down, 
almost all the proteins of the Nup107-Nup160 complex (human Y complex, member of the 
human NPC) were detected using the Nup43-linker-BioID2.67 In contrast, the BioID2 ligase 
fusion to Nup43 lacking the molecular linker resulted in a more restricted set of biotinylated 
Nups (Nup85, Nup96, and Nup107).67 In this way, the biotin-labeling radius can be tuned for 
specific applications by inserting flexible linkers.67 
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Figure 6 – Overview of the human Y complex and the fusion proteins used to label this complex .67 
A) Schematic representation of the human Y complex. B) The biotin ligase used for BioID2 was fused to Nup43 with or 
without the linker existing of 13 GGGGS repeats.
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A limitation of both BioID approaches is the relatively long time (18-24 hours) required to obtain sufficient quantities of biotinylated material for proteomic analysis. Branon and 
coworkers developed a next-generation BirA* system requiring a much shorter labeling time, 
called TurboID and miniTurboID.68 The two promiscuous BioID variants were engineered by a 
yeast display-based directed evolution followed by fluorescence activated cell sorting (FACS) 
to select for the desired mutants (Figure 7).68 After a library of BirA* mutants was created, 
the enzymes were displayed on the surface of yeast cells. Subsequently, yeast displaying the 
most active mutant BirA* enzymes were selected by their ability to promiscuously biotinylate 
the yeast surface. The intensity of biotinylation signals was increased by performing several 
FACS selection rounds.68 In addition, the labeling time was gradually reduced from 18 hours 
to 1 hour within six rounds.68 The clones derived from this screen were further optimized 
resulting in efficient labeling within 10 minutes. MiniTurboID and TurboID appeared to be 
7- to 26-fold more active than BioID.68 TurboID is the most active and can be used best in 
order to maximize the sensitivity and recovery of the biotinylated proteins.68 In contrast, 
miniTurboID is about 20 % smaller than TurboID (28 kDa versus 35 kDa, respectively) and 
gives less biotinylation background in the absence of exogenous biotin.68
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proximity
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Figure 7 – Generation of TurboID and miniTurboID via yeast display-directed evolution.68 
A mutant library of the biotin ligase was prepared and expressed at the yeast surface. The most intense labeled yeast 
clones expressing the mutant enzyme were selected by FACS.
1.2.2 Future perspectives regarding the BioID system
The BioID tool allows the identification of more than hundreds of interacting proteins for one 
single target.69–72 The majority of the detected interacting candidates are a result of random 
labeling in close proximity of the biotin ligase.66 Proteins that are frequently labeled are 
likely highly abundant in the cell.66 However, proteins that are not labeled frequently may 
still be important for the function of the complex studied.22,66 The frequency of the identified 
associating partners does not relate to their biological relevance, for example low-abundant 
candidates might be more relevant than the more prominent ones.22,66
In order to distinguish between true targets and randomly labeled proteins by BioID, multiple repeats of the experiment using the same fusion protein to the biotin ligase must 
be performed.53,66 Alternatively, the biotin ligase can also be fused to multiple components of 
the target complex, each resulting in a specific interacting map of proteins.66 Using different 
fusions to the enzyme in parallel, the most significant associating partners can be cross-
validated by comparing several interacting profiles from distinct target proteins.66 Notably, 
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associating partners of the ligase itself must be excluded by simply taking along a BioID-only 
control without fusing the enzyme to a POI.73 Although repeatedly identified PPIs by BioID 
might still be derived from associations with the biotin ligase, such proteins more likely represent core interactions that are important for the formation of the complex containing 
the POI.73
Another aspect of BioID to consider before applying this PDL system is the uptake and free 
diffusion of the biotin molecule. Biotin is a water-soluble B vitamin and functions as a cofactor 
for biotin-dependent enzymes (e.g. carboxylases), making biotin essential for many cellular 
processes.74,75 Cells are unable to synthesize biotin de novo and therefore actively transport 
free biotin for cellular uptake or hydrolyze protein-bound biotin into free forms of biotin.76,77 
Although the small molecule is free to diffuse after the import in the cytoplasm, biotin is 
not accessible in the secretory pathway.78 As a result, the labeling efficacy of BioID might be 
reduced in the secretory pathway as well as other subcellular regions where biotin is not 
available for labeling.53,54 Another limitation of local labeling by BioID involves the reactive 
5’-AMP-biotin intermediate, which mainly reacts with lysine residues residing in proximal 
proteins. Proteins having a limited number of lysine residues or lacking accessible amines at 
the surface will be missed using this approach for identifying PPIs.54
Biotin is not toxic for cells, however the longer periods of biotinylation may impact protein 
functions or lead to artificial interactions.53,54 The first wild-type BirA system that only 
labels proteins bearing the AP-tag was applied in vivo by generating transgenic mice.79 The 
essential erythropoietic transcription factor, EKLF, was fused to the AP-tag at the genetic 
level.79 This construct was then micro-injected in mouse oocytes.79 In parallel, transgenic 
mouse lines were established by microinjecting the BirA construct containing the erythroid 
expression cassette.79 Transgenic lines expressing the tagged EKLF and BirA were selected 
and crossbred.79 In vivo biotinylation of the AP-tagged EKLF was assessed in nuclear extracts, 
prepared from the fetal livers of the mice embryos, and the presence of biotinylated EKLF 
having the AP-tag was confirmed.79 However, in this specific experiment the target protein 
in the mice has to be labeled with the AP-tag in advance limiting the use of BirA in vivo. 
Although the existing BioID approaches have not been applied yet in animal models, BioID is 
an attractive approach to identify PPIs in vivo using the non-toxic biotin.
1.3 Peroxidase-based PDL methods
Compared to the BioID systems, peroxidase-based PDL approaches are much faster. 
Peroxidases catalyze the oxidation of a wide range of phenolic substrates, often in the 
presence of hydrogen peroxide, to form highly reactive radicals. The short-lived free radicals 
label electron-rich amino acids in proteins, including tyrosines, tryptophans, cysteines, and 
histidines.80 In this way, the peroxidase enzymes can be used for proximal protein labeling by 
targeting the enzyme towards a specific subcellular location of interest or POI.
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One of the first peroxidases used for protein labeling in cells is horseradish peroxidase  (HRP), 
an enzyme that oxidizes a wide variety of organic and inorganic reagents using hydrogen 
peroxide.81–83 The enzyme contains four disulfide bonds and two Ca2+ ion-binding sites, which 
are required for HRP to be active.84,85 Since these interactions are disrupted under reducing 
conditions and the calcium concentrations are insufficient in cells, HRP is generally inactive 
in intracellular regions limiting the use of the enzyme.84,85 The cell surface and the plasma 
membrane of living cells have been investigated using HRP (Figure 8A). The enzyme is often directed to the cell surface by conjugation to antibodies or genetic fusion to a plasma 
membrane-associated POI (Figure 8B).86 With this strategy, the interactions between the 
glycosylphosphatidylinositol-anchored proteins and the receptor tyrosine kinases in lipid 
rafts have been studied.86 The most frequently used substrates, arylazide or biotin-phenol, 
are activated by the HRP enzyme using hydrogen peroxide and used for the enzyme-mediated 
activation of radical source (EMARS)87–89 or the selective proteomic proximity labeling assay 
using tyramide (SPPLAT)90,91, respectively.
1
A
cell surface
D
phenol,
reactive group
cleavable
disulfide bond
biotin,
affinity handle
+ H2O2
HRP
i iii
N
OH
C
biotin
fluorophore
H2O2
HRP
N3
OH
biotin
fluorophore
proximity
labeling
ii
cell surfacei iii
extracellular
extracellular
B
i i
HRP
cell surface
extracellular
HRP
HRP
HRP
O
S H
NH
H
OHN
N
H
S
S
HN
O
O
O
S H
NH
H
OHN
N
H
S
S
HN
O
OH
ii
Figure 8 – Illustration of protein biotinylation by HRP using arylazides or tyramides. 
A) Schematic overview of protein biotinylation at the plasma membrane. B) HRP is either localized at the cell surface by a 
conjugated antibody (left) or expressed at the cell surface by genetic fusion with a plasma membrane-associating protein 
(right). Activating the arylazides by HRP, which are functionalized with a biotin or fluorophore86 (C) or the cleavable 
biotin-phenol90 (D), into reactive radicals that label residues residing in proteins.
The EMARS method is based on localizing HRP at the plasma membrane of cells facing towards 
the extracellular environment.87–89 At the plasma membrane the enzyme activates arylazide 
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substrates functionalized either with a biotin or a fluorescent molecule, upon addition of 
hydrogen peroxide to generate reactive radical species (Figure 8C). Nearby proteins of the 
HRP enzyme are then labeled by these reactive species within a labeling radius of 200-300 
nm from the enzyme.92 The labeled proteins are directly visualized by fluorescence or by 
streptavidin conjugates or can be purified by immunoaffinity chromatography using anti-
fluorescein antibody- or streptavidin-immobilized resins. 
The SPPLAT labeling method is based on activating biotin-phenol substrates by a membrane-
localized HRP enzyme, resulting in reactive radicals (Figure 8D).90,91 The main difference 
between SPLATT and EMARS is the substrate. The SPLATT substrate is a biotin-phenol 
derivative consisting of a cleavable linker and a spacer containing a disulfide bond, which 
can be cleaved under reducing conditions allowing the recovery of biotinylated proteins 
from immobilized streptavidin. In this method, labeled cells are lysed under harsh conditions 
and the labeled proteins are isolated using avidin-based affinity chromatography. After 
elution under reducing conditions, the isolated proteins are analyzed by tandem MS. To our 
knowledge, SPPLAT has only been applied for a B-lymphoma cell line to detect and identify 
proteins at the plasma membrane.90 The HRP enzyme was directed to the B cell receptor using 
anti-IgM antibodies resulting in identification of six novel PPIs and six known associating 
partners.90
Besides the difference in the substrate used for labeling, there is no clear difference between 
EMARS and SPPLAT. The EMARS approach is nowadays applied to evaluate the organization 
of the plasma membrane by targeting HRP to many different cell surface proteins.92–97 As 
mentioned above, EMARS and SPPLAT are limited to identifying proteins on the cell surface 
due to the limited activity of the HRP inside the cell. Although the membrane permeable 
labeling reagents might lead to false positives, HRP can be used to address questions regarding 
the characterization of receptors and/or ligands at the cell surface.98,99
1.3.1 An engineered ascorbate peroxidase (APEX)
Besides biotin ligase and HRP, another enzyme used for proximity labeling is the engineered 
ascorbate peroxidase (APEX) (Figure 9A). The ascorbate peroxidase enzyme (APX) is 
expressed in the cytosol of plant cells to scavenge radicals from peroxides (e.g. hydrogen 
peroxide) using ascorbate as a substrate.100 In contrast to the HRP enzyme, APX lacks disulfide 
bonds, is not dependent on calcium ions, and is naturally active as a homodimeric enzyme in 
a reducing environment.100 In 2012, Martell and coworkers developed a monomeric variant 
of the APX enzyme (called APEX) to image cellular structures by electron microscopy (EM) 
with nanometer resolution.101 Here, the APEX enzyme was targeted to a subcellular region 
by genetic fusion to a POI.101 Cells were fixed and hydrogen peroxide was added resulting 
in APEX-catalyzed oxidative polymerization of a diaminobenzidine (DAB) substrate (Figure 
9B).101 The resulting locally deposited precipitate was subsequently ‘stained’ with electron-
dense osmium tetroxide to generate EM contrast.101 Hence, the APEX system allows imaging 
of organelles and specific proteins in mammalian cells by EM.
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streptavidin conjugates or can be purified by immunoaffinity chromatography using anti-
fluorescein antibody- or streptavidin-immobilized resins. 
The SPPLAT labeling method is based on activating biotin-phenol substrates by a membrane-
localized HRP enzyme, resulting in reactive radicals (Figure 8D).90,91 The main difference 
between SPLATT and EMARS is the substrate. The SPLATT substrate is a biotin-phenol 
derivative consisting of a cleavable linker and a spacer containing a disulfide bond, which 
can be cleaved under reducing conditions allowing the recovery of biotinylated proteins 
from immobilized streptavidin. In this method, labeled cells are lysed under harsh conditions 
and the labeled proteins are isolated using avidin-based affinity chromatography. After 
elution under reducing conditions, the isolated proteins are analyzed by tandem MS. To our 
knowledge, SPPLAT has only been applied for a B-lymphoma cell line to detect and identify 
proteins at the plasma membrane.90 The HRP enzyme was directed to the B cell receptor using 
anti-IgM antibodies resulting in identification of six novel PPIs and six known associating 
partners.90
Besides the difference in the substrate used for labeling, there is no clear difference between 
EMARS and SPPLAT. The EMARS approach is nowadays applied to evaluate the organization 
of the plasma membrane by targeting HRP to many different cell surface proteins.92–97 As 
mentioned above, EMARS and SPPLAT are limited to identifying proteins on the cell surface 
due to the limited activity of the HRP inside the cell. Although the membrane permeable 
labeling reagents might lead to false positives, HRP can be used to address questions regarding 
the characterization of receptors and/or ligands at the cell surface.98,99
1.3.1 An engineered ascorbate peroxidase (APEX)
Besides biotin ligase and HRP, another enzyme used for proximity labeling is the engineered 
ascorbate peroxidase (APEX) (Figure 9A). The ascorbate peroxidase enzyme (APX) is 
expressed in the cytosol of plant cells to scavenge radicals from peroxides (e.g. hydrogen 
peroxide) using ascorbate as a substrate.100 In contrast to the HRP enzyme, APX lacks disulfide 
bonds, is not dependent on calcium ions, and is naturally active as a homodimeric enzyme in 
a reducing environment.100 In 2012, Martell and coworkers developed a monomeric variant 
of the APX enzyme (called APEX) to image cellular structures by electron microscopy (EM) 
with nanometer resolution.101 Here, the APEX enzyme was targeted to a subcellular region 
by genetic fusion to a POI.101 Cells were fixed and hydrogen peroxide was added resulting 
in APEX-catalyzed oxidative polymerization of a diaminobenzidine (DAB) substrate (Figure 
9B).101 The resulting locally deposited precipitate was subsequently ‘stained’ with electron-
dense osmium tetroxide to generate EM contrast.101 Hence, the APEX system allows imaging 
of organelles and specific proteins in mammalian cells by EM.
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Figure 9 – Subcellular labeling by the ascorbate peroxidase (APEX) using biotin-phenol or DAB. 
A) Schematic overview of protein biotinylation by APEX using biotin-phenol.80 B) Activating DAB by APEX for electron 
microscopy (EM).101 C) Scheme of three-state Stable Isotope Labeling by Amino acids in Cell culture (SILAC).102 Three 
cell cultures express IMS-localized APEX, cytosolic-localized APEX, or are untransfected, and are labeled with heavy, 
medium, or light medium, respectively. The cultures are then treated identically with biotin-phenol and hydrogen 
peroxide and after labeling the lysates are combined and processed together.
In order to identify the proteins labeled by APEX, a biotin-phenol substrate was designed to 
biotinylate proteins in close proximity of the enzyme.80 The APEX generated reactive biotin-
phenoxy radicals by oxidizing biotin-phenol in the presence of 1 mM hydrogen peroxide 
(Figure 9A).80 The short-lived free phenoxy radicals react within less than 1 ms with a labeling 
radius of less than 20 nm with electron-rich amino acids, including tyrosines, tryptophans, 
cysteines, and histidines.80 In first instance, endogenous proteins in the mitochondrial matrix 
were biotinylated by APEX and subsequently identified using the stable isotope labeling by 
amino acids in cell culture (SILAC) approach in order to distinguish between biotinylated 
proteins and non-specific binders.80 After culturing the cells in medium containing heavy or 
light variants of an amino acid, ‘heavy cultures’ expressing APEX localized in the mitochondrial 
matrix were biotinylated using biotin-phenol and hydrogen peroxide, and ‘light cultures’ were 
processed as negative controls (without APEX or biotin-phenol and hydrogen peroxide). After 
lysis of the cells, heavy and light lysates were combined and enriched for biotinylated proteins 
using streptavidin beads. Subsequently, the pool of enriched proteins was analyzed by tandem 
MS and compared with annotated proteins.
About 495 proteins were found in the mitochondrial matrix, and 31 of these were not 
previously reported to be present in this organelle.80 As a result of the membrane impermeable 
radicals, APEX expressed in the mitochondrial matrix resulted in biotinylation of proteins 
residing in the matrix as well as in the inner-membrane facing towards the matrix. Proteins 
residing in the inner-membrane facing towards the inter-membrane space (IMS) were not 
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labeled. Interestingly, a number of proteins previously annotated to reside in the IMS or the 
outer membrane of mitochondria were reassigned to the mitochondrial matrix, which was 
confirmed by EM.
A three-state SILAC experimental setup was developed in order to study the proteome in 
cellular regions that are not fully membrane-enclosed, such as the IMS (Figure 9C).102 Porins 
in the outer-mitochondrial membrane (OMM) allow free exchange of small molecules (< 5 
kDa) between the cytosol and the IMS.102 Labeling by APEX restricted in the IMS results in 
biotinylation of IMS proteins as well as cytosolic proteins residing outside the mitochondria. 
For this SILAC approach, cells were cultured in medium containing heavy, medium, or light 
variants of an amino acid, and incubated with biotin-phenol and hydrogen peroxide. ‘Heavy 
cultures’ expressed IMS-targeted APEX, ‘medium cultures’ expressed APEX in the cytosol, and 
‘light cultures’ were omitted from the enzyme. After labeling and cell lysis, the lysates were 
combined and measured by tandem MS to determine for each protein the different SILAC 
ratios (heavy/light, heavy/medium, and medium/light). For each protein, the different SILAC 
ratios reflect the extent of labeling by each of the cultures. Heavy/light reflects the extent 
of labeling by IMS-targeted APEX, heavy/medium by IMS- versus cytosolic-targeted APEX, 
and medium/light by cytosolic-targeted APEX. Using this approach, biotinylated proteins are 
assigned to originate from the IMS, the cytosol, or from non-specific protein binding. However, 
dual-localized proteins are not detected, because proteins present in both the organelles will 
be filtered out.102 This three-state SILAC approach resulted in identifying 127 proteins within 
the IMS and included 9 novel mitochondrial proteins.102
1.3.2	 APEX2,	an	upgrade	of	the	first	APEX	generation
A major limitation of the APEX system is low sensitivity.80,101,102 Biotinylation of proteins 
becomes undetectable when cells express APEX at low levels, but overexpressing the enzyme 
is often detrimental for the cell as a result of severe organelle aggregation.103 Therefore, 
biotinylation by the APEX system was further optimized to enhance the efficiency by 
employing a yeast display-directed evolution protocol as previously described to optimize 
the labeling time for BioID.103 A mutant enzyme (A134P mutant; called APEX2) with superior 
activity was obtained compared to APEX (about 7 times stronger labeling by APEX2).103 Even 
in cells expressing low levels of APEX2 extensive labeling was observed while no labeling 
was detected in cells expressing low levels of APEX incubated with similar biotin-phenol 
and hydrogen peroxide concentrations.103 In contrast, labeling by APEX was not detected 
in cells expressing this enzyme at low levels.103 Targeting APEX2 to the outer membrane of 
mitochondria or the endoplasmic reticulum membrane resulted in high biotinylation profiles, 
whereas biotinylation by APEX was undetectable under equivalent conditions.103 
Nowadays, the APEX and APEX2 approaches are widely applied to study the proteome of 
subcellular regions in living systems.104–109 In a special application, APEX2 was combined with 
RNA Immunoprecipitation (APEX2-RIP) to isolate RNAs with high specificity and sensitivity.110 
After the expression of APEX2 in a subcellular region of interest, proximity labeling was 
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labeled. Interestingly, a number of proteins previously annotated to reside in the IMS or the 
outer membrane of mitochondria were reassigned to the mitochondrial matrix, which was 
confirmed by EM.
A three-state SILAC experimental setup was developed in order to study the proteome in 
cellular regions that are not fully membrane-enclosed, such as the IMS (Figure 9C).102 Porins 
in the outer-mitochondrial membrane (OMM) allow free exchange of small molecules (< 5 
kDa) between the cytosol and the IMS.102 Labeling by APEX restricted in the IMS results in 
biotinylation of IMS proteins as well as cytosolic proteins residing outside the mitochondria. 
For this SILAC approach, cells were cultured in medium containing heavy, medium, or light 
variants of an amino acid, and incubated with biotin-phenol and hydrogen peroxide. ‘Heavy 
cultures’ expressed IMS-targeted APEX, ‘medium cultures’ expressed APEX in the cytosol, and 
‘light cultures’ were omitted from the enzyme. After labeling and cell lysis, the lysates were 
combined and measured by tandem MS to determine for each protein the different SILAC 
ratios (heavy/light, heavy/medium, and medium/light). For each protein, the different SILAC 
ratios reflect the extent of labeling by each of the cultures. Heavy/light reflects the extent 
of labeling by IMS-targeted APEX, heavy/medium by IMS- versus cytosolic-targeted APEX, 
and medium/light by cytosolic-targeted APEX. Using this approach, biotinylated proteins are 
assigned to originate from the IMS, the cytosol, or from non-specific protein binding. However, 
dual-localized proteins are not detected, because proteins present in both the organelles will 
be filtered out.102 This three-state SILAC approach resulted in identifying 127 proteins within 
the IMS and included 9 novel mitochondrial proteins.102
1.3.2	 APEX2,	an	upgrade	of	the	first	APEX	generation
A major limitation of the APEX system is low sensitivity.80,101,102 Biotinylation of proteins 
becomes undetectable when cells express APEX at low levels, but overexpressing the enzyme 
is often detrimental for the cell as a result of severe organelle aggregation.103 Therefore, 
biotinylation by the APEX system was further optimized to enhance the efficiency by 
employing a yeast display-directed evolution protocol as previously described to optimize 
the labeling time for BioID.103 A mutant enzyme (A134P mutant; called APEX2) with superior 
activity was obtained compared to APEX (about 7 times stronger labeling by APEX2).103 Even 
in cells expressing low levels of APEX2 extensive labeling was observed while no labeling 
was detected in cells expressing low levels of APEX incubated with similar biotin-phenol 
and hydrogen peroxide concentrations.103 In contrast, labeling by APEX was not detected 
in cells expressing this enzyme at low levels.103 Targeting APEX2 to the outer membrane of 
mitochondria or the endoplasmic reticulum membrane resulted in high biotinylation profiles, 
whereas biotinylation by APEX was undetectable under equivalent conditions.103 
Nowadays, the APEX and APEX2 approaches are widely applied to study the proteome of 
subcellular regions in living systems.104–109 In a special application, APEX2 was combined with 
RNA Immunoprecipitation (APEX2-RIP) to isolate RNAs with high specificity and sensitivity.110 
After the expression of APEX2 in a subcellular region of interest, proximity labeling was 
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initiated and followed by crosslinking of the RNAs to nearby proteins using formaldehyde 
before cell lysis. Lysates were then enriched for biotinylated proteins, and the co-eluting 
RNAs were identified by regular sequencing techniques. The APEX2-RIP technology was 
used to isolate and identify RNAs from a variety of subcellular compartments, including the 
mitochondrial matrix, the nucleus, the cytosol, and the ER.110
The first generation of APEX was also applied in vivo in the Drosophila melanogaster using 
isobaric tagging for relative and absolute quantification (iTRAQ).111 The enzyme was targeted to the mitochondrial matrix of Drosophila muscle cells and compared to endogenously 
biotinylated proteins in order to distinguish between APEX and endogenous biotinylation. 
After APEX labeling in the fly, the biotinylated proteins were isolated followed by chemically 
labeling of the proteins with ion reporters resulting in distinct protein masses for each of 
the sample sets. (Non)-labeled samples were then mixed and analyzed by MS resulting in 
a selection of 389 genes as final dataset for the mitochondrial matrix proteome. Chen and 
coworkers demonstrated that biotinylation in the Drosophila fly by APEX combined with 
iTRAQ is a successful tool to generate a proteomic profile of the mitochondrial proteins in 
vivo.111
Recently, the APEX-based PDL method was combined with protein fragment complementation 
(PFC) to detect PPIs as well as the interaction site of the associating partners (Figure 
10).112 The APEX2 enzyme was split in an N-terminal and C-terminal region, which do 
not spontaneously reassemble and are not able to activate biotin-phenol. Each of the two 
APEX2 regions was then fused to the homodimer STIM1 protein. Upon dimerization of the 
STIM1 proteins, the N- and C-terminal APEX2 fragments are reconstituted leading to a fully 
active enzyme. Biotinylation after the assembly of the two halves of APEX2 resulted in the 
identification of five different biotinylation sites within the interaction region of STIM1.112 
The PFC pair of APEX2 provides another potential method for detecting PPIs (like protein 
dimerization-dependent interactions) and is a promising approach to identify the binding 
regions of associating partners with high specificity in living cells.
STIM1 STIM1 STIM1 STIM1 STIM1 STIM1
dimerization,
active enzyme
enzymatic
probe activationAPEX2AP EX2 APEX2
Figure 10 – Principle of labeling by the split APEX upon dimerization of the STIM1 protein.112 
The N- and C-terminal fragment of APEX are genetically fused to the homodimer STIM1. The dimer STIM1 will 
reconstitute the APEX2 enzyme leading to an active enzyme that biotinylates mainly the STIM1 homodimer as well as 
other proximal proteins.
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1.4 Pros and cons of the PDL systems
Identifying PPIs with spatial and temporal control contributes to knowledge about the 
function of associating proteins as well as their localization in time. Versatile in vitro and in 
vivo techniques have been developed and used to identify possible PPIs, including affinity 
chromatography, chemical crosslinking, photo-crosslinking, and enzymatic tagging. The latter approach enables rapid visualizing proteins in their native environment by enzymatically 
tagging potentially interacting partners in close vicinity of the enzyme.
The biotin ligase and peroxidase-based PDL methods have been extensively discussed in this 
chapter including their advantages and limitations. Briefly, biotin ligases activate biotin and 
ATP in the reactive 5’-AMP-biotin intermediate, whereas HRP and APEX oxidize biotin-phenol 
derivatives into reactive radicals upon the addition of hydrogen peroxide. In both enzymatic 
strategies, the reactive intermediates (5’-AMP-Biotin or the biotin-phenoxy radicals) will 
label proteins positioned in close proximity to the enzyme. The enzymatic PDL strategies are 
summarized in Table 1.
The more sensitive BioID systems (BioID and BioID2) require at least one day labeling, 
whereas the much faster TurboID and miniTurboID approaches (10 minutes) result in higher 
background biotinylation due to endogenous biotin levels. Similar to the faster BioID systems, 
the labeling time of the peroxidase-based systems is also within minutes (1-10 minutes). 
In addition, the high temporal resolution by APEX enables detection of a specific event for 
comparative experiments. For example, proximity labeling by APEX in cells just before and after a drug treatment may be used to determine the effect of the treatment on the proteome 
of cells. Studies focusing on transient protein associations during various stages of the cell 
cycle will probably prefer proximity labeling by the BioID approach, because this method will 
provide a history of protein associations over time.
Between the PDL systems, the nature of the proteins that are labeled vary. In BioID, the 5’-AMP-
biotin intermediate mostly reacts with lysine, whereas the less abundant tyrosine residues 
are mostly labeled by the phenoxy radicals generated by APEX.113,114 Labeling depends on the 
accessibility of these residues at the surface of the protein complexes for both systems. In case 
of the APEX system, the abundance of tyrosines in proteins is often limited in mammalian 
cells and proteins lacking surface-exposed tyrosine will likely not be labeled.53,54 Associating 
partners lacking available residues required for protein labeling will be missed during the 
analysis, resulting in low coverage of the region of interest. In addition, Hung and coworkers 
detected heterogenous adducts after tandem MS analysis of the APEX biotinylated protein 
samples.102 These adducts could not be linked to biotinylation of tyrosines residing in proteins 
or other labeled residues in proteins.102 Determining the exact adducts that are formed during 
labeling via the reactive radicals will be of great value for analyzing the biotinylated protein 
samples using the APEX approach.
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Table 1 – Overview of the different PDL strategies.
enzyme
size (kDa)
variants
labeling substrates
half-life of generated
reactive species
labeling time
labeling radius
labeling region
organisms used
main advantage
major challenge
biotin ligase
(BirA)
27-35
BioID63, BioID267,
TurboID68, miniTurbo68
biotin,
endogenous ATP
biotin-AMP, minutes
10 minutes - 24 hours
10-30 nm
intracellular
mammalian cells,
xenograft tumors in
mice, Trypanasoma
brucei, Toxoplasma
gondii, Dictyostelium
discoideum, 
Plesmodium berghei
can be applied in vivo
long labeling times 
and/or endogenous
biotinylation
horseradish peroxidase
(HRP)
44
HRP86,91,93, split HRP99
biotin-phenol, 
biotin-arylazide, 
fluorescent-arylazide,
hydrogen peroxide
radicals < 1 milliseconds
5-10 minutes
200-300 nm
extracellular
mammalian cells,
lipid rafts
high temporal resolution
inactive in reducing
environments
ascorbate peroxidase
(APEX)
27
APEX80,101, APEX2103,
split APEX2112
biotin-phenol,
hydrogen peroxide
radicals < 1 milliseconds
1 minute
biotin-phenol is incubated
30-60 minutes in advance
20 nm
intracellular
mammalian cells,
Schizosaccharomyces
pombe, Saccharomyces
cerevisiae, Drosophila
melanogaster
high temporal and 
spatial resolution
cellular toxicity due 
to high levels of
hydrogen peroxide
The biotin ligase as well as the peroxidase system might induce cellular toxicity. Although the 
additional biotin used for BioID is not toxic, the longer incubation time required for BioID 
might impact protein functions or lead to artificial interactions disturbing the native cellular 
environment. Proximity labeling by HRP and APEX is fast, but the use of high concentrations 
of biotin-phenol and hydrogen peroxide might affect signal transduction pathways.115–117 The 
APEX system was applied to Drosophila demonstrating the use in vivo, though they did not 
examine any possible toxic effects of the labeling system on the fly.111 APEX or APEX2 have not 
been applied yet in other animal models. It is possible that the impact of high biotin-phenol 
levels and oxidative damage caused by hydrogen peroxide will prevent the further use of the 
APEX system in vivo.
Each PDL system is based on the local expression of the enzyme in the cell, which can be 
achieved by a genetic fusion to a protein of interest or a targeting motif. Transfecting cells with 
1
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enzyme-fusions is straightforward, although some subcellular regions cannot be targeted 
with high specificity, for example fusing the enzyme with a protein that shuttles between 
two subcellular regions will complicate the analysis. Furthermore, using the PDL systems by 
genetically fusing the enzymes to a specific protein might also interfere with the localization 
or function of the POI.67,103
In general, enzymatic proximity labeling is a sensitive method to study weak PPIs in living 
cells that cannot be detected using affinity purification, for example. It is difficult to assign 
one PDL technique as superior to another and the optimal choice may depend on the 
biological question. For example, the BioID approach will result in low cellular toxicity and 
might be preferred for studying PPIs in vivo, whereas the APEX systems are more suitable for 
snapshots of a certain proteome in living cells due to the short labeling times. Combining the 
two enzymatic strategies in parallel will improve the outcome even further, because the most 
significant associating partners can be cross-validated by comparing the interacting profiles 
derived from BioID and APEX.
1.5 Concluding remarks
In this introductory chapter, we discussed a wide variety of methods to visualize and identify 
proteins involved in different assemblies. The promising enzymatic labeling approaches allow 
identifying PPIs with high temporal and spatial control, though each PDL system has its own 
limitations. The BioID system generally requires one day labeling before biotinylated proteins 
can be identified67,118, whereas the faster TurboID systems (10 minutes labeling) result in 
higher background labeling.68 Furthermore, the peroxidase-based techniques require the 
presence of high biotin-phenol and hydrogen peroxide levels80,103, which might interfere with 
the native environment of the cell and result in a cellular stress response.115–117
In order to identify proteins without disturbing the native cell conditions, the (enzymatic) 
labeling method should (1) label proteins at a subcellular level with a small labeling radius 
(2) display fast labeling to allow visualization of dynamic protein changes in time, and (3) tag 
living cells under physiological conditions without perturbing cellular processes. Since the 
existing enzymatic approaches (e.g. BioID, HRP, and APEX) do not fulfill all these requirements 
simultaneously, the overall aim of the research described in this thesis was to develop a 
novel PDL system that is fast and independent of the use of potentially harmful factors (e.g. 
hydrogen peroxide). To achieve this goal, we selected and evaluated the use of the arylamine 
N-acetyltransferase (NAT) enzyme. In Chapter 2, we will first introduce the NAT enzymes by 
a short literature survey. The reactions performed by this enzyme are highlighted, including the N,O-acetyl transfer reaction required for proximity labeling by NAT using hydroxamic 
acids. Different homologs of NAT enzymes are discussed along with important structural 
characteristics of this enzyme for substrate recognition.
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enzyme-fusions is straightforward, although some subcellular regions cannot be targeted 
with high specificity, for example fusing the enzyme with a protein that shuttles between 
two subcellular regions will complicate the analysis. Furthermore, using the PDL systems by 
genetically fusing the enzymes to a specific protein might also interfere with the localization 
or function of the POI.67,103
In general, enzymatic proximity labeling is a sensitive method to study weak PPIs in living 
cells that cannot be detected using affinity purification, for example. It is difficult to assign 
one PDL technique as superior to another and the optimal choice may depend on the 
biological question. For example, the BioID approach will result in low cellular toxicity and 
might be preferred for studying PPIs in vivo, whereas the APEX systems are more suitable for 
snapshots of a certain proteome in living cells due to the short labeling times. Combining the 
two enzymatic strategies in parallel will improve the outcome even further, because the most 
significant associating partners can be cross-validated by comparing the interacting profiles 
derived from BioID and APEX.
1.5 Concluding remarks
In this introductory chapter, we discussed a wide variety of methods to visualize and identify 
proteins involved in different assemblies. The promising enzymatic labeling approaches allow 
identifying PPIs with high temporal and spatial control, though each PDL system has its own 
limitations. The BioID system generally requires one day labeling before biotinylated proteins 
can be identified67,118, whereas the faster TurboID systems (10 minutes labeling) result in 
higher background labeling.68 Furthermore, the peroxidase-based techniques require the 
presence of high biotin-phenol and hydrogen peroxide levels80,103, which might interfere with 
the native environment of the cell and result in a cellular stress response.115–117
In order to identify proteins without disturbing the native cell conditions, the (enzymatic) 
labeling method should (1) label proteins at a subcellular level with a small labeling radius 
(2) display fast labeling to allow visualization of dynamic protein changes in time, and (3) tag 
living cells under physiological conditions without perturbing cellular processes. Since the 
existing enzymatic approaches (e.g. BioID, HRP, and APEX) do not fulfill all these requirements 
simultaneously, the overall aim of the research described in this thesis was to develop a 
novel PDL system that is fast and independent of the use of potentially harmful factors (e.g. 
hydrogen peroxide). To achieve this goal, we selected and evaluated the use of the arylamine 
N-acetyltransferase (NAT) enzyme. In Chapter 2, we will first introduce the NAT enzymes by 
a short literature survey. The reactions performed by this enzyme are highlighted, including the N,O-acetyl transfer reaction required for proximity labeling by NAT using hydroxamic 
acids. Different homologs of NAT enzymes are discussed along with important structural 
characteristics of this enzyme for substrate recognition.
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2.1 Introduction
Every day, we are exposed to harmful environmental factors such as drugs, chemicals, 
cigarette smoke, car exhaust fumes or unsafe food ingredients. These possible hazardous compounds are either directly eliminated from our bodies or processed by xenobiotic 
metabolizing enzymes before secretion. Arylamine N-acetyltransferase (NAT) is one of the human metabolizing enzymes and is involved in detoxifying a variety of arylamines 
and several non-aromatic amines, widely present in many products.119–123 Already in 1946, 
Lipmann and Kaplan reported the first role of the human NAT enzyme (hNAT) as a heat-
stable coenzyme acetylating aromatic amines in the liver and the brain.124 During the 1960s, it became clear that the NAT enzyme catalyzes the transfer of an acetyl group from the thiol 
ester of acetyl coenzyme A (acetyl-CoA) to a variety of substituted anilines and to several non-
aromatic amines.125–128 Until today the exact biological role of the NAT enzyme is still unclear, though NAT enzymes are extensively studied for their potential role in drug metabolism and 
bioactivation of various carcinogens.NAT enzymes are expressed in many prokaryotes and eukaryotes129,130. Humans express two 
NAT enzymes, human NAT1 (hNAT1) and human NAT2 (hNAT2), which are 81 % identical in 
amino acid sequence. Several allelic variants of the NAT enzymes exist resulting in phenotypic differences131,132, which are categorized in two classes: mutations causing an unstable protein 
and mutations that affect the activity of the folded protein.133–136 The slow acetylating phenotype is caused by reduced enzymatic activity resulting in a decreased rate of acetylation 
by the allelic hNAT variants.133–136 In contrast, the phenotype expressing wild type NAT is 
considered a rapid acetylator.133–136 Mammalian species, including rabbits, mice, rats, and 
hamsters, express as well two NAT isoenzymes with similar expression and substrate profiles 
as the human NAT enzymes.129,130 The similar nomenclature of the human NAT enzymes 
is used for rabbit NAT enzymes, rabbit NAT1 and rabbit NAT2. In contrast, the equivalent 
of hNAT1 in mice is called mouse NAT2 and mouse NAT1 is homologues to hNAT2.137,138 In 
addition, the eukaryotic NAT1 and NAT2 enzymes expressed by rat134,139 and hamster140,141 are 
as well the equivalents of hNAT2 and hNAT1, respectively. These animal NAT isoenzymes are 
extensively studied and information on their activity was important to examine the functional 
role and the different polymorphisms of the NAT enzymes.142–144
In this chapter, we discuss the enzymatic reactions catalyzed by the hNAT enzymes in more 
detail. hNAT1 and hNAT2 have distinct expression and substrate profiles.145–149 hNAT1 is 
widely expressed in endocrine tissues, blood cells, neural tissues, as well as the gut and 
liver.145–149 The expression of hNAT2 is mainly restricted to the kidney, gut, and liver.145–147 
In general, the substrate binding pocket of hNAT2 is larger than that of hNAT1 resulting in 
the recognition of bulkier substrates by hNAT2.150 The substrate preferences of both hNAT enzymes are explained in this chapter in more detail by comparing structural dissimilarities 
between hNAT1 and hNAT2.
2
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2.2 Acetylation mechanism by the catalytic triad of NAT
The hNAT enzymes are involved in the catalysis of acetyl-CoA-dependent O- and N-acetylation 
of arylamine- and hydrazine-containing xenobiotics (Figure 1).128,151 The first identified 
substrates that are acetylated by hNAT were the anti-tubercular drug isoniazid125,152 and 
the anti-hypertensive hydralazine152–154 (structures are shown in Figure 1). It appeared that 
these two hydrazine-containing drugs have adverse effects resulting in an increased risk 
of the autoimmune disease systemic lupus erythematosus (SLE).125,152 Both drugs bind and 
inactivate complement component C4 of the immune system and thereby prevent a proper 
immune response.125,152,155 Studies showed that there was polymorphism in the inactivation 
of these drugs leading to the increased risk for SLE.125,156 These polymorphisms were related 
to the slow and fast acetylation phenotype of the hNAT enzymes.157,158 The slow acetylation 
phenotype was associated with isoniazid-induced toxicity as well as hydralazine-induced 
SLE.159,160 The reduced risk for SLE in patients expressing the fast acetylation phenotype 
was explained by the N-acetylation of isoniazid and hydralazine by NAT, which prevents the 
binding of these drugs to C4.152–154
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Figure 1 – Acetyl-CoA dependent N- and O-acetylation reactions by the NAT enzyme. The NAT enzymes are able to N-, and O-acetylate various arylamines and hydrazine xenobiotics using acetyl-CoA as 
acetyl source.
The acetylation reactions by the NAT enzymes occur in two sequential steps following a ping-
pong bi-bi mechanism (Figure 2A).140,141,161 First, the acetyl from the cofactor acetyl-CoA is 
transferred onto a cysteine present in the enzymatic active site. Subsequently, the acetyl is transferred onto a nucleophilic moiety on the substrate resulting in an acetylated product 
and regeneration of the enzyme. The NAT-mediated acetylation reactions are dependent 
on a catalytic triad (Cys68-His107-Asp122), which is highly conserved in all known functional NAT enzymes162–164 and is structurally similar to that of cysteine proteases165 and transglutaminases166. The arrangement of the catalytic pocket is maintained by highly 
conserved residues forming a complex network of non-covalent interactions, including 
hydrogen bonds and hydrophobic van der Waals interactions.32 Chapter 2
Figure 2 – Overview of the mechanism of acetylation at the active site of NAT. 
A) Schematic representation of the acetylation mechanism by the NAT enzyme. B) Close up of the catalytic triad in the 
binding cleft of the NAT enzyme and acetylation of Cys68 followed by acetylating strong nucleophilic arylamine (ANS; 
upper route) or a weak nucleophilic arylamine (PABA; lower route).
In general, the overall structure of the NAT enzymes consists of three domains: (i) N-terminal 
domain, consisting of five α-helices and one short β-strand, (ii) a middle domain, consisting of nine β-strands with two short α-helices, (iii) C-terminal domain having four anti-parallel 
β-strands and an α-helix leading to a buried C-terminus, which contributes to the stability of 
the enzyme (see Figure 5A for the structure of hNAT1).150,162 The catalytic triad is positioned in 
a deep cleft between an interdomain region connecting the middle and C-terminal domain.150 
In the absence of acetyl-CoA or the arylamine substrates, a thiolate-imidazolium ion pair is 
formed between the reduced Cys68 and His107 (Figure 2B).150 The structural stability and 
catalytic activity of the NAT enzyme is preserved by the Asp122 residue (Figure 2B).150 The 
enzyme is acetylated by acetyl-CoA by transferring the acetyl from acetyl-CoA to the sulfhydryl 
group of Cys68, thereby disrupting the thiolate-imidazolium ion pair.
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The mechanism of acetyl transfer from the NAT enzyme to the arylamine depends on the 
nucleophilic strength of the substrates (Figure 2B).140,141,167 Weak nucleophiles (pKa < 5.5) such as p-aminobenzoic acid (PABA) are acetylated via a nucleophilic attack on the thiol ester 
intermediate (lower route Figure 2B).140,141 In contrast, strong nucleophiles (pKa ≥ 5.5) like 
anisidine (ANS) will deprotonate the tetrahedral intermediate leading to the acetylation of 
the substrate (upper route Figure 2B).140,141
Besides acetylation of arylamines, it was noted that NAT enzymes are also involved in 
O-acetylation of arylhydroxylamines, generating N-acetoxy arylamines (Figure 1).168,169 
In addition, the NAT enzyme catalyzes the acetyl-CoA-independent N,O-acetyl transfer of N-acetyl-N-hydroxy arylamines (arylhydroxamic acids; AHA) resulting as well in the formation of N-acetoxy-arylamines (Figure 3).169–171 These N-acetoxy arylamines are unstable 
species resulting in the generation of reactive nitrenium ions, which we will discuss in more 
detail below.
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Figure 3 – Overview of the nitrenium ion formation followed by nucleophilic reactions and the irreversible 
inactivation	of	NAT	via	the	sulfinamide.172,173 The NAT enzyme catalyzes the N,O-acetyl transfer reaction in two steps, (i) acetyl is transferred to the enzyme and (ii) 
the acetyl group is then transferred to the hydroxy group of the hydroxylamine. The intermediate hydroxylamine is 
oxidized leading to the nitrosobenzene, that inhibits the NAT enzyme by forming a sulfinic acid at the catalytic Cys68 of 
the NAT enzyme (shown in red). Transfer of the acetyl group by NAT on the hydroxy group of the hydroxylamine results in the unstable N-acetoxy ester. Heterolytic N-O bond cleavage of the N-acetoxy ester will result in nitrenium ions, that 
will react with nucleophiles like azide ions or nucleophiles residing in DNA (mainly guanine) and proteins (e.g. tyrosine).
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2.3 Reactivity of the nitrenium ions
The N,O-acetyl transfer reaction catalyzed by NAT was already discovered in the early 60’s 
and 70’s.128,174,175 Measuring the conversion of the hydroxamic acids in the rat liver cytosol 
revealed formation of arylamine adducts with DNA (Figure 3).128 Because of these findings, it has been postulated that these metabolic conversions of arylamines by the NAT enzyme are at the onset of carcinogenesis as a result of the spontaneous heterolytic N,O-bond cleavage of the 
N-acetoxy arylamines intermediates into nitrenium ions.176–178 The potential role of the NAT 
enzyme in carcinogenesis has been well studied, including the reactivity of the nitrenium ions 
with nucleophiles in aqueous solvents.175,179,180
The reaction of nitrenium ions with DNA or other nucleophiles can only effectively occur when 
the reaction rate with the solvent is much lower than that with the nucleophile. The lifetime of 
nitrenium ions was studied in order to determine the reactivity of the cations with different 
solvents or nucleophiles.181–183 A laser flash photolysis technique was used to generate 
nitrenium ions by a short pulse of laser light and the nitrenium ions were subsequently 
trapped by the solvent or by a nucleophile such as the azide ion (Figure 3).181–183
In water, arylnitrenium ions (ArNH+) are longer-lived than for example their arylcarbenium 
analogs (ArCH2+), which is likely due to the resonance structures of the nitrenium ion.184,185 The positive charge on the nitrogen is a minor resonance form compared to the structures 
where the cation is delocalized in the ring.185 Because of the resonance structures of the 
nitrenium ion, incorporating different groups with different electrophilic properties will affect 
the stability of the nitrenium ion.174,186–188 Introducing more electron withdrawing properties at the para position of the arylamine will decrease the stability of the nitrenium ion due to 
the inhibited charge delocalization at the para position.174 On the contrary, substituting the ring of the hydroxamic acids at the para position with electron-donating groups will promote the heterolytic bond cleavage of the N-acetoxy arylamine due to the stabilizing effect by the 
oxygen on the arylnitrenium ion (Figure 4).174,188
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Figure 4 – Resonance structures of the nitrenium ion.188
Unlike the relatively long lifetime of arylnitrenium ions in water (100 ns to one ms), the 
reaction rates of nitrenium ions with 2’-deoxyguanosine were close to or at the diffusion limit 
(2 x 109 M-1s-1).189 The majority of this nucleoside is forming a C8 adduct upon reaction with 
the nitrenium ion (Figure 3).190–192 In addition, arylhydroxamic acids were also irreversibly 
inactivating the NAT enzyme indicating reactivity of the activated substrate towards residues 
residing in the enzyme.170,193,194 After incubating the NAT enzyme with N-arylhydroxamic acids, 
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the irreversible inactivation was caused by forming a sulfinamide adduct with the catalytic 
Cys68 in the enzyme (Figure 3) rather than by reacting with the nitrenium ions.172,193,194 In this 
process, the transfer of the acetyl group to the NAT enzyme results in an arylhydroxylamine, 
which is oxidized to a nitrosoarene.172,193,194 Subsequently, the nitrosoarene reacts with the 
catalytic Cys68 of the NAT enzyme forming a covalent sulfinamide adduct, which results in 
irreversibly inactivation of the NAT enzyme.172,193,194
Although the majority of the NAT enzymes formed the sulfinamide adduct, minor arylamine 
adducts were also identified at tyrosine residues in the NAT enzyme as a result of the 
reaction with the formed nitrenium ions.193,194 Thomas and Falvey showed that N-methyl-N-4-
biphenylnitrenium ions rapidly react (> 108 M-1 s-1) with tryptophan, tyrosine, methionine, and 
cysteine residues (Table 1).182 Although slower (107-108 M-1 s-1), lysine, histidine, and arginine 
residues also react with the nitrenium ion (Table 1).182 In addition, fast adduct formation of 
the hydroxamic acids (6-8 x 108 M-1 s-1) was observed with several proteins, such as bovine 
serum albumin (BSA), lysozyme, and chymotrypsin.182 The reactivity of these proteins seems 
to depend on structural factors, such as the number of readily accessible reactive amino 
acids.182
Table 1 – Reactivity of the N-methyl-N-4-biphenylnitrenium ion towards amino acids and proteins.
A) Structure of the N-methyl-N-4-biphenylnitrenium ion. B) The reaction rate constants were measured by trapping of 
N-acetyl-N-biphenylylnitrenium ion (k
q
). L-derivatives of all amino acids were measured, the amino acids not shown did 
not result in measurable quenching. Source: Thomas and Falvey182 
A B amino acid
or protein kq (M
-1 s-1)
L-Arg
L-Cys
L-His
L-Lys
L-Met
L-Ser
L-Trp
L-Tyr
BSA
Lysozyme
Chymotrypsin
3.04 x 107
2.79 x 108
5.39 x 107
8.04 x 107
1.29 x 109
7.93 x 106
2.91 x 109
2.95 x 108
8.22 x 108
5.79 x 108
7.71 x 108
size
(kDa)
66.5
14.4
25.0
# Met
4
2
2
# Cys
35
8
10
# Tyr
20
3
3
# Trp
2
6
8
% reactive
amino acids
10.5
14.7
9.9
N
N-methyl-
N-4-biphenyl
nitrenium ion
2.4	 Substrate	specificities	of	the	hNAT	enzymes
While the hNAT1 and hNAT2 proteins make use of the same enzymatic acetylation mechanism, 
they showed distinct substrate preferences.138,144,195–197 The N-acetylation activity of hNAT1 
has been compared for a wide range of substrates with that of hNAT2.138,196,197 Both enzymes catalyze the N-acetylation of aniline (ANL) and although the N-acetylation of ANL by hNAT1 
is about 2.5-fold slower than by hNAT2, the binding affinity for ANL of hNAT1 is about 4.5-
fold higher than that of hNAT2 (Table 2).196,197 Selective substrates for hNAT1 include PABA, 
2-aminofluorene (2-AF), and ANS (Table 2A).121,150,198 Bulkier substrates, like sulfamethazine 
(SMZ), isoniazid (INZ), and hydralazine (HDZ) are preferentially acetylated by hNAT2 (Table 
2v
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2.4	 Substrate	specificities	of	the	hNAT	enzymes
While the hNAT1 and hNAT2 proteins make use of the same enzymatic acetylation mechanism, 
they showed distinct substrate preferences.138,144,195–197 The N-acetylation activity of hNAT1 
has been compared for a wide range of substrates with that of hNAT2.138,196,197 Both enzymes catalyze the N-acetylation of aniline (ANL) and although the N-acetylation of ANL by hNAT1 
is about 2.5-fold slower than by hNAT2, the binding affinity for ANL of hNAT1 is about 4.5-
fold higher than that of hNAT2 (Table 2).196,197 Selective substrates for hNAT1 include PABA, 
2-aminofluorene (2-AF), and ANS (Table 2A).121,150,198 Bulkier substrates, like sulfamethazine 
(SMZ), isoniazid (INZ), and hydralazine (HDZ) are preferentially acetylated by hNAT2 (Table 
2v
2).121,150,198 The binding of hNAT2 to larger substrates is caused by the larger binding pocket 
(257 Å) than that of hNAT1 (162 Å), as a result of two key residues at position 127 and 129 
(Figure 5B).150 The bulky Arg127 and Tyr129 of hNAT1 reduce the pocket of hNAT1 by almost 
40% compared with the substrate binding pocket of hNAT2, which contains serines at these 
positions (Figure 5B).
Table	2	–	Binding	affinity	(Km) and catalytic rate (kcat,app) for aniline substrates of the hNAT enzymes.
A) Structures of the arylamine- and hydrazine-based substrates. B) The initial velocities of the N-acetylation were determined by monitoring the increase in absorbance due to the loss of the acetyl group from the acetyl acceptor 
(p-nitrophenyl acetate) in presence of the substrate. The mean and standard deviation are shown (n = 3). n.d. not 
determined. An absorbance change of 0.1 min-1 was defined as the lowest quantifiable rate. a The rate of N-acetylation of 
SMZ (3 mM) was 7.1 µmol mg-1 min -1. b The rate of N-acetylation of 2-EA (20 mM) by hNAT1 was 2.2 µmol mg-1 min-1. c 
N-acetylation of 2,6-DMA was not detectable at a concentration of 50 mM. Source: Liu et al.197
ANL
PABA
2-AF
SMZ
2-MA
2-EA
2,6-DMA
3-EA
3,5-DMA
4-MA
4-EA
hNAT1 hNAT2
2,490 ± 140
84 ± 7.9
109 ± 11
n.d.b
2,320 ± 170
n.d.a
n.d.b
576 ± 27
742 ± 27
483 ± 28
205 ± 20
Km,app 
(µM)
281 ± 5.1
298 ± 10
449 ± 17
n.d.b
12 ± 0.83
n.d.a
n.d.b
310 ± 7.0
308 ± 5.2
303 ± 8.2
430 ± 14
kcat,app 
(s-1)
11,200 ± 1790
152,000 ± 39,100
286 ± 38
5,390 ± 520
7,180 ± 130
2,110 ± 180
n.d.b
1,320 ± 150
280 ± 21
11,800 ± 1290
3270 ± 390
Km,app 
(µM)
711 ± 70
38 ± 7.5
759 ± 46
387 ± 20
111 ± 8.1
61 ± 5.0
n.d.b
1,960 ± 68
1,220 ± 37
1,600 ± 120
700 ± 34
kcat,app 
(s-1)
B
[kcat/Km (hNAT1)]/
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1.79
14,200
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0.10
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hNAT1 and hNAT2 display distinct affinities for ANL and a series of ring-substituted 
alkylanilines.138,196,197 Substitution of ANL with 2-alkyl groups resulted in a substantially lower 
activity and binding affinity by both the hNAT enzymes.197 N-acetylation of ANL by hNAT1 is 
about 22 times faster than that of 2-methylaniline (2-MA), whereas the binding affinity for 
both substrates is almost the same (Table 2).197 In case of hNAT2, the N-acetylation rate was 
about 7 times slower for 2-MA compared to ANL and the binding affinity was decreased by 
about 1.5-fold (Table 2).197 The influence of 2-alkyl substituted arylamines on the enzymatic 
activity of hNAT might be a result of steric hindrance between the tetrahedral intermediate Reactions catalyzed by the arylamine N-acetyltransferases  37
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enzyme-bound thio-acetyl ester and the arylamine substrate, and/or any unfavorable steric 
clashes between the 2-alkyl substituent and amino acid side chains in the hNAT binding 
sites.197
B
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Figure 5 – Overview of structural characteristics of the hNAT enzymes. 
A) Overall structure of hNAT1 (pdb file: 2pqt), the three main domains are colored green, blue, and grey. Cys68 of hNAT1 
binds covalently to acetanilide (red). B) Comparison of the binding pocket of hNAT1 (grey, pdb file: 2pqt) and hNAT2 
(blue, pdf file: 2pfr). The active site cysteine of hNAT1 binds covalently to acetanilide (Cys68-acetanilide; red).
Compared to 2-alkyl substituted arylamines, stronger binding affinities are observed for 
arylamines with substituents at the third or fourth position of the carbon ring.197 These 
arylamines form ring-stacking pi-pi interactions with aromatic residues in the active site of 
the hNAT enzymes.150 Although N-acetylation of 3-ethylaniline (3-EA) and 3,5-dimethylaniline 
(3,5-DMA) by hNAT1 is almost equally efficient as that of ANL, the binding affinities of 3-EA and 3,5-DMA are about 3.5-4-fold higher.197 It was suggested that the 3-alkyl position of the 
aromatic ring contributes to favorable binding interactions, including interactions between 
3,5-DMA and Phe125 in hNAT1, which is not present in hNAT2 (Ser125; Figure 5B).197 
Enhanced binding as well as more efficient catalysis was observed for 3-alkyl arylamines for hNAT2 compared to ANL (Table 2).197 The substrate selectivity for 3,5-DMA of hNAT2 is 
about 10-fold greater compared to that of hNAT1 (Table 2).197 This is presumably the result 
of interactions between 3,5-DMA and Phe93 in hNAT2; at the corresponding position hNAT1 
contains a valine (Figure 5B).197 In contrast, the binding affinity of hNAT1 for 4-methylaniline 
(4-MA) and 4-ethylaniline (4-EA) is stronger compared to that of hNAT2 (about 25 and 16 
times, respectively; Table 2).197 Likely, these arylamines interact with the side chain methyl 
group of Val216 in hNAT (Ser216 in hNAT2; Figure 5B).197
In addition, the acetylation rate of a series of lipophilic arylamines was compared for hNAT1 
and hNAT2.138 It was hypothesized that substituting ANL with an electron-donating alkoxy 
group at the fourth position of the ring will increase the nucleophilicity of the substrate. In 
addition, increasing the chain length of the alkoxy group will also increase the nucleophilicity 
as well as the substrate size and thereby affect the interaction with the catalytic pocket of 
the hNAT enzymes. As mentioned above, ANS is efficiently acetylated by hNAT1 but not by 
hNAT2, whereas almost similar acetylating activities for hNAT1 and hNAT2 were measured 
2
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addition, increasing the chain length of the alkoxy group will also increase the nucleophilicity 
as well as the substrate size and thereby affect the interaction with the catalytic pocket of 
the hNAT enzymes. As mentioned above, ANS is efficiently acetylated by hNAT1 but not by 
hNAT2, whereas almost similar acetylating activities for hNAT1 and hNAT2 were measured 
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for 4-ethoxyaniline (EOA; Table 2A).138 Increasing the chain length of alkoxyaniline, 
4-butoxyaniline (BOA), 4-hexyloxyaniline (HOA), and 4-phenoxyaniline (POA) (Table 2A) 
resulted in a decrease in acetylation activity by hNAT1, while similar catalytic activities were 
observed for hNAT2.138 The difference in activity between hNAT1 and hNAT2 for bulkier alkoxyanilines is probably the result of the smaller size of the substrate binding pocket of 
hNAT1 compared to that of hNAT2.138 Furthermore, these data suggest that the nucleophilicity 
of the anilines competes with the increase in bulkiness, though the steric hindrance of larger substrates plays a more dominant role in acetylation of substrates by the hNAT1 compared 
to hNAT2.
2.5 Aim and outline of this thesis
2.5.1 Aim
NAT enzymes are involved in the catalysis of acetyl-CoA dependent N- and O-acetylation, as 
well as the N,O-acetyl transfer reaction of many arylamines and hydrazine xenobiotics. The 
acetylation reactions by the NAT enzymes are suggested to occur in two sequential steps 
following a ping-pong bi-bi mechanism via the highly conserved catalytic triad (Cys68, 
His107, and Asp122). The acetyl group of acetyl-CoA is first transferred to the NAT enzyme 
followed by transfer of the acetyl from the NAT enzyme to the arylamine or hydrazine-based 
structures, resulting in an acetylated substrate. The O-acetylation and the N,O-acetyl transfer reactions catalyzed by the NAT enzymes result in the formation of N-acetoxy arylamines, which can undergo fast and spontaneous N-O 
heterolytic bond cleavage generating nitrenium ions. Depending on the substituents of the 
arylnitrenium ions, these species are relatively stable in aqueous environments (up to µs-ms), 
whereas they are highly reactive towards nucleophilic residues residing in DNA, RNA, and 
proteins with rates approaching the diffusion limit. The DNA, RNA, or protein adducts might 
play an important role in the onset of carcinogenesis.
hNAT1 and hNAT2 have affinity for a wide range of substrates with a preference for arylamines, 
due to ring-stacking interactions between the substrate and aromatic side chains at the NAT 
active site. Despite the similarities between hNAT1 and hNAT2, these enzymes exhibit distinct 
affinities for identical substrates as a result of differences in the residue composition of the 
substrate binding pocket. The binding pocket of hNAT2 is about 40 % larger than that of 
hNAT1 and as a consequence bulkier arylamines are preferentially acetylated by hNAT2 (e.g. 
INH, HDZ, and SMZ) compared to the smaller hNAT1 selective substrates PABA, 2-AF, and 
ANS.
The aim of the research described in this thesis is to set out a novel enzymatic proximity-
dependent labeling (PDL) strategy based on the hNAT enzyme (Figure 6). PDL techniques are 
Reactions catalyzed by the arylamine N-acetyltransferases  39
2
used to rapidly visualize protein-protein interactions (PPIs) in living cells by enzymatically 
activating a small molecule, which subsequently covalently labels the enzyme itself and 
proteins located in close proximity of the enzyme (the PDL methods are extensively discussed 
in Chapter 1).53–56 For our strategy, we aim to exploit the unique N,O-acetyl transfer reaction 
catalyzed by NAT and investigate if this enzyme is suitable for fast PDL in living cells without 
making use of potentially disturbing cofactors. By subjecting synthetic arylhydroxamic acid 
probes directly to cells, we expect that NAT converts these probes into the unstable N-acetoxy 
arylamine intermediates, which undergo heterolytic N-O bond cleavage resulting in the 
formation of nitrenium ions (Figure 6, reaction mechanism).170,184,185 Directing the NAT enzyme 
to a specific cellular location results in the covalent modification of nucleophilic residues in 
close proximity of the enzyme in that subcellular region (Figure 6, cell and protein level).
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Figure 6 – Scheme of the PDL strategy using the NAT enzyme. 
The NAT enzyme is locally restricted to the nucleus and activates AHA probes resulting in local labeling of proteins 
residing in the nucleus, illustrated at the protein level (top) and cell level (middle). The reaction mechanism of AHA 
probe activation by NAT followed by protein labeling is shown at the bottom. After protein labeling using AHA probes, 
labeling is directly visualized (labeled probes) or via bioorthogonal chemistry (azide-labeled probes).
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2.5.2 Outline
The molecular features of NAT-mediated acetylation described in this chapter form the basis 
for the design of probes and the subcellular labeling by the hNAT enzymes. This includes 
the tertiary structures of hNAT1 and hNAT2, the arylamine substrate preference, and the 
reactivity of the nitrenium ions. 
In Chapter 3, we explored the use of several hydroxamic acid probes for labeling by the NAT 
enzyme. Three azide-functionalized AHA probes and corresponding control probes were 
designed and synthesized. The effects of different electronic properties of the AHA moiety 
were assessed by analyzing the labeling efficiency by the NAT enzyme. The azide group was 
used as a handle to visualize the tagged proteins by bioorthogonal chemistry using fluorescent 
moieties. 
In Chapter 4, cultured cells were treated with AHA probes described in the previous chapter 
in order to assess the level of endogenous NAT in mammalian cells. This information is important to estimate the background labeling by NAT in living cells before measuring the 
ability of a targeted enzyme to label proteins locally.
Most importantly, the concept of the NAT PDL approach was demonstrated in Chapter 5. 
The NAT enzyme was directed to specific subcellular areas followed by labeling of proximal 
proteins by NAT. We assessed local protein labeling in time by AHA probes of Chapter 3 
visualized by bioorthogonal chemistry using a fluorescent conjugate.
In order to improve the labeling efficiency by the NAT enzyme, we redesigned the catalytic binding pocket of the NAT enzyme in order to create a mutant that recognizes bulkier 
substrates (Chapter 6). This approach is useful to avoid labeling by the endogenous wild type 
NAT enzymes expressed, which are not able to recognize and activate the larger substrates in 
contrast to the novel designed mutant.
Finally, we will reflect in Chapter 7 on the findings presented in this thesis by placing our NAT 
strategy in the context of related PDL methods. Additionally, promising features are described, 
as well as the challenges to overcome for applying the NAT proximity labeling strategy in vivo.
2
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In vitro protein labeling by the arylamine 
N-acetyltransferase
3Part of this Chapter is published in:Kleinpenning, F.; Eising, S.; Berkenbosch, T.; Garzero, V.; Schaart, J. M.; Bonger, K. M.; ACS Chem. Biol. 2018, 13 (8), 1932–1937.
Abstract
Identifying proteins in their native cellular environment is crucial to understand cellular 
homeostasis. Proximity-dependent labeling (PDL) techniques allow rapid protein labeling 
to visualize cellular dynamics at high spatial and temporal resolution. In this thesis, we 
aim to develop a novel PDL approach based on the human arylamine N-acetyltransferase 
(hNAT). The hNAT enzyme activates hydroxamic acid into nitrenium ions, which react fast 
and covalently with nucleophilic residues residing in proteins. In this chapter, we will first explore the ability of the hNAT enzyme to label proteins in vitro by subjecting recombinant 
hNAT to synthetic arylhydroxamic acid (AHA) probes. We designed and synthesized a set of 
AHA probes varying in the electronic properties of the aromatic hydroxamic acid moiety and 
explored their potential to label proximal nucleophilic residues, residing in hNAT enzyme 
itself, upon enzymatic activation. The electron density on the aromatic ring proved important 
for probe activation as strong labeling of the recombinant hNAT enzyme was only observed 
with an arylhydroxamic acid moiety bearing an electron donating substituent.
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3.1 Introduction
The ability to track proteins in their native cellular environment is crucial in order to 
understand the function of proteins in living systems.2,13,199 Proximity-dependent labeling 
(PDL) techniques have been developed to rapidly visualize proteins in the cell, including the 
engineered biotin ligase system (BioID)63 and the engineered ascorbate peroxidase method 
(APEX)80 (reviewed in Chapter 1).19,200,201 Both, BioID and APEX are based on the enzymatic 
activation of small molecules, which covalently labels the enzyme and proteins in close 
vicinity of the enzyme.
In case of BioID, the engineered biotin ligase (BirA) activates biotin by catalyzing the 
conjugation of biotin and ATP into the reactive 5’-AMP-biotin intermediate, which reacts with 
lysine residues in close proximity of the enzyme.63 Protein labeling by the first generation 
BioID is rather slow, requiring about 16-24 hours in living cells, and therefore cell dynamics 
cannot be followed over time.67,118 Although the labeling time was improved to about 10 
minutes, biotinylation by this approach resulted in higher background due to the presence of 
endogenous biotin.68 APEX generates short-lived biotin-phenoxy radicals by oxidizing biotin-
phenol in the presence of hydrogen peroxide allowing protein labeling within minutes.80,103 
The biotin-phenoxy radicals react fast and covalently with electron-rich amino acids, including 
tyrosine, tryptophan, cysteine, and histidine.80,103 Although the APEX system labels proteins 
within minutes, the exposure of a living cell to high levels of hydrogen peroxide (1 mM), 
required for the enzymatic APEX reaction, might cause adverse effects, such as the induction 
of a cellular stress response.115–117,202
In order to avoid the use of hydrogen peroxide and still preserve fast labeling times for 
proximal protein labeling, we set out to establish a novel PDL strategy using the human arylamine N-acetyltransferase (hNAT; reviewed in Chapter 2) (Figure 1).122,123 Humans express 
the two homologues human NAT1 (hNAT1) and human NAT 2 (hNAT2), which catalyze O- and 
N-acetylation of a wide range of arylamines and hydrazine xenobiotics.128,151 The enzymes have 
distinct substrate specificities, where bulkier aromatic amines are preferentially acetylated 
by hNAT2 as this isoform has a larger binding pocket (257 Å) compared to that of hNAT1 
(162 Å).150
Besides the direct acetylation of arylamines by NATs, an additional enzymatic conversion observed for NATs is the catalysis of the N,O-acetyl transfer of N-acetyl-N-hydroxy arylamine 
(arylhydroxamic acid; AHA) into N-acetoxy arylamine (Figure 1B).170 Depending on the aryl 
substituents, these N-acetoxy esters undergo fast heterolytic N-O bond cleavage into nitrenium 
ions.184,185 For example, introducing electron donating properties at the para position of the 
phenyl ring will promote the heterolytic bond cleavage of the N-acetoxy arylamine due to the 
stabilizing effect of the oxygen on the generated arylnitrenium ion (see Chapter 2).174,188 The 
nitrenium ions are highly reactive towards nucleophilic residues residing in DNA, RNA, and 
proteins with rates approaching the diffusion limit.189,203 Because of this mechanism and the 
reactivity of nitrenium ions towards nucleophilic residues, it has been postulated that these metabolic conversions of arylamines are the onset of the observed carcinogenicity of these 
3
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compounds.121,176,194,204 We envisioned that we could exploit this unique N,O-acetyl transfer capacity of NAT and the resulting formation of reactive nitrenium ions for the development of 
a novel PDL strategy using probes containing the arylhydroxamic acid moiety. 
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Figure 1 - Overview of labeling by the NAT enzyme using AHA probes.
A) Schematic representation of labeling on protein level. The NAT enzyme activates AHA probe, which covalently labels 
proteins. AHA probes contain either a reactive group or a fluorophore to visualize protein labeling. B) The mechanism 
of AHA probe activation by the NAT enzyme is shown. The activation of AHA probe results in the formation of the 
acetoxy ester intermediate. This intermediate undergoes N-O bond cleavage generating nitrenium ions, which react with 
nucleophilic residues.
To evaluate the potential of the NAT enzyme for protein labeling, we tested in this chapter the 
ability of recombinant hNAT enzymes to activate various arylhydroxamic acid probes as a first 
step towards the NAT PDL method. We designed and synthesized a set of AHA molecules, as 
well as control probes that cannot form nitrenium ions, and assessed the labeling potential 
upon enzymatic activation by hNAT. As most proximal nucleophilic residues reside in hNAT 
itself, we expect to observe mainly self-labeling in the absence of other nucleophiles. We 
further explore the influence of electronic factors of the arylhydroxamic acids and the optimal conditions to visualize the labeled proteins using various bioorthogonal chemistries and 
detection methods.
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3.2 Results and Discussion
3.2.1 Design of AHA and AAA probes
In this Chapter, our main focus is to explore the ability of the recombinant hNAT enzymes 
to activate the synthetic AHA probes and to assess the influence of electronic factors of the 
hydroxamic acids on the labeling efficiency. We hypothesized that the electronic factors at the 
para position of the hydroxamic acid group might be crucial for the stability of the reactive 
intermediates and thereby of importance for efficient protein labeling.
As reviewed in Chapter 2, the electronic properties at the para position of the hydroxamic 
acid probes will affect the stability of the acetoxy ester intermediate.174,188 Because of the 
resonance structures of the nitrenium ion, introducing more electron withdrawing properties at the para position of the arylamine will decrease the stability of the nitrenium ion.174 On the 
contrary, hydroxamic acid probes having electron-donating properties at the para position 
will promote the heterolytic bond cleavage of the N-acetoxy arylamine due to the stabilizing 
effect of the oxygen on the arylnitrenium ion.174,188 Thereby, decreasing the stability of the 
acetoxy ester intermediate might result in faster nitrenium ion formation and in this way 
influence the level of protein labeling. 
Three probes were designed having distinct properties at the para position of the arylamine: 
(i) the electron-rich AHA probe 1, wherein an alkoxy group was attached directly to the 
phenyl ring, (ii) the intermediate electron-donating AHA probe 3, with an amide attached to a 
benzylhydroxamic acid, and (iii) the more electron-poor AHA probe 5, with the amide directly 
attached to the phenyl ring (Figure 2). In addition, three structurally similar arylacetamide 
(AAA) probes were designed lacking the hydroxy group (AAA probes 2, 4, and 6, respectively). 
Since the hydroxy function is essential for the N,O-acetyl transfer by the NAT enzymes, we use 
these as control probes in our experiments as nitrenium ion formation is impeded. 
In addition to the hydroxamic acid reactive group, we introduced an azide moiety at the end of each linker in order to introduce a reporter molecule into the labeled proteins via a 
bioorthogonal reaction (Figure 3). Widely used bioorthogonal chemistry techniques are the 
strain-promoted alkyne-azide cycloaddition (SPAAC)205 and the copper(I)-catalyzed alkyne-
azide cycloaddition (CuAAC)206,207 resulting both in the formation of a stable triazole linkage 
in the absence or presence of a Cu(I) catalyst, respectively (Figure 3).208 Although the CuAAC 
reaction is very selective in the presence of biomolecules, the copper required for the reaction 
is cytotoxic for living cells.209 In contrast, the SPAAC reaction does not require the Cu(I) 
catalyst, though the thiol-yne reaction of the strained alkynes with thiol-containing proteins 
often results in background labeling.210
3
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Figure 2 – Structures of AHA and AAA probes 1-10 used for hNAT labeling.
The main advantage of the incorporation of an azide in the hydroxamic acid probes is the 
ability to both visualize and/or enrich the labeled proteins at a later stage using alkyne 
molecules containing either a fluorophore or a biotin functionality, respectively. Labeled 
proteins reacted with a fluorophore can be visualized directly, whereas biotinylated proteins 
can be visualized and enriched using a streptavidin moiety. Here, we will explore both the 
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SPAAC and CuAAC reactions for visualizing and purifying labeled proteins with the azide-containing probes 1, 3, and 5 using a DBCO-Cy5.5 11 and DBCO-biotin 13, or Cy5.5-alkyne 12 
and biotin-alkyne 14 (Figure 3). Besides the azide-containing probes, we synthesized a set of 
probes that were conjugated to a BODIPY fluorophore (AHA probe 7 and AAA probe 8) or a 
biotin functionality (AHA probe 9 and AAA probe 10) in advance (Figure 2).
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Figure 3 – Schematic overview of the SPAAC or CuAAC reaction. 
Molecules labeled with an azide are visualized via the SPAAC reaction using the fluorophore DBCO-Cy5.5 11 or DBCO-biotin 13 (A) or via the CuAAC reaction using Cy5.5-alkyne 12 or biotin-alkyne 14 (B).
3.2.2 Synthesis of AHA and AAA probes
The three azide-functionalized AHA probes were synthesized from iodophenyl building 
blocks that were prepared with the different azide linkers (Supplementary Scheme S1-3). 
The building blocks were coupled to THP-protected N-hydroxyacetamide to provide THP-
protected AHA probes in reasonable to good yields via a copper-mediated Ullmann-type 
reaction in heated DMF (Figure 4A).211 Other attempts to synthesize AHA probes, including 
the partial reduction of a nitro group to the arylhydroxylamine followed by acetylation212–214 
or the Pd-catalyzed Buchwald-Hartwich amination of a bromophenyl building block with 
protected hydroxylamines,215,216 proved less satisfying (data not shown). After the Ullmann-
type reaction, the THP-protecting groups were removed and AHA probes 1, 3, and 5 were 
obtained in good yields (Figure 4A).AAA control probes 2, 4, and 6, lacking the essential hydroxy moiety for N,O-acetyl transfer, 
were obtained in good yields via a similar Ullmann-type reaction using acetamide instead of 
the THP-protected N-hydroxy acetamide (Figure 4A, Supplementary Scheme S1-3).
In addition to the azide-containing molecules, we synthesized the conjugated AHA and AAA probes 7-10 by reacting the readily available BODIPY-alkyne 12 or biotin-alkyne 14 with the 
azides using standard CuAAC conditions (Figure 4B). AHA probes 7 and 9 were obtained in 
good yields by coupling the THP-protected AHA probe, containing the ether linkage, with 
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BODIPY-alkyne 12 or biotin-alkyne 14 (Supplementary Scheme S4). The THP-protecting 
groups were removed and AHA probes 7 and 9 were obtained in good yields (Figure 4B). 
Similarly, AAA probes 8 and 10 were synthesized by reacting AAA probe 2, with BODIPY-alkyne 12 or biotin-alkyne 14 and obtained in good yields (Figure 4B, Supplementary Scheme 
S4). 
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A) Synthetic route of azide-functionalized probes. i) CuI, DMEDA, Cs2CO3, DMF, 80 °C, 1-2 days. ii) CuI, DMEDA, Cs2CO3, 
DMF, 80 °C, 1 day. For AHA probe 1 iii) PPTS, EtOH, 55 °C, 1 day. For AHA probe 3 and 5: iv) 4 M HCl in dioxane, CH2Cl2, 
2h. B) Synthetic route of BODIPY- and biotin-functionalized probes. For AHA probe 7: v) CuSO
4
, sodium ascorbate, DMF/
H2O, 16 h, rt; For AHA probe 9: vi) CuSO4, sodium ascorbate, H2O/tBuOH, 16 h, rt; vii) PPTS, EtOH, 16 h, 55 °C. For AAA probe 8: viii) CuSO
4
, sodium ascorbate, H2O/tBuOH, 16 h, rt; For AAA probe 10: ix) CuSO4, sodium ascorbate, H2O/
tBuOH/DMF, 16 h, rt.
3.2.3	 Expression	and	purification	of	the	hNAT	enzymes
To investigate the scope of hNAT1 and hNAT2 enzyme labeling with AHA and AAA probes 1-10, 
we expressed and purified the hNAT enzymes from Escherichia coli (E. coli) using standard 
techniques. We equipped both hNAT1 and hNAT2 with a histidine-tag at the N-terminus (H
6
-
hNAT1 or H
6
-hNAT2) to purify the enzyme using Ni2+ NTA affinity chromatography. As the 
histidine-tag might influence the activity of the hNAT1 enzyme, a Tobacco Etch Virus (TEV) 
cleavage site was incorporated between the histidine-tag and the hNAT for removal by the 
highly sequence-specific TEV protease.After expression of the hNAT1 enzyme in E. coli, we incubated the soluble protein fraction of 
bacterial lysates with Ni2+ NTA agarose beads and discarded the flow through. An attempt was 
made for on-bead cleavage of the histidine-tag from H
6
-hNAT1 through incubation with the 
TEV protease. However, the enzyme remained bound to the Ni2+ NTA beads and cleavage of 
the histidine-tag was not observed (data not shown). In contrast, purifying H
6
-hNAT1 without 
cleavage of the TEV site resulted in a relatively pure protein as shown by SDS-PAGE gel and 
western blotting (Figure 5A). We purified H
6
-hNAT1 further by size-exclusion chromatography, 
though the majority of the co-purified proteins having distinct sizes from H
6
-hNAT1 could not 
be separated from the enzyme (Supplementary Figure S1). This co-eluting pattern is likely 
the result of possible interactions of these impurities with the H
6
-hNAT1 enzyme rather than 
the result of (a)specific binding to the Ni2+ NTA beads. Since we were not able to purify the H
6
-
hNAT1 enzyme further, all elution fractions containing the H
6
-hNAT1 enzyme were combined, 
dialyzed, and stored directly after Ni2+ NTA affinity chromatography.
3 Figure 5 –Expression and purification of recombinant hNAT1 and hNAT2.
H
6
-hNAT1 (± 40.1 kDa) and GST-hNAT2 (± 60.7 kDa) were expressed in E. coli and purified using Ni2+ NTA or GST sepharose affinity chromatography, respectively. Purification fractions of H
6
-hNAT1 (A) and GST-hNAT2 (B) were analyzed on SDS-PAGE gel and western blot. The SDS-PAGE gel was stained with Coomassie Brilliant Blue or transferred to western blot, that was stained with an antibody against the hNAT enzyme, histidine-, or GST-tag to detect the recombinant proteins. Lys = total lysate (10 %); I = insoluble fraction (10 %); S = soluble fraction (10 %); FT = flow through of Ni2+ NTA or GST sepharose (10 %); b = residual proteins on the coated beads.vasdfasdfasdfasdfasdf
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Figure	5	–Expression	and	purification	of	recombinant	hNAT1	and	hNAT2.
H
6
-hNAT1 (± 40.1 kDa) and GST-hNAT2 (± 60.7 kDa) were expressed in E. coli and purified using Ni2+ NTA or GST sepharose 
affinity chromatography, respectively. Purification fractions of H
6
-hNAT1 (A) and GST-hNAT2 (B) were analyzed on SDS-
PAGE gel and western blot. The SDS-PAGE gel was stained with Coomassie Brilliant Blue or transferred to western blot, 
which was stained with an antibody against the hNAT enzyme, histidine-, or GST-tag to detect the recombinant proteins. 
Lys = total lysate (10 %); I = insoluble fraction (10 %); S = soluble fraction (10 %); FT = flow through of Ni2+ NTA or GST 
sepharose (10 %); b = residual proteins on the coated beads.
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The expected molecular weight (40,138 Da) of the H
6
-hNAT1 protein was verified by 
electrospray ionization time-of-flight (ESI-TOF) mass spectrometry (Supplementary 
Figure S2). The results confirmed the integrity of the H
6
-hNAT1 protein. In addition to the 
major peak, we observed a second deconvoluted peak (+ 178 Da) in the H
6
-hNAT1 sample, 
which is possibly gluconoylated H
6
-hNAT1. This can be explained by the posttranslational 
gluconoylation of the histidine-tag, which occurs spontaneously in E. coli.217,218 Furthermore, 
one of the copurifying proteins was detected having a molecular weight of 20,854 Da.
We additionally analyzed the purified hNAT1 sample with liquid chromatography tandem 
mass spectrometry (LC-MS/MS) to confirm the presence of H
6
-hNAT1 and to determine 
the identity of the copurified proteins. Therefore, we fragmented the sample first into 
poly-peptides by a standard trypsin digestion followed by the LC-MS/MS measurement. 
Subsequently, the measured data was compared with the online Swissprot database in order 
to define the identity of the proteins (summarized in Table 1). The identity of hNAT1 was 
confirmed with high protein sequence coverage (above 70 %) as well as the presence of three 
other proteins, including the ferric uptake regulation protein, FKBP-type peptidyl-prolyl cis-
trans isomerase SlyD, and the protein YrdA. The FKBP-type peptidyl cis-trans isomerase SlyD 
protein has a theoretical size of 20,853 Da and is likely the similar protein measured by ESI-
TOF MS above. Importantly, these proteins with high protein sequence coverage present in the 
hNAT1 sample are all three able to bind metal ions.219–223 This might explain the copurification 
of these proteins during the H
6
-hNAT1 isolation using Ni2+ affinity chromatography. On the 
other hand, we were not able to isolate the recombinant hNAT1 further by size-exclusion 
chromatography, which indicates potential additional interactions of these impurities with 
the H
6
-hNAT1 enzyme.
Table	1	–	Identity	of	proteins	residing	in	the	purified	hNAT1	sample	by	LC-MS/MS.
Theoretical size for each protein was derived from www.uniprot.org using the UniProt accession number.
Uniprot
accession
P06975
P18440
P30856
P45770
theoretical
size (Da)
16,795
33,889
20,853
20,245
function
Regulates the expression of
several  outer-membrane
proteins, including the iron
transport operon47,48
Acetylation of N- or
O-arylamines,
N,O-acetyl transfer52
Folding helper with both
chaperone and peptidyl-
prolyl cis-trans isomerase
activities49,50
Not clear: zinc binding and
protein homotrimerization51
Ferric uptake 
regulation protein
human arylamine 
N-acetyltransferase
(hNAT1)
FKBP-type peptidyl-prolyl
cis-trans isomerase SlyD
Protein YrdA
protein
name
prot. seq.
coverage (%)*
81.08
74.14
73.98
73.37
* protein sequence coverage (%)
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After successful purifying the H
6
-hNAT1 enzyme, we tested the expression and purification 
of H
6
-hNAT2 in the bacteria. Although H
6
-hNAT2 was expressed in E. coli, we were unable to 
purify this enzyme from the bacterial lysate (Supplementary Figure S3). H
6
-hNAT2 was not bound to the Ni2+ NTA beads and remained in the flow through of the soluble fraction. This 
suggests that the N-terminal histidine-tag is not available and therefore, this tag cannot be 
used for purifying the hNAT2 enzyme.
To circumvent the use of the N-terminal histidine-tag, we attempted to express hNAT2 fused 
to glutathione S-transferase (GST) via a TEV cleavage site. GST binds strongly to glutathione 
and can be used to purify proteins using glutathione-immobilized beads. As for H
6
-hNAT1, we 
were not able to cleave hNAT2 from the GST-tag upon incubation with TEV protease (data not 
shown) and continued with purifying GST-hNAT2 as a complete fusion protein. As shown in 
Figure 5B, we obtained recombinant GST-hNAT2, however two polypeptides of approximately 
25 kDa co-eluted. These co-eluting proteins are likely the result of spontaneous cleavages 
of the linker region between the GST-moiety and hNAT2 as both are recognized by the anti-
GST-antibody (see full western blot image Supplementary Figure S4). Although, we cannot completely exclude the possibility that these impurities represent contaminating proteins 
interacting with GST-hNAT2.
3.2.4 Labeling of recombinant hNAT1 using AHA probes
Evaluation of probe activation by hNAT1
Having the azide-containing AHA and AAA probes (1-6) and the recombinant H
6
-hNAT1 
enzyme in hand, we examined the ability of this enzyme to activate AHA probes 1, 3, or 5 
(Figure 6A). We incubated H
6
-hNAT1 with these AHA probes for one hour and performed a 
SPAAC or CuAAC reaction using DBCO-Cy5.5 11 or Cy5.5- alkyne 12, respectively, to visualize 
the labeled protein by fluorescence scanning of a SDS-PAGE gel (Figure 6A). As most proximal 
nucleophilic residues are present in hNAT enzyme itself, we expected that this protein is the 
most labeled in our experiments. Indeed, to our delight, we observed labeling of H
6
-hNAT1 for 
all AHA probes 1, 3, and 5. A strong difference in protein labeling was observed between the 
probes where the strongest fluorescent signal was observed for AHA probe 1, containing an 
electron donating alkoxy linker.
We also incubated recombinant hNAT1 also with AAA probe 2, for which no activation was expected because of the lack of the N-hydroxy functionality. Indeed, no protein labeling was 
observed when hNAT1 was subjected to AAA probe 2 and subsequently reacted with the 
fluorescent alkynes in the SPAAC and CuAAC reaction. The background signals measured 
for the enzyme incubated with AAA probe 2 were similar to the signals observed when 
recombinant hNAT1 was not subjected to any probe. Additional controls, including hNAT1 
samples incubated with AHA probe 1 followed by SPAAC reactions lacking DBCO-Cy5.5 11 
or CuAAC reaction lacking Cy5.5-alkyne 12 of the copper sulfate, also resulted in similar 
background signals. 
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Figure 6 – Comparison of the SPAAC and CuAAC reaction using the azide moieties 1-6 activated by H6-hNAT1.
A) H
6
-hNAT1 was incubated with probes 1-6 followed by the SPAAC or CuAAC reaction using DBCO-Cy5.5 11 or Cy5.5-alkyne 12. The molar ratio probe:DBCO-Cy5.5 11 or probe:Cy5.5-alkyne 12 was 1:0.1. B) Labeled H
6
-hNAT1 using probes 1 and 2 was visualized via the SPAAC reaction using different molar ratios of probe:DBCO-Cy5.5 11 (1:0.1, 
1:1, and 1:10). In-gel fluorescence of the SDS-PAGE gel is shown. As a reference, the SDS-PAGE gel was stained with 
Coomassie Brilliant Blue.
Comparing the labeling efficiency of the reporter molecules, we observed enhanced hNAT1 
labeling signals using the SPAAC reaction compared to the CuAAC reaction (the CuAAC signals 
were about ten times less intense than those after SPAAC, Figure 6A). The SPAAC and CuAAC 
reactions can be compared because these two bioorthogonal reactions were performed 
under similar conditions and contained the same fluorophore. Because we observed stronger 
labeling signals using the SPAAC reaction with DBCO-Cy5.5 11, this reaction was used in all 
subsequent labeling experiments involving the recombinant hNAT1 enzyme.
Optimization of the reporter labeling using SPAAC
We optimized the SPAAC reaction by adding different molar ratios of the DBCO-Cy5.5 11 to 
the hNAT1 enzyme that was incubated with AHA probe 1, AAA probe 2 or without probe. As 
shown in Figure 6B, the most intense signal was observed when a tenfold molar excess of 
DBCO-Cy5.5 11 relative to AHA probe 1 was added. Although much less intense, we observed 
slight concentration-dependent background signals for samples that were incubated with AAA probe 2 and reacted with DBCO-Cy5.5 11. Since similar background signals were measured 
in the absence of probe, these were most likely caused by non-specific binding of the strained 
alkyne during the SPAAC reaction and not by non-specific binding of the AHA or AAA probe.
Compared to the signals observed at a 1:0.1 molar ratio AHA probe 1:DBCO-Cy5.5 11, 
the labeling intensity increased two-fold by increasing the molar ratio to 1:10, while the background signal using AAA probe 2 increased six-fold. Hence, for future labeling 
experiments we used the lower 1:0.1 molar ratio probe:DBCO-Cy5.5 11 as this provided the 
most optimal readout window.
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Figure 6 – Comparison of the SPAAC and CuAAC reaction using the azide moieties 1-6 activated by H6-hNAT1.
A) H
6
-hNAT1 was incubated with probes 1-6 followed by the SPAAC or CuAAC reaction using DBCO-Cy5.5 11 or Cy5.5-alkyne 12. The molar ratio probe:DBCO-Cy5.5 11 or probe:Cy5.5-alkyne 12 was 1:0.1. B) Labeled H
6
-hNAT1 using probes 1 and 2 was visualized via the SPAAC reaction using different molar ratios of probe:DBCO-Cy5.5 11 (1:0.1, 
1:1, and 1:10). In-gel fluorescence of the SDS-PAGE gel is shown. As a reference, the SDS-PAGE gel was stained with 
Coomassie Brilliant Blue.
Comparing the labeling efficiency of the reporter molecules, we observed enhanced hNAT1 
labeling signals using the SPAAC reaction compared to the CuAAC reaction (the CuAAC signals 
were about ten times less intense than those after SPAAC, Figure 6A). The SPAAC and CuAAC 
reactions can be compared because these two bioorthogonal reactions were performed 
under similar conditions and contained the same fluorophore. Because we observed stronger 
labeling signals using the SPAAC reaction with DBCO-Cy5.5 11, this reaction was used in all 
subsequent labeling experiments involving the recombinant hNAT1 enzyme.
Optimization of the reporter labeling using SPAAC
We optimized the SPAAC reaction by adding different molar ratios of the DBCO-Cy5.5 11 to 
the hNAT1 enzyme that was incubated with AHA probe 1, AAA probe 2 or without probe. As 
shown in Figure 6B, the most intense signal was observed when a tenfold molar excess of 
DBCO-Cy5.5 11 relative to AHA probe 1 was added. Although much less intense, we observed 
slight concentration-dependent background signals for samples that were incubated with AAA probe 2 and reacted with DBCO-Cy5.5 11. Since similar background signals were measured 
in the absence of probe, these were most likely caused by non-specific binding of the strained 
alkyne during the SPAAC reaction and not by non-specific binding of the AHA or AAA probe.
Compared to the signals observed at a 1:0.1 molar ratio AHA probe 1:DBCO-Cy5.5 11, 
the labeling intensity increased two-fold by increasing the molar ratio to 1:10, while the background signal using AAA probe 2 increased six-fold. Hence, for future labeling 
experiments we used the lower 1:0.1 molar ratio probe:DBCO-Cy5.5 11 as this provided the 
most optimal readout window.
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3.2.5 Assessing the effect of the linker of AHA probes
Since a difference in reactivity between the three different azide-functionalized probes was 
observed after one hour of incubation (Figure 6A), we monitored the activation of probes 1-6 
by recombinant hNAT1 in time (Figure 7). The electron-rich AHA probe 1 resulted in strong 
hNAT1 labeling within one hour, whereas the signal intensities of AHA probes 3 and 5 did not 
reach the level observed for AHA probe 1, even after eight hours of incubation (Figure 7C). As 
observed before, the incubation of hNAT1 with AAA probes 2, 4, and 6 resulted in only very 
weak signals (Figure 7B).The strongest labeling observed for the ether derivative 1 using hNAT1 can be explained 
by distinct binding affinities of AHA probes to the hNAT1 enzyme and/or by a difference in 
the stability and reactivity of the acetoxy ester intermediate and resulting nitrenium ion. 
According to literature, the electron donating properties at the para position will enhance the reaction catalyzed by the hNAT enzyme138 and will also promote heterolytic bond 
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Figure 7 – Activation of the probes 1-6 by H6-hNAT1 followed in time.
A) Experimental overview. B) H
6
-hNAT1 was incubated with probe 1-6 up to eight hours followed by the SPAAC reaction 
using a DBCO-Cy5.5 11. In-gel fluorescence of the SDS-PAGE gel is shown. As a reference, the SDS-PAGE gel was stained 
with Coomassie Brilliant Blue. C) Analysis of the time response shown in B by normalizing the fluorescent intensity of 
the AHA probe time points to the eight-hour time point of AHA probe 1, fitted by a one phase decay model. Error bars 
indicate the standard deviation for the results of three independent experiments.
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cleavage of the N-acetoxy arylamine intermediate.174,188 If the activation of AHA probe 1 
by the enzyme is higher than that of AHA probes 3 and 5, there will be an increase in the formation of the unstable acetoxy ester intermediate resulting in enhanced labeling of the 
hNAT1 enzyme. Moreover, if the stability of the acetoxy ester intermediate itself is decreased, 
due to the electron-rich oxygen that contributes to the resonance structures of the nitrenium 
ion by delocalization of the positive charge in the ring,188 this results in faster nitrenium ion 
formation leading to more intense hNAT1 labeling by AHA probe 1.
3.2.6 hNAT1 tagging using BODIPY AHA probe 7
After exploring hNAT1 labeling by the azide-functionalized probes, we examined the ability 
of recombinant hNAT1 to activate the fluorescent BODIPY AHA probe 7 to gain information 
about the efficiency of the SPAAC reaction, the effect of additional substituents, and the most 
optimal method to visualize the labeled proteins. Similar to the conditions used for the azide-
functionalized AHA probe 1, we incubated the hNAT1 enzyme for different time periods 
with AHA probe 7 and the corresponding AAA probe 8 (Figure 8A). As 7 and 8 contained a 
BODIPY fluorophore, we visualized hNAT1 labeling directly with fluorescent scanning of the 
SDS-PAGE gel. Strong labeling was observed within minutes using AHA probe 7 and maximal 
labeling was reached after approximately two hours (Figure 8A). AAA probe 8 lacking the 
hydroxy functionality did not result in enzyme labeling, even after eight hours of incubation 
(Figure 8A).
BA
1 2.5 10 15 30 45 60 12
0
24
0
48
0 min
2 -
48
0
48
0
1
5
streptavidin (800 nm)
37
Ponceau S
37
fluorescence (488 nm)
coomassie
37
kDa
fluorescence (700 nm)
coomassie
37
37
37
AHA probe 7 (488 nm)
AHA probe 9 (800 nm) 
AHA probe 1 (700 nm)
H6-hNAT1
H6-hNAT1
H6-hNAT1
H6-hNAT1
H6-hNAT1
H6-hNAT1
1 2.5 10 15 30 45 60 12
0
24
0
48
0 min
8 -
48
0
48
0
7
5
1 2.5 10 15 30 45 60 12
0
24
0
48
0 min
10 -
48
0
48
0
9
5
0 1 2 3 4 5 6 7 8
0.0
0.2
0.4
0.6
0.8
1.0
Time (hours)
No
rm
al
iz
ed
 F
lu
or
es
ce
nc
e 
In
te
ns
ity
kDa
kDa
Figure 8 – Protein labeling by H6-hNAT1 using azide AHA probe 1 or labeled AHA probes 7 or 9.
(A) SDS-PAGE gel of H
6
-hNAT1 incubated with probe 1-2, 7-10, or no probe (-) up to eight hours. In-gel fluorescence of 
the SDS-PAGE gel is shown. As a reference, the SDS-PAGE gel was stained with Coomassie Brilliant Blue. Biotinylation by probe 9 and 10 was analyzed on western blot and detected with the streptavidin-800 conjugate. As a reference, the 
western blot was stained with Ponceau S to detect the loaded proteins.
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In order to compare the labeling rate of AHA probe 1 and BODIPY probe 7, we normalized 
the signals observed in time with the signal measured after eight hours. Therefore, the 
intensity measured for each of the time points by AHA probe 1 and AHA probe 7 was divided 
by the eight-hour point of that same probe. As shown in Figure 8B, the labeling rate using 
AHA probe 1 was slower than that observed for AHA probe 7. This might be explained by the 
positive effect of the BODIPY group on the activation of AHA probe 7 by the hNAT1 enzyme 
or on formation of the nitrenium ion. Despite the slower reaction of AHA probe 1, the azide-
function may be beneficial as it allows the visualization of the labeled proteins by conjugating 
a fluorescent moiety as well as purification of the labeled proteins by conjugating a biotin 
functionality, for example.
3.2.7 Biotinylation of hNAT1 after the reaction with AHA probe 1
Despite the fact that we observed promising labeling results by fluorescence scanning of SDS-
page gels, it does not provide information on the fraction of proteins that are actually labeled. 
Therefore, we aimed to tag the labeled hNAT1 enzyme with a biotin moiety and to isolate of 
the biotinylated hNAT1 enzyme using streptavidin beads. We incubated recombinant hNAT1 
with AHA probe 1 and subsequently subjected the protein mixture to the SPAAC reaction 
using DBCO-biotin 13. Biotinylated proteins were then visualized by a fluorescent conjugate 
of streptavidin having strong biotin binding affinity. 
First, various amounts of DBCO-biotin 13 were evaluated in order to optimize the SPAAC 
reaction after the labeling reaction with AHA probe 1 or AAA probe 2 (Figure 9). About 1.5-
fold increase in biotinylation signal was obtained for AHA probe 1 using different DBCO-biotin 13 concentrations compared to samples that were not subjected to a probe or to the 
3
× 
DBCO-
biotin 13
1
- 2
10 50 1 10 50
1
1 10 50
streptavidin (800 nm)
Ponceau S
37
kDa
37
Cy5.5-
alkyne 12
biotin-
alkyne 14
37
kDa
37
H6-hNAT1
- 2
1
1
1
-* 1
0.1
- 2
1
1
1
-* 1
0.1 (mM)
-
+ +
- -
+
-
+
-
+
+ + + + +
Ponceau S
A B
fluorescence
(700 nm)
streptavidin
(800 nm)
- - - - -
H6-hNAT1
probe
Figure 9 – Biotinylation of labeled hNAT1 by the SPAAC or CuAAC reaction.
A) H
6
-hNAT1 incubated with probe 1, 2, or no probe (-) was biotinylated by SPAAC using different molar ratios of AHA probe 1:DBCO-biotin 13 (1:1, 1:10, or 1:50). B) Incubated H
6
-hNAT1 with probe 1, 2, or no probe in absence (-) or 
presence of DMSO (-*) was biotinylated via the CuAAC reaction using biotin-alkyne 14 with at least a molar ratio of 
AHA probe 1:biotin-alkyne 14 (1:1.5). Biotinylation was visualized on western blot stained with the streptavidin-800 
conjugate. In-gel fluorescence of the SDS-PAGE gel is shown. As a reference, the SDS-PAGE gels were transferred to 
western blot and Ponceau S was used to detect the loaded proteins.
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control probe 2. As for the DBCO-Cy5.5 11 experiments described above, a concentration-
dependent increase of biotinylation signal was observed upon increasing ratio of DBCO-biotin 
13, although this was also observed in the control samples.
As the most optimal signal to noise ratio was observed when using a low concentration of 
DBCO-biotin 13, we used these conditions to explore the isolation of biotinylated proteins. 
We incubated the biotinylated proteins with streptavidin-coated beads in various binding 
buffers and temperatures (see also Materials and Methods section for detailed information), 
however, we did not observe protein enrichment (data not shown). In addition, we evaluated 
the enrichment of biotinylated proteins using a higher concentration of DBCO-biotin 13, 
which also did not result in the isolation of biotinylated proteins. The poor enrichment of 
biotinylated proteins is possibly the result of the low amount of biotinylated proteins caused 
by the efficiency of the SPAAC reaction using DBCO-biotin 13. For example, the incubation of 
hNAT1 labeled by AHA probe 1 with the DBCO-biotin 13 resulted in 1.5-fold enhanced signals compared to AAA probe 2, whereas a hundred-fold difference was observed when performing 
the SPAAC reaction with the DBCO-Cy5.5 11. Due to the difficulties of the biotin enrichment, 
we were not able to quantify the fraction of hNAT1 labeled by AHA probe 1 via the SPAAC 
reaction using DBCO-biotin 13.
In parallel to the SPAAC reaction using DBCO-biotin 13, we also attempted to biotinylate the 
labeled hNAT1 enzyme with a biotin-alkyne 14 using the CuAAC reaction (Figure 9). Again, 
only about 1.5-fold stronger biotinylation signals were observed when hNAT1 was incubated 
with AHA probe 1 compared to AAA probe 2 or no probe and a significant biotin background 
signals of the control samples was observed. This indicates the lower efficiency of the CuAAC 
reaction with biotin-alkyne 14 compared to Cy5.5-alkyne 12, as the latter resulted in a 100-
fold increase in signal when using AHA probe 1 compared to AAA probe 2. The incubation 
of the material generated by the CuAAC reaction with streptavidin beads did not lead to 
detectable isolation of the labeled hNAT1 enzyme using the alkyne-biotin 14 for the CuAAC 
reaction (data not shown, see Materials and Methods section for protocol).
3.2.8 The level of labeling of hNAT1 determined by AHA probe 9
We continued to assess the level of hNAT1 labeling further by biotinylating the enzyme directly 
using the biotin-conjugated probe 9. The efficiency of hNAT1 labeling was determined in time 
and a strong signal was observed within one hour using AHA probe 9 and only very weak 
signal was observed for the corresponding AAA probe 10 (Figure 8A). The labeling efficiency 
of AHA probe 9 compared to that of AHA probe 1 or BODIPY AHA probe 7 was less efficient 
(Figure 8B). Although complete labeling was almost achieved within two hours for AHA probes 1 and 7, biotinylation was still increasing after two hours of incubation with AHA probe 9. 
After validating that hNAT1 activated AHA probe 9, we isolated the biotinylated enzyme 
by removal of the excess of probe molecules and incubated the samples with streptavidin 
magnetic beads. As shown in Figure 10, approximately 50 % of the hNAT1 enzyme bound 
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to the streptavidin beads by incubating the recombinant hNAT1 enzyme only with 50 µM of 
AHA probe 9 for one hour. The isolation of biotinylated hNAT1 by streptavidin-coated beads 
occurred in a concentration-dependent manner, with close to full recovery of tagged hNAT1 
when 0.5-5 mM of AHA probe 9 was used. In contrast, incubating the hNAT1 without the probe 
or with AAA probe 10 resulted in weak background binding of hNAT1 to the streptavidin 
beads (10-20%). Note that at least some of the copurifying polypeptides present in the hNAT1 
eluate were also biotinylated and purified using the streptavidin beads and more molecules 
were recovered when increasing the concentration of AHA probe 9. 
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Figure 10 – Enrichment of biotinylated hNAT1 eluate using streptavidin magnetic beads.
 (A) Schematic overview. B) H
6
-hNAT1 was incubated with probes 9, 10, or no probe (-) at different concentrations. 
Fractions of the enrichment of biotinylated proteins were visualized on SDS-PAGE gel by silver stain. C) The percentage 
indicates the level of protein recovery on the beads relative to the input, based on B.
3.2.9 Labeling by hNAT1 versus hNAT2
Up to this point, we focused on using hNAT1 to label proteins using AHA probes 1-10, though 
we were as well interested in tagging by GST-hNAT2. hNAT1 and hNAT2 catalyze both the 
acetylation (transfer) reactions in humans nd have distinct tissue distribution and substrate 
specificities (Chapter 2 for more details).136,147,198 hNAT1 is widely distributed in the body 
and expressed in almost all cell types, whereas hNAT2 is mainly expressed in the kidney, 
gut, and liver.145,146,148,149 Although both hNAT enzymes acetylate aniline (ANL), the binding 
affinity of ANL towards the hNAT1 enzyme is higher than towards the hNAT2 enzyme, 
whereas the acetylation reaction rate for hNAT2 is about 2.5-fold faster than for hNAT1.138,197 
These differences in tissue distribution and substrate specificities are important for the 
development of the PDL strategy using the NAT enzyme in living systems. In order to select 
the best hNAT enzyme for the labeling strategy, we evaluated here the ability of recombinant 
hNAT2 to activate AHA probe 7 as already observed for recombinant hNAT1.
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After purifying the GST-hNAT2 enzyme as described previously, we incubated this enzyme 
with BODIPY AHA probe 7 to directly visualize the labeling by fluorescence. H
6
-hNAT1 was 
used in parallel as a reference. In Figure 11, hNAT labeling was observed for both recombinant 
H
6
-hNAT1 and GST-hNAT2 using AHA probe 7, whereas the control experiments did not show 
any fluorescent signal. More intense GST-hNAT2 labeling was observed using AHA probe 7 
compared to H
6
-hNAT1 labeling.
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Figure 11 – Labeling by H6-hNAT1 and GST-hNAT2 using the probes 7-8.
Recombinant enzymes were incubated with the labeled probe 7, 8 or no probe (-) and labeling was analyzed on SDS-
PAGE gel. In-gel fluorescence of the SDS-PAGE gel is shown. As a reference, the SDS-PAGE gel was stained with Coomassie 
Brilliant Blue.The enhanced labeling by recombinant hNAT2 compared to hNAT1 might be the result of 
the higher amount of the hNAT2 than hNAT1 present in the reaction, as evidenced by the 
Coomassie staining. Another explanation might be the influence of the histidine and GST-
tag on the activity of the enzyme. The GST-tag often promotes the correct folding of proteins during expression in E. coli224 and might therefore positively affects the folding hNAT2 and 
consequently the activation of AHA probe 7. Furthermore, the affinity and activation of AHA probe 7 might be different for both recombinant hNAT1 and hNAT2 resulting in different 
labeling intensities by these enzymes using the similar AHA probe. The results in Figure 11 
indicate that both hNAT1 and hNAT2 are able to activate AHA probe 7 resulting in protein labeling in vitro, however, the exact mechanism on the increased labeling by hNAT2 is of great 
interest for future development and applications of hNAT PDL methods.
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3.3 Concluding Remarks
In this chapter, we explored the ability of the recombinant hNAT enzyme to activate synthetic 
arylhydroxamic acid probes as a first step towards a novel PDL strategy to rapidly visualize 
protein interactions in living systems. The hNAT approach is based on the catalysis of the 
N,O-acetyl transfer of AHA probes into N-acetoxy arylamine, that undergo fast heterolytic 
N-O bond cleavage into nitrenium ions. The nitrenium ions react covalently with nucleophilic 
residues residing in DNA, RNA, and proteins. We demonstrated the ability of both the hNAT1 
and hNAT2 enzyme to activate AHA probes and assessed the influence of the electronic 
factors of the hydroxamic acid probes. A set of three azide-functionalized AHA and the 
corresponding AAA probes were synthesized via an Ullmann-type reaction varying in their 
electron donating and withdrawing properties, including (i) an electron-rich AHA probe 1, (ii) 
an intermediate electron-donating AHA probe 3, and (iii) a more electron-poor AHA probe 5. 
The corresponding AAA probes (AAA probes 2, 4, and 6) lack the hydroxy functionality that is crucial for the N,O-acetyl transfer by the NAT enzymes impeding the nitrenium ion formation. 
In addition, the azide characteristic was used as a handle to visualize the tagged proteins by 
bioorthogonal chemistry, such as the SPAAC and CuAAC reaction.
After successful cloning, expression, and partial purification of the H
6
-hNAT1 enzyme, we 
have shown that this enzyme activates AHA probe 1 within minutes, and that the efficiency by 
which the other AHA probes 3 and 5 are used is inversely related to their electron-donating 
capacity. As expected, AAA probes resulted in minimal labeling, which was similar to that 
observed when the hNAT1 enzyme was not subjected to any probe. As discussed, the difference 
in labeling efficiency observed with the azide-functionalized AHA probes was likely caused by 
a decreased amount of nitrenium ion formation as a result of distinct binding affinities of the 
probes towards the hNAT1 enzyme and/or by a difference in the stability of the acetoxy ester 
intermediate.
Besides labeling of the hNAT enzyme itself, we have also observed labeling of other 
polypeptides present in the recombinant hNAT eluate using the electron-rich AHA probe. 
Since the final purpose is to develop a hNAT PDL strategy, we will further examine the ability of proximal protein tagging by the recombinant hNAT enzyme or by endogenous NAT enzymes 
in living cells in Chapter 4.
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Figure	S1	–	Purification	of	the	elution	fractions	of	H6-hNAT1 by size-exclusion chromatography.
A) After Ni2+ NTA affinity chromatography of H
6
-hNAT1, the eluate was separated by size-exclusion chromatography. 
Graph of the chromatogram at 260 nm (black) and 280 nm (red). B) Fractions of A were analyzed by SDS-PAGE gel 
stained against silver stain. The letters above the SDS-PAGE gel correspond to the letters of the eluting volume in A.
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Figure S2  ESI-TOF mass spectrometry multiply charged ion series (right) and deconvoluted total mass spectrum 
(left) of the eluted H6-hNAT1 protein.
Expected size: 40,138 Da; Observed size: 40,138 Da. 
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Figure	S3	–	Expression	and	purification	of	recombinant	H6-hNAT2.
H
6
-hNAT2 (± 39.8 kDa) was expressed in E. coli and purified by Ni2+ NTA affinity chromatography. Fractions were 
analyzed on SDS-PAGE gel, stained with Coomassie Brilliant Blue. lys = total lysate (10 %); I = insoluble fraction (10 %); 
S = soluble fraction (10 %); FT = flow through of Ni2+ NTA (10 %); b = residual proteins on the coated beads; 
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Figure	S4	–	Expression	and	purification	of	recombinant	hNAT2.
GST-hNAT2 (± 60.7 kDa) was expressed in E. coli and purified using GST sepharose affinity chromatography. Purification 
fractions of GST-hNAT2 was analyzed on western blot, that was stained using the NAT and GST-tag antibody to detect 
the recombinant protein. Lys = total lysate (10 %); I = insoluble fraction (10 %); S = soluble fraction (10 %); FT = flow through of Ni2+ NTA or GST sepharose (10 %); b = residual proteins on the coated beads; 
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Table S1 – Oligonucleotide sequences used for amplifying the hNAT1 and hNAT2 gene.
primer name
BamHI-TEVsite-hNAT1
hNAT1-STOP-NotI
BamHI-TEVsite-hNAT2
hNAT2-STOP-NotI
details comments
GATC GGATCC
GAGAACTTGTATTTTCAGAGCGGC
GACATTGAAGCATATCTTG
ATATAT GCGGCCGC CTA AATA
GTAAAAAATCTATCACCATGTTT
GGGCACAAG
GATC GGATCC 
GAGAACTTGTATTTTCAGAGCGGC
GACATTGAAGCATATTTTG
ATATAT GCGGCCGC C CTA AA
TAGTAAGGGAGCCATCACC 
forward primer encoding BamHI
restriction site, TEV protease
cleavage site, and overlapping with
hNAT1
reverse primer encoding NotI
restriction site, a STOP codon, and
overlapping with hNAT1
forward primer encoding BamHI
restriction site, TEV protease
cleavage site, and overlapping with
hNAT2
reverse primer encoding NotI
restriction site, a STOP codon, and
overlapping with hNAT2
Table S2 – gBlock fragment encoding hNAT1 used for cloning of the H6-hNAT1 construct.
3
gene
GACATTGAAGCATATCTTGAAAGAATTGGCTATAAGAAGTCTAGGAACAAATTGGACTTGGAAACATTAA
CTGACATTCTTCAACACCAGATCCGAGCTGTTCCCTTTGAGAACCTTAACATCCATTGTGGGGATGCCAT
GGACTTAGGCTTAGAGGCCATTTTTGATCAAGTTGTGAGAAGAAATCGGGGTGGATGGTGTCTCCAGGTC
AATCATCTTCTGTACTGGGCTCTGACCACTATTGGTTTTGAGACCACGATGTTGGGAGGGTATGTTTACA
GCACTCCAGCCAAAAAATACAGCACTGGCATGATTCACCTTCTCCTGCAGGTGACCATTGATGGCAGGAA
CTACATTGTCGATGCTGGGTTTGGACGCTCATACCAGATGTGGCAGCCTCTGGAGTTAATTTCTGGGAAG
GATCAGCCTCAGGTGCCTTGTGTCTTCCGTTTGACGGAAGAGAATGGATTCTGGTATCTAGACCAAATCA
GAAGGGAACAGTACATTCCAAATGAAGAATTTCTTCATTCTGATCTCCTAGAAGACAGCAAATACCGAAA
AATCTACTCCTTTACTCTTAAGCCTCGAACAATTGAAGATTTTGAGTCTATGAATACATACCTGCAGACA
TCTCCATCATCTGTGTTTACTtcaAAATCATTTTGTTCCTTGCAGACCCCAGATGGGGTTCACTGTTTGG
TGGGCTTCACCCTCACCCATAGGAGATTCAATTATAAGGACAATACAGATCTAATAGAGTTCAAGACTCT
GAGTGAGGAAGAAATAGAAAAAGTGCTGAAAAATATATTTAATATTTCCTTGCAGAGAAAGCTTGTGCCC
AAACATGGTGATAGATTTTTTACTATT
amino acid sequence
D I E A Y L E R I G Y K K S R N K L D L E T L T D I L Q H Q I R A V P F
E N L N I H C G D A M D L G L E A I F D Q V V R R N R G G W C L Q V N H
L L Y W A L T T I G F E T T M L G G Y V Y S T P A K K Y S T G M I H L L
L Q V T I D G R N Y I V D A G F G R S Y Q M W Q P L E L I S G K D Q P Q
V P C V F R L T E E N G F W Y L D Q I R R E Q Y I P N E E F L H S D L L
E D S K Y R K I Y S F T L K P R T I E D F E S M N T Y L Q T S P S S V F
T S K S F C S L Q T P D G V H C L V G F T L T H R R F N Y K D N T D L I
E F K T L S E E E I E K V L K N I F N I S L Q R K L V P K H G D R F F T
I
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Table S2 – gBlock fragment encoding hNAT1 used for cloning of the H6-hNAT1 construct.
3
Table S3 – gBlock fragment encoding hNAT2 used for cloning of the H6-hNAT2 and GST-hNAT2 construct
gene
amino acid sequence
GACATTGAAGCATATTTTGAAAGAATTGGCTATAAGAACTCTAGGAACAAATTGGACTTGGAAACATTAAC
TGACATTCTTGAGCACCAGATCCGGGCTGTTCCCTTTGAGAACCTTAACATGCAcTGTGGGCAAGCCATGG
AGTTGGGCTTAGAGGCTATTTTTGATCACATTGTAAGAAGAAACCGGGGTGGGTGGTGTCTCCAGGTCAAT
CAACTTCTGTACTGGGCTCTGACCACAATCGGTTTTCAGACCACAATGTTAGGAGGGTATTTTTACATCCC
TCCAGTTAACAAATACAGCACTGGCATGGTTCACCTTCTCCTGCAGGTGACCATTGACGGCAGGAATTACA
TTGTCGATGCTGGGTCTGGAAGCTCCTCCCAGATGTGGCAGCCTCTAGAATTAATTTCTGGGAAGGATCAG
CCTCAGGTGCCTTGCATTTTCTGCTTGACAGAAGAGAGAGGAATCTGGTAtCTGGACCAAATCAGGAGAGA
GCAGTATATTACAAACAAAGAATTTCTTAATTCTCATCTCCTGCCAAAGAAGAAACACCAAAAAATATACT
TATTTACGCTTGAACCTCGAACAATTGAAGATTTTGAGTCTATGAATACATACCTGCAGACGTCTCCAACA
TCTTCATTTATAACCACATCATTTTGTTCCTTGCAGACCCCAGAAGGGGTTTACTGTTTGGTGGGCTTCAT
CCTCACCTATAGAAAATTCAATTATAAAGACAATACAGATCTGGTCGAGTTTAAAACTCTCACTGAGGAAG
AGGTTGAAGAAGTGCTGAGAAATATATTTAAGATTTCCTTGGGGAGAAATCTCGTGCCCAAACCTGGTGAT
GGcTCCCTTACTATTTAG
D I E A Y F E R I G Y K N S R N K L D L E T L T D I L E H Q I R A V P F
E N L N M H C G Q A M E L G L E A I F D H I V R R N R G G W C L Q V N Q
L L Y W A L T T I G F Q T T M L G G Y F Y I P P V N K Y S T G M V H L L
L Q V T I D G R N Y I V D A G S G S S S Q M W Q P L E L I S G K D Q P Q
V P C I F C L T E E R G I W Y L D Q I R R E Q Y I T N K E F L N S H L L
P K K K H Q K I Y L F T L E P R T I E D F E S M N T Y L Q T S P T S S F
I T T S F C S L Q T P E G V Y C L V G F I L T Y R K F N Y K D N T D L V
E F K T L T E E E V E E V L R N I F K I S L G R N L V P K P G D G S L T
I    
3.6 Supplementary Information
Synthetic procedures
Caution: All arylamines should be handled in accordance with NIH Guidelines for the 
Laboratory use of Chemical Carcinogens.
If no further details are given, the reaction was performed under ambient atmosphere and at 
room temperature (rt). Analytical thin layer chromatography (TLC) was performed on silica 
gel-coated plates (Merck, 60 F254) with the indicated solvent mixture, visualization was 
done using ultraviolet (UV) irradiation (λ = 254 nm) and/or staining with aqueous KMnO
4
 or 
ninhydrin. Purification by column chromatography was carried out using silica gel 60 (Merck, 
0.040-0.063 mm). 1H NMR and 13C NMR spectra were recorded on a Bruker DMX 300 (300 
MHz), Bruker Advance III 400 (400 MHz) or 500 (500 MHz) spectrometer. For the 1H NMR 
spectra, TMS (δH 0.00) or the NMR solvent residual peak of CDCl3 ((CHCl3) δH 7.26) ), CD3OD 
((CHD3O) δH 3.31), or (CD3)2SO ((C2HD5SO) δH 2.50) were used as the internal reference. For the 13C NMR spectra, the central resonance of CDCl3 (δC 77.2), CD3OD (δC 49.0) or (CD3)2SO 
(δC 39.5) was used as the internal reference, all 13C NMR spectra were proton decoupled. 
The spectra of the THP-protected probes S4, S7 and S11 were measured at 50 °C, in order 
to narrow down the broad peaks in the 13C NMR. Low-resolution mass spectra (LRMS) of the 
small molecules were recorded on a Thermo LCQ Advantage Max (Electrospray Ionization 
(ESI)), high-resolution mass spectra (HRMS) were recorded on a JEOL AccuTOF JMS-T100CS 
(ESI).
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Scheme S1 – Synthesis of AHA probe 1 and AAA probe 2.
i) DHP, pTsOH, DMF, 16 h, 89%; ii) NaN3, DMF, 55 °C, 16 h, 56 %; iii) K2CO3, DMF, 70 °C, 16 h, 97 %; iv) CuI, DMEDA, Cs2CO3, 
DMF, 80 °C, 48 h, 75 %; v) S1, CuI, DMEDA, Cs2CO3, DMF, 80 °C, 16 h, 73 %; vi) PTTS, EtOH, 55 °C, 16 h, 67 %.
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N-((Tetrahydro-2H-pyran-2-yl)oxy)acetamide (S1). 
Acetohydroxamic acid (500 mg, 6.66 mmol, 1. 0 equiv.) was dissolved 
in dry dimethylformamide (DMF, 13 mL) and dihyropyran (608 µl, 6.66 
3
mmol, 1.0 equiv.) and p-toluenesulfonic acid (p-TsOH, 114 mg, 0.67 mmol, 0.1 equiv.) were 
added. The mixture was stirred overnight (o/n). Then brine (100 mL) was added and the 
solution was extracted with CH2Cl2 (20x 20 mL). The combined organic layers were dried 
with Na2SO4, the volatiles were removed under reduced pressure and the crude product 
was purified with column chromatography (70 % EtOAc in heptane) yielding THP-protected acetohydroxamic acid S1 (750 mg, 71 %) as a white solid. Rf = 0.30 (70 % EtOAc in heptane, 
v/v). 1H NMR (300 MHz, CDCl3) δ 8.41 – 8.14 (m, 1H), 5.00 – 4.84 (m, 1H), 4.10 – 3.79 (m, 1H), 
3.62 (dd, J = 11.4, 5.5 Hz, 1H), 2.14 – 1.49 (m, 9H). 13C NMR (125 MHz, CDCl3) δ 167.7, 102.5, 
62.6, 28.1, 25.1, 20.0, 18.7. HRMS (ESI) Calculated for C
7
H13NO3 [M+Na]+ 182.07931, found 
182.07842.
I
O
N3
1-((6-Azidohexyl)oxy)-4-iodobenzene (S3). 1-Azido-6-bromohexane S2225 (843 mg, 4.1 mmol, 1.2 equiv.) was dissolved in 
dry DMF (15 mL) and 4-iodophenol (750 mg, 3.4 mmol, 1.0 equiv.) 
and K2CO3 (1.17 gr, 8.5 mmol, 2.5 equiv.) were added. The mixture was 
stirred at 70°C o/n, whereupon it was poured into water (100 mL) and 
extracted with CH2Cl2 (3x). The combined organic layers were washed 
with brine, dried with Na2SO4, and the volatiles were removed in vacuo. 
The crude mixture was purified by column chromatography (1 % 
EtOAc in heptane) yielding ether S3 (1.15 g, 97 %) as a colourless oil 
which solidified upon storage in the freezer. Rf = 0.29 (1 % EtOAc in heptane). 1H NMR (300 
MHz, CDCl3) δ 7.58 – 7.51 (m, 2H), 6.71 – 6.63 (m, 2H), 3.92 (t, J = 6.4 Hz, 2H), 3.28 (t, J = 6.8 
Hz, 2H), 1.85 – 1.73 (m, 2H), 1.70 – 1.58 (m, 2H), 1.54 – 1.38 (m, 4H). 13C NMR (75 MHz, CDCl3) 
δ 159.05, 138.31, 117.05, 82.65, 67.97, 51.51, 29.15, 28.93, 26.63, 25.78. Iodobenzene S3 was 
not visible on mass spectrometry.
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N-((Tetrahydro-2H-pyran-2-yl)oxy)acetamide (S1). 
Acetohydroxamic acid (500 mg, 6.66 mmol, 1. 0 equiv.) was dissolved 
in dry dimethylformamide (DMF, 13 mL) and dihyropyran (608 µl, 6.66 
3
N-(4-((6-Azidohexyl)oxy)phenyl)acetamide (2). Iodobenzene S3 (255 
mg, 0.67 mmol, 1.0 equiv.) and acetamide (48 mg, 0.81 mmol, 1.2 equiv.) 
were dissolved in dry DMF (2.0 mL) and CuI (11 mg, 0.059 mmol, 0.1 equiv.), 
DMEDA (36 µl, 0.33 mmol, 0.5 equiv.), Cs2CO3 (306 mg, 0.94 mmol, 1.4 
equiv.) and molecular sieves (4 Å) were added and the reaction was heated 
at 80 °C for 2 days. The mixture was cooled down to room temperature (rt), 
EtOAc was added and the suspension was filtered over celite. The volatiles 
were removed under reduced pressure and the crude product was purified 
with column chromatography (60 % EtOAc in heptane), yielding acetemide 
2 (101 mg, 75 %) as a white solid. Rf = (60 % EtOAc in heptane, v/v). 1H NMR 
N-(4-((6-Azidohexyl)oxy)phenyl)-N-((tetrahydro-2H-pyran-2-yl)-
oxy)acetamide (S4). Iodobenzene S3 (255 mg, 0.76 mmol, 1.2 equiv.) and 
THP-protected N-hydroxyacetamide S1 (85 mg, 0.53 mmol, 1.0 equiv.) were 
dissolved in dry DMF (2.0 mL) and CuI (14 mg, 0.072 mmol, 0.1 equiv.), 
1,2-dimethylethylenediamine (DMEDA, 30 µl, 0.275 mmol, 0.5 equiv.), 
Cs2CO3 (259 mg, 0.79 mmol, 1.4 equiv.) and molecular sieves (4 Å) were 
added and the reaction was heated at 80 °C o/n. The mixture was cooled 
down to rt, EtOAc was added and the suspension was filtered over celite. 
The volatiles were removed under reduced pressure and the crude product 
was purified with column chromatography (40 % EtOAc in heptane), 
yielding THP-protected N-hydroxyacetamide S4 (147 mg, 73 %) as a yellow oil. Rf = 0.27 (40 
% EtOAc in heptane, v/v). 1H NMR (400 MHz, 50 °C, (CD3)2SO) δ 7.33 – 7.23 (m, 2H), 6.99 – 
6.90 (m, 2H), 5.02 – 4.93 (m, 1H), 4.00 (t, J = 6.5 Hz, 2H), 3.66 (ddd, J = 11.5, 8.0, 3.6 Hz, 1H), 
3.41 – 3.30 (m, 3H), 2.07 (s, 3H), 1.78 – 1.37 (m, 14H). 13C NMR (100 MHz, 50 °C, (CD3)2SO) δ 
169.3, 157.6, 132.9, 127.2, 114.3, 101.3, 67.5, 62.1, 50.4, 28.2, 27.9, 27.8, 25.5, 24.6, 24.1, 21.4, 
18.4. HRMS (ESI) Calculated for C19H28N4O4 [M+Na]+ 399.20082, found 399.20057.
N-(4-((6-Azidohexyl)oxy)phenyl)-N-hydroxyacetamide (1). THP-protected alcohol S4  (50 mg, 133 µmol, 1.0 equiv.) was dissolved in EtOH 
(1.0 mL) at ambient atmosphere and pyridinium p-toluenesulfonate (PTTS, 
3.3 mg, 13 µmol, 0.1 equiv.) was added and the mixture was stirred at 55 
ᵒC o/n. The solvent was evaporated and the solid was purified by column 
chromatography (60 % EtOAc in heptane) yielding N-hydroxyacetamide 1 
(26 mg, 67 %) as a white solid. Rf = 0.28 (60 % EtOAc in heptane, v/v). 1H 
NMR (500 MHz, CDCl3) δ 7.40 – 7.34 (m, 2H), 7.03 (s, 1H), 6.87 – 6.82 (m, 
2H), 3.94 (t, J = 6.3 Hz, 2H), 3.32 – 3.24 (m, 2H), 2.16 (s, 3H), 1.78 (p, J = 6.4 
Hz, 2H), 1.64 (p, J = 7.0 Hz, 2H), 1.52 – 1.41 (m, 4H). 13C NMR (125 MHz, 
CDCl3) δ 165.0, 159.8, 130.6, 128.5, 115.2, 68.2, 51.5, 29.2, 28.9, 26.6, 25.8, 19.6. HRMS (ESI) 
Calculated for C
14
H20N4O3 [M+Na]+ 315.14331, found 315.14305.
(500 MHz, CDCl3) δ 7.42 – 7.32 (m, 2H), 7.11 (s, 1H), 6.90 – 6.73 (m, 2H), 3.93 (t, J = 6.4 Hz, 
2H), 3.28 (t, J = 6.8 Hz, 2H), 2.15 (s, 3H), 1.85 – 1.72 (m, 2H), 1.70 – 1.57 (m, 2H), 1.56 – 1.37 
(m, 4H). 13C NMR (125 MHz, CDCl3) δ 167.6, 155.4, 130.3, 121.4, 114.3, 67.5, 50.9, 28.6, 28.3, 
26.0, 25.2, 23.9. HRMS (ESI) Calculated for C
14
H20N4O2 [M+Na]+ 299.14839, found 299.14814. 
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Scheme S2 – Synthesis of AHA probe 3 and AAA probe 4.
i) Imidazole-1-sulfonyl azide, CuSO
4
, K2CO3, MeOH, 16 h, quant; ii) 4-Iodobenzylamine, EDC, HOBt, DIPEA, CH2Cl2, 16 h, 
74%; iii) CuI, DMEDA, Cs2CO3, DMF, 80 °C, 16 h, 49%; iv) S1, CuI, DMEDA, Cs2CO3, DMF, 80 °C, 16 h, 94%; v) 4 M HCl in 
dioxane, CH2Cl2, 2 h, 95%.
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6-Azido-N-(4-iodobenzyl)hexanamide (S6). 6-Azidohexanoic acid 
S5 was synthesized from 6-aminohexanoic acid using imidazole-1-sulfonyl azide226 as diazotransfer reagent.227 Then, 4-iodobenzylamine 
(135 mg, 0.86 mmol, 1.0 equiv.) and 6-azidohexanoic acid S5 (200 
mg, 0.86 mmol, 1.0 equiv.) were dissolved in dry CH2Cl2 (9 mL) and 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, 
197 mg, 1.03 mmol, 1.2 equiv.), 1-hydroxybenzotriazole hydrate (HOBt, 
158 mg, 1.03 mmol, 1.2 equiv.) and diisopropylethylamine (DIPEA, 448 
µL, 2.57 mmol, 3.0 equiv.) were added. The mixture was stirred o/n, 
whereupon it was diluted with CH2Cl2 and washed with 1 M HCl. The 
aqueous layer was extracted with CH2Cl2 (2x) and the combined organic layers were washed 
with sat. NaHCO3 and brine and dried with Na2SO4. The mixture was purified using column 
chromatography (30 to 50 % EtOAc/heptane) yielding amide S6 (237 mg, 74 %) as a white 
solid. Rf = 0.40 (EtOAc/heptane 1:1, v/v). 1H NMR (400 MHz, CDCl3) δ 7.75 – 7.55 (m, 2H), 7.13 
– 6.91 (m, 2H), 5.77 (br. s, 1H), 4.37 (d, J = 5.8 Hz, 2H), 3.27 (t, J = 6.8 Hz, 2H), 2.22 (t, J = 7.5 Hz, 
2H), 1.74 – 1.55 (m, 4H), 1.45 – 1.35 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 172.6, 138.2, 137.9, 
129.9, 93.0, 51.4, 43.2, 36.5, 28.8, 26.5, 25.2. HRMS (ESI) m/z calcd. for C13H17IN4O [M+Na]+ 
395.03447, found: 395.03431. 
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6-Azido-N-(4-(N-hydroxyacetamido)benzyl)hexanamide (3). THP-protected probe S7  (24 mg, 0.059 mmol, 1.0 equiv.) was dissolved in dry 
CH2Cl2 (1.0 mL) and 4 M HCl in dioxane (150 µL, 0.59 mmol, 10.0 equiv.) 
was added. After the mixture had stirred for 2 h, the volatiles were removed under reduced pressure yielding N-hydroxyacetamide 3 (18 mg, 95 %) as a 
white solid. 1H NMR (500 MHz, (CD3)2SO) δ 10.58 (s, 1H), 8.30 (t, J = 6.0 Hz, 
1H), 7.60 – 7.49 (m, 2H), 7.26 – 7.17 (m, 2H), 4.23 (d, J = 5.9 Hz, 2H), 3.31 
(t, J = 6.9 Hz, 2H), 2.18 (s, 3H), 2.14 (t, J = 7.4 Hz, 2H), 1.58 – 1.50 (m, 4H), 
1.34 – 1.28 (m, 2H). 13C NMR (125 MHz, (CD3)2SO) δ 171.9, 140.3, 136.01, 
127.16, 120.14, 50.55, 41.53, 35.16, 28.0, 25.8, 24.8, 22.4. HRMS (ESI) m/z 
calcd. for C15H21N5O3 [M+Na]+ 342.15421, found: 342.15477.
N
NH
O
N3
THPO
O 6-Azido-N-(4-(N-((tetrahydro-2H-pyran-2-yl)oxy)acetamido)ben-
zyl)hexanamide (S7). Iodobenzene S6 (62 mg, 0.19 mmol, 1.2 equiv.) 
and THP-protected N-hydroxyacetamide S1 (25 mg, 0.16 mmol, 1.0 equiv.) 
were dissolved in dry DMF (1.0 mL) and CuI (30 mg, 0.16 mmol, 1.0 equiv.), 
DMEDA (25 µL, 0.24 mmol, 1.5 equiv.), Cs2CO3 (72 mg, 0.22 mmol, 1.4 
equiv.) and molecular sieves (4 Å) were added and the reaction was heated 
at 80 °C o/n. Then the mixture was cooled to rt, EtOAc was added and it was 
filtered over celite. The volatiles were removed under reduced pressure 
and the crude mixture was purified with column chromatography (50 to 
75 % EtOAc in heptane) yielding THP-protected N-hydroxyacetamide S7 
(60 mg, 94 %) as a white solid. Rf = 0.24 (EtOAc/heptane 3:1, v/v). 1H NMR 
(500 MHz, 50 °C, CDCl3) δ 7.42 – 7.37 (m, 2H), 7.32 – 7.27 (m, 2H), 5.67 (s, 1H), 4.95 (t, J = 4.0 
Hz, 1H), 4.45 (d, J = 5.7 Hz, 2H), 3.80 – 3.71 (m, 1H), 3.44 – 3.36 (m, 1H), 3.28 (t, J = 6.8 Hz, 
2H), 2.27 – 2.17 (m, 5H), 1.88 – 1.67 (m, 5H), 1.67 – 1.59 (m, 2H), 1.59 – 1.49 (m, 3H), 1.48 
– 1.40 (m, 2H). 13C NMR (125 MHz, 50 °C, CDCl3) δ 172.6, 171.0, 139.9, 137.6, 128.4, 125.8, 
102.8, 63.8, 51.5, 43.4, 36.6, 29.0, 28.8, 26.6, 25.3, 25.1, 22.3, 19.7. HRMS (ESI) m/z calcd. for 
C20H29N5O4 [M+Na]+ 426.21172, found: 426.21127.
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O
N
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N3
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O N-(4-Acetamidobenzyl)-6-azidohexanamide (4). Iodobenzene S6 (50 
mg, 0.134 mmol, 1.0 equiv.) and acetamide (7.9 mg, 0.134 mmol, 1.0 equiv.) 
were dissolved in DMF (1.0 mL) and CuI (6.4 mg, 0.034 mmol, 0.25 equiv.), 
DMEDA (7.2 µL, 0.067 mmol, 0.5 equiv.), Cs2CO3 (61 mg, 0.188 mmol, 1.4 
equiv.) and molecular sieves (4 Å) were added and the reaction was heated 
at 80 °C o/n. After the mixture was cooled to rt, EtOAc was added and it 
was filtered over celite. Then the volatiles were removed under reduced 
pressure and the crude mixture was purified with column chromatography 
(60 % EtOAc/heptane to 100 % EtOAc) yielding acetamide 4 (20 mg, 49 
%) as a slightly yellow solid. Rf = 0.24 (EtOAc). 1H NMR (500 MHz, CDCl3) 
δ 7.48 – 7.42 (m, 2H), 7.25 – 7.18 (m, 3H), 5.69 (s, 1H), 4.39 (d, J = 5.7 Hz, 
2H), 3.27 (t, J = 6.9 Hz, 2H), 2.22 (t, J = 7.5 Hz, 2H), 2.17 (s, 3H), 1.74 – 1.64 (m, 2H), 1.65 – 1.58 
(m, 2H), 1.46 – 1.36 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 172.6, 168.4, 137.4, 134.4, 128.7, 
120.3, 51.4, 43.3, 36.6, 28.8, 26.5, 25.3, 24.8. HRMS (ESI) m/z calcd. for C15H21N5O2 [M+Na]+ 
326.15929, found: 326.15962.
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Scheme S3 – Synthesis of AHA probe 5 and AAA probe 6.
i) NaN3, DMF, 60 °C, 4 h, 89%; ii) PPh3, Et2O, EtOAc, 5% HCl (aq), 16 h, 37%; iii) EDC, HOBt, DIPEA, CH2Cl2, 16 h, quant; 
iv) CuI, DMEDA, Cs2CO3, DMF, 80 °C, 16 h, 90%; v) S1, CuI, DMEDA, Cs2CO3, DMF, 80 °C, 16 h, 63%; vi) 4 M HCl in dioxane, 
CH2Cl2, 2 h, 97%.
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N-(6-Azidohexyl)-4-iodobenzamide (S10). 6-Azidohexan-1-amine 
S9228 was synthesized from 1,6-dibromohexane via 1,6-diazidohexane 
S8211. Then, amine S9 (115 mg, 0.81 mmol, 1.0 equiv.) was dissolved in 
dry CH2Cl2 and 4-iodobenzoic acid (200 mg, 0.81 mmol, 1.0 equiv.), EDC 
hydrochloride (186 mg, 0.97 mmol, 1.2 equiv.), HOBt hydrate (148 mg, 
0.97 mmol, 1.2 equiv.) and DIPEA (421 µL, 2.42 mmol, 3.0 equiv.) were 
added and the mixture was stirred o/n. The solution was diluted with 
CH2Cl2 and washed with 1M HCl. The aqueous layer was extracted with 
CH2Cl2 (2x) and the combined organic layers were washed with sat. 
NaHCO3 and brine and dried with Na2SO4. The volatiles were removed 
in vacuo yielding amide S10 (308 mg, quant.) as an off-white solid. Rf = 0.59 (EtOAc/heptane 
1:1, v/v). 1H NMR (400 MHz, CDCl3) δ 7.81 – 7.75 (m, 2H), 7.51 – 7.45 (m, 2H), 6.11 (br. t, J = 5.9 
Hz, 1H), 3.44 (td, J = 7.2, 5.9 Hz, 2H), 3.27 (t, J = 6.8 Hz, 2H), 1.68 – 1.55 (m, 4H), 1.48 – 1.35 (m, 
4H). 13C NMR (100 MHz, CDCl3) δ 166.8, 137.9, 134.3, 128.6, 98.4, 51.5, 40.1, 29.7, 28.9, 26.7, 
26.6. HRMS (ESI) m/z calcd. for C13H17IN4O [M+Na]+ 395.03447, found: 395.03473.
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N-(6-Azidohexyl)-4-(N-((tetrahydro-2H-pyran-2-yl)oxy)-
acetamido)benzamide (S11). Iodobenzene S10 (60 mg, 0.161 mmol, 
1.2 equiv.) and THP-protected N-hydroxyacetamide S1 (21 mg, 0.134 
mmol, 1.0 equiv.) were dissolved in dry DMF (1.0 mL) and CuI (13 
mg, 0.067 mmol, 0.5 equiv.), DMEDA (11 µL, 0.10 mmol, 0.75 equiv.), 
Cs2CO3 (61 mg, 0.188 mmol, 1.4 equiv.) and molecular sieves (4 Å) 
were added and the reaction was heated at 80 °C o/n. The mixture was 
cooled down to rt, EtOAc was added and the suspension was filtered 
over celite. The volatiles were removed under reduced pressure and 
the crude mixture was purified with column chromatography (50 to 75 
% EtOAc in heptane) yielding THP-protected N-hydroxyacetamide S11 
3
(34 mg, 63 %) as a white solid. Rf = 0.27 (EtOAc/heptane 3:2, v/v). 1H NMR (500 MHz, 50 °C, 
CDCl3) δ 7.79 – 7.74 (m, 2H), 7.56 – 7.51 (m, 2H), 6.06 (s, 1H), 4.93 – 4.88 (m, 1H), 3.81 – 3.74 
(m, 1H), 3.46 (td, J = 7.2, 5.9 Hz, 2H), 3.42 – 3.36 (m, 1H), 3.27 (t, J = 6.8 Hz, 2H), 2.29 (s, 3H), 
1.89 – 1.69 (m, 3H), 1.69 – 1.59 (m, 4H), 1.59 – 1.53 (m, 3H), 1.50 – 1.37 (m, 4H). 13C NMR 
(125 MHz, 50 °C, CDCl3) δ 171.3, 167.0, 143.1, 133.0, 127.5, 124.0, 103.5, 64.3, 51.6, 40.2, 
29.8, 28.99, 29.05, 26.7, 26.6, 25.0, 22.4, 19.9. HRMS (ESI) m/z calcd. for C20H29N5O4 [M+Na]+ 
426.21172, found: 426.21202.
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N-(6-Azidohexyl)-4-(N-((tetrahydro-2H-pyran-2-yl)oxy)-
acetamido)benzamide (S11). Iodobenzene S10 (60 mg, 0.161 mmol, 
1.2 equiv.) and THP-protected N-hydroxyacetamide S1 (21 mg, 0.134 
mmol, 1.0 equiv.) were dissolved in dry DMF (1.0 mL) and CuI (13 
mg, 0.067 mmol, 0.5 equiv.), DMEDA (11 µL, 0.10 mmol, 0.75 equiv.), 
Cs2CO3 (61 mg, 0.188 mmol, 1.4 equiv.) and molecular sieves (4 Å) 
were added and the reaction was heated at 80 °C o/n. The mixture was 
cooled down to rt, EtOAc was added and the suspension was filtered 
over celite. The volatiles were removed under reduced pressure and 
the crude mixture was purified with column chromatography (50 to 75 
% EtOAc in heptane) yielding THP-protected N-hydroxyacetamide S11 
3
(60 % EtOAc/heptane to 100 % EtOAc) yielding acetamide 6 (37 mg, 90 %) as a white solid. 
Rf = 0.31 (EtOAc). 1H NMR (500 MHz, CDCl3) δ 7.75 – 7.69 (m, 2H), 7.61 – 7.54 (m, 2H), 7.50 
(s, 1H), 6.14 (br. t, J = 5.8 Hz, 1H), 3.45 (td, J = 7.2, 5.9 Hz, 2H), 3.27 (t, J = 6.9 Hz, 2H), 2.20 
(s, 3H), 1.67 – 1.59 (m, 4H), 1.47 – 1.36 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 168.6, 167.0, 
140.9, 130.3, 128.0, 119.3, 51.5, 40.1, 29.8, 28.9, 26.7, 26.6, 24.9. HRMS (ESI) m/z calcd. for 
C15H21N5O2 [M+Na]+ 326.15929, found: 326.15979.
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N-(6-Azidohexyl)-4-(N-hydroxyacetamido)benzamide (5). THP-protected probe S11 (30 mg, 0.074 mmol, 1.0 equiv.) was dissolved in dry 
CH2Cl2 (1.0 mL) and 4 M HCl in dioxane (186 µL, 0.74 mmol, 10.0 equiv.) 
was added. After the mixture had stirred for 2 h, the volatiles were removed under reduced pressure yielding N-hydroxyacetamide 5 (23 mg, 97 %) as 
a slightly yellow solid. 1H NMR (500 MHz, (CD3)2SO) δ 10.75 (s, 1H), 8.38 
(br. t, J = 5.6 Hz, 1H), 7.86 – 7.79 (m, 2H), 7.76 – 7.69 (m, 2H), 3.32 – 3.26 
(m, 2H), 3.28 – 3.18 (m, 2H), 2.24 (s, 3H), 1.59 – 1.43 (m, 4H), 1.40 – 1.25 
(m, 4H). 13C NMR (125 MHz, (CD3)2SO) δ 170.3, 165.4, 143.7, 130.1, 127.5, 
118.5, 50.6, 39.0, 29.0, 28.2, 26.0, 25.9, 22.8. HRMS (ESI) m/z calcd. for 
C15H21N5O3 [M+Na]+ 342.15421, found: 342.15477.
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4-Acetamido-N-(6-azidohexyl)benzamide (6). Iodobenzene S10 (50 
mg, 0.134 mmol, 1.0 equiv.) and acetamide (7.9 mg, 0.134 mmol, 1.0 equiv.) 
were dissolved in dry DMF (1.0 mL) and CuI (6.4 mg, 0.034 mmol, 0.25 
equiv.), DMEDA (7.2 µL, 0.067 mmol, 0.5 equiv.), Cs2CO3 (61 mg, 0.188 
mmol, 1.4 equiv.) and molecular sieves (4 Å) were added and the mixture 
was heated at 80 °C o/n. The conversion of S10 was not complete, so again 
CuI (12.8 mg, 0.067 mmol, 0.5 equiv.) and DMEDA (7.2µL, 0.067 mmol, 0.5 
equiv.) were added and the reaction was stirred again at 80 °C overnight. 
The mixture was cooled down to rt, EtOAc was added and the suspension 
was filtered over celite. The volatiles were removed under reduced 
pressure and the crude product was purified with column chromatography 
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BODIPY N-(4-((6-azidohexyl)oxy)phenyl)-N-hydroxyacetamide (7). 
THP protected hydroxamic acid probe S4 (15 mg, 53 µmol, 1.0 equiv.), 
alkynated BODIPY S12229 (12.5 mg, 64 µmol, 1.0 equiv.), CuSO
4
 (1.0 mg, 1.0 
µmol, 0.1 equiv.), and sodium ascorbate (1.6 mg, 5.0 µmol, 0.2 equiv.) were 
dissolved in DMF/H2O (9:1, 200 μL). After the mixture was stirred o/n at rt, 
the reaction was diluted with EtOAc and washed with H2O and brine, dried over Na2SO4 and then concentrated under reduced pressure. The brown 
solid was dissolved in EtOH (200 μL), PPTS (5.0 mg, 16 µmol, 0.5 equiv.) 
and the solution was heated o/n at 55 °C. The solvent was evaporated, and 
the mixture was purified using column chromatography (0 to 20% MeOH 
in EtOAc, v/v) yielding BODIPY hydroxyamic acid 7 as an orange solid (19 
mg, 79%). Rf = 0.33 (10% MeOH in EtOAc). 
1H NMR (500 MHz, CD3OD): δ 
7.73 (s, 1H), 7.29-7.26 (m, 2H), 6.79-6.75 (m, 2H), 6.00 (s, 2H), 4.29 (t, J = 
7.0 Hz, 2H), 3.88-3.85 (m, 2H), 2.94-2.91 (m, 2H), 2.80 (t, J = 7.1 Hz, 2H), 
2.33 (s, 6H), 2.25-2.10 (m, 9H), 1.86-1.81 (m, 4H), 1.70-1.65 (m, 2H), 1.47-1.41 (m, 2H), 1.32-
1.27 (m, 2H). HRMS (ESI): Calculated for C32H41BF2N6O3 [M+Na]+ 629.3235, found 629.3224.
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Scheme S4 – Synthesis of AHA and AAA probes 7-10.
i) a) N-hydroxysuccinimide, EDC, DMF, 16 h, rt; b) Propargyl amine, Me3N, DMF, 16 h, rt, 96%; For AHA probe 7: ii) CuSO4, 
sodium ascorbate, DMF/H2O, 16 h, rt; For AHA probe 9: iii) CuSO4, sodium ascorbate, H2O/tBuOH, 16 h, rt; iv) PPTS, 
EtOH, 16 h, 55 °C, AHA probe 7: 79% or AHA probe 9: 40%; For AAA probe 8: v) CuSO
4
, sodium ascorbate, H2O/tBuOH, 
16 h, rt, 47%; For AAA probe 10: vi) CuSO
4
, sodium ascorbate, H2O/tBuOH/DMF, 16 h, rt, 78%. 
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BODIPY N-(4-((6-azidohexyl)oxy)phenyl)acetamide (8). Acetamide probe 2 (22 mg, 80 μmol, 1.0 equiv.) was dissolved in H2O/
tBuOH (1:1, 300 μL) and alkynated BODIPY S12229 (25 mg, 80 μmol, 1.0 
equiv.), CuSO4 (0.50 mg, 2.0 µmol, 0.025 equiv.), and sodium ascorbate 
(1.6 mg, 8.0 µmol, 0.1 equiv.) were added. The mixture was stirred o/n 
at rt, concentrated, and purified by column chromatography (50 to 100 
% EtOAc in heptane, v/v) yielding BODIPY acetamide 8 as an orange 
solid (22 mg, 47%). Rf = 0.40 (100% EtOAc). 
1H NMR (500 MHz, CDCl3) 
δ 7.23 – 7.20 (m, 2H), 7.19 (s, 1H), 7.18 (s, 1H), 6.72 – 6.66 (m, 2H), 
5.95 (s, 2H), 4.27 (t, J = 7.0 Hz, 2H), 3.82 (t, J = 6.2 Hz, 2H), 2.94 – 2.86 
(m, 2H), 2.82 (t, J = 7.2 Hz, 2H), 2.44 (s, 6H), 2.20 (s, 6H), 2.03 (s, 3H), 
1.92 – 1.79 (m, 4H), 1.72 – 1.64 (m, 2H), 1.49 – 1.40 (m, 2H), 1.36 – 1.26 
(m, 2H).13C NMR (126 MHz, CDCl3) δ 168.3, 155.8, 154.0, 146.8, 146.0, 
140.6, 131.6, 131.2, 121.9, 121.8, 121.0, 114.7, 67.7, 50.2, 31.8, 30.4, 
29.0, 27.9, 26.2, 26.1, 25.6, 24.4, 16.4, 14.6. HRMS (ESI): Calculated for 
C32H41BF2N6O2 [M+Na]+ 613.32498, found 613.32429.
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Biotinylated N-(4-((6-azidohexyl)oxy)phenyl)acetamide (10). Acetamide probe 2 (30.0 mg, 0.11 mmol, 1.0 equiv.) was dissolved 
in H2O/tBuOH/DMF (1:1:1, 1.5 mL) and alkynated biotin 14 (36.6 
mg, 0.13 mmol, 1.2 equiv.), CuSO
4
 (0.68 mg, 2.7 µmol, 0.025 equiv.), 
and sodium ascorbate (2.15 mg, 11 µmol, 0.1 equiv.) were added. 
The mixture was stirred o/n at rt, concentrated, and purified by 
column chromatography (0 to 20% MeOH in CH2Cl2, v/v) yielding the biotinylated acetamide 10 as a white solid (48 mg, 78%). Rf = 0.48 
(10% MeOH in CH2Cl2, v/v). 1H NMR (500 MHz, CD3OD) δ 7.91 (s, 1H), 
N
H
NHO H
HN
H S
O Alkynated biotin (14). Biotin (200 mg, 0.82 mmol, 1.0 equiv.) 
was dissolved in dry DMF (10 mL) and N-hydroxysuccinimide 
(104 mg, 0.90 mmol, 1.1 equiv.) and 1-(3-dimethylaminopropyl)-
3-ethylcarbodimide hydro-chloride (EDC, 188 mg, 0.98 mmol, 
1.2 equiv.) were added. After the mixture was stirred o/n at rt, the reaction was concentrated 
and washed with methanol (3x). The solvent was removed under reduced pressure yielding 
biotin-OSu, which was directly applied in the next step without further purification. The 
biotin-OSu was dissolved in DMF (7.8 mL) and Et3N (159 µL, 1.17 mmol, 3.0 equiv.) and 
propargyl amine (37 µL, 0.88 mmol, 2.3 equiv.) were added. After the mixture was stirred 
o/n at rt, the volatiles were removed under reduced pressure. The crude solid was purified 
by column chromatography (15% MeOH in CH2Cl2, v/v) yielding the alkynated biotin 14 as a 
white solid (102 mg, 96%). Rf = 0.23 (5% MeOH in CH2Cl2, v/v). 1H NMR (500 MHz, CD3OD) δ 
4.52 – 4.45 (m, 1H), 4.34 – 4.27 (m, 1H), 3.96 – 3.93 (m, 2H), 3.25 – 3.17 (m, 1H), 2.97 – 2.88 
(m, 1H), 2.74 – 2.67 (m, 1H), 2.59 – 2.55 (m, 1H), 2.25 – 2.17 (m, 2H), 1.79 – 1.54 (m, 4H), 
1.50 – 1.39 (m, 2H). 13C NMR (125 MHz, CD3OD) δ 175.6, 166.1, 80.7, 72.1, 63.4, 61.6, 57.0, 
41.0, 36.5, 29.7, 29.5, 29.4, 26.7. LRMS (ESI+) m/z calcd. for C13H19N3O2S [M+H]+ 282.1, found: 
282.1. The data agrees with the reported literature values.216
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Biotinylated N-(4-((6-azidohexyl)oxy)phenyl)-N-hydroxy-
acetamide (9). THP protected hydroxamic acid probe S4 (20 mg, 53 
µmol, 1.0 equiv.), alkynated biotin 14 (18 mg, 64 µmol, 1.2 equiv.), 
CuSO
4
 (0.33 mg, 1.0 µmol, 0.025 equiv.), and sodium ascorbate (1.1 
mg, 5.0 µmol, 0.1 equiv.) were dissolved in H2O/tBuOH (1:1, 1.5 mL). 
After the mixture was stirred o/n at rt, the reaction was diluted with 
CH2Cl2 and washed by H2O (3× 10 mL), dried over Na2SO4 and then 
concentrated under reduced pressure. The brown solid was dissolved 
in EtOH (1.0 mL), PTTS (4.0 mg, 16 µmol, 0.3 equiv.) and the solution 
was heated o/n at 55 °C. The solvent was evaporated, and the mixture was purified using column 
chromatography (0 to 20% MeOH/CH2Cl2, v/v) yielding biotinylated hydroxyamic acid 9 as a 
brown solid (12 mg, 40%). Rf = 0.38 (10% MeOH in CH2Cl2). 1H NMR (500 MHz, CD3OD) δ 7.74 
(s, 1H), 7.64 – 7.58 (m, 2H), 7.28 (br. s, 1H), 7.17 – 7.11 (m, 3H), 6.81 (br. s, 1H), 4.38 (dd, J = 
7.8, 4.9 Hz, 1H), 4.33 – 4.26 (m, 3H), 4.18 (dd, J = 7.9, 4.4 Hz, 1H), 3.88 (t, J = 5.6 Hz, 2H), 3.10 
– 3.05 (m, 1H), 2.81 (dd, J = 12.7, 4.9 Hz, 1H), 2.59 (d, J = 12.7 Hz, 1H), 2.27 (s, 3H), 2.13 (t, J 
= 7.4 Hz, 3H), 1.83 (p, J = 7.1 Hz, 2H), 1.71 – 1.37 (m, 8H), 1.36 – 1.20 (m, 4H). 13C NMR (125 
MHz, CD3OD) δ 176.0, 166.5, 146.3, 143.4, 141.8, 129.8, 127.0, 124.2, 69.1, 63.4, 61.6, 57.0, 
51.3, 41.1, 36.5, 35.6, 31.2, 30.1, 29.7, 29.5, 27.2, 26.7, 26.6, 21.3. Peak of quaternary carbon 
of the acetyl is missing. HRMS (ESI+) m/z calcd. for C
27
H39N7O5S [M+Na]+ 596.26311, found: 
596.26359.
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7.34 – 7.22 (m, 2H), 6.79 – 6.64 (m, 2H), 4.38 (dd, J = 7.8, 4.8 Hz, 1H), 4.32 (t, J = 6.8 Hz, 3H), 
4.19 (dd, J = 7.9, 4.4 Hz, 1H), 3.83 (t, J = 6.3 Hz, 2H), 3.10 (dd, J = 8.1, 3.1 Hz, 1H), 2.82 (dd, J 
= 12.7, 5.0 Hz, 1H), 2.63 – 2.56 (m, 1H), 2.23 – 2.13 (m, 2H), 1.99 (s, 3H), 1.88 – 1.79 (m, 2H), 
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1.70 – 1.37 (m, 8H), 1.37 – 1.21 (m, 4H). 13C NMR (125 MHz, CD3OD) δ 170.0, 155.9, 131.4, 
121.6, 114.2, 67.6, 66.7, 61.9, 60.3, 55.6, 50.2, 39.6, 35.9, 29.7, 28.7, 28.3, 28.0, 25.8, 25.3, 
25.2, 22.1 (4 peaks are missing). HRMS (ESI+) m/z calcd. for C
27
H39N7O4S [M+Na]+ 580.26819, 
found: 580.26861.
Design and cloning of H6-hNAT1 and GST-hNAT2
For the expression and purification of hNAT1 and hNAT2 in E. coli, the gene encoding hNAT1 
or hNAT2 was cloned in the pET-30A (+) vector containing a T7 promoter and a N-terminal 
histidine tag. hNAT2 was as well introduced in the pGEX4T-1 vector having a T7 promoter 
and a N-terminal GST tag. First, BamHI restriction site and TEV cleavage site (sequence: 
ENLYFQSG) were introduced at the N-terminus of the hNAT genes and NotI restriction site at 
the C-terminus. Subsequently, the BamHI-TEVsite-hNAT1-NotI or BamHI-TEVsite-hNAt2-NotI 
insert were cloned by standard techniques in the pET30A or pGEX-4T1 vector. Oligonucleotide 
primers and gBlock fragments encoding the hNAT1 gene were synthesized by Integrated DNA 
Technologies (Supplementary Table S1-3).
PCR reactions were conducted with 1× HF Buffer (New England Biolabs), 1 unit of Phusion 
polymerase, 20 ng of DNA template, 100 µM dNTP, 10 pmol of each of the primers in a total volume of 50 µL. The reaction mixtures were heated at 98 °C for 30 sec, followed by 25 cycles 
for 20 sec at 98 °C, 30 sec at 58 °C, and 2 min at 72 °C. To ensure complete extension, the 
reaction mixture was incubated at 72 °C for 4 min after the 25 cycles. The PCR products were 
purified with a QIAquick PCR purification kit (Qiagen). Subsequently, the PCR products and 
the plasmid vector were digested with 2 units of each restriction enzyme for 1 h at 37 °C. 
The digestion products were isolated with a QIAquick gel extraction kit (Qiagen). The vector 
DNA (50 ng) was ligated with one of the hNAT1 inserts (30 ng) with T4 Ligase (New England 
Biolabs) o/n at 16 °C. After heat inactivation of T4 Ligase (20 min at 65 °C), supercompetent 
Top 10 cells were transformed with the ligation mix (25 ng vector) and selected for the 
correct antibiotic resistance. The plasmids from positive colonies were isolated with the 
Miniprep DNA purification system (Qiagen) and sequences were verified by automated DNA 
sequencing (RadboudUMC sequence facility Nijmegen, the Netherlands).
Expression	and	purification	of	the	tagged	hNAT1	and	hNAT2	enzymes
The gene encoding hNAT1 or hNAT2 was cloned into a pET30a plasmid containing a 
hexahistidine (H
6
) tag (see section “Design and cloning of H
6
-hNAT1”). The pET-30 hNAT 
expression vectors were transformed into E. coli BL21 Rosetta(DE3) pLysS cells and selected 
for chloramphenicol and kanamycin resistance, the pGEX-4T1 vector encoding hNAT2 
was as well transformed into E. coli BL21 Rosetta (DE3) pLysS cells though selected for 
chloramphenicol and ampicillin. A single colony was inoculated in LB-medium (100 mL) 
supplemented with chloramphenicol (25 µg/mL) and kanamycin (50 µg/mL) or ampicillin 
(100 µg/mL) and grown o/n at 37 °C, 200 rpm. 20 mL of o/n culture was used to inoculate 
TB-medium (1 L) supplemented with kanamycin (50 µg/mL) or ampicillin (100 µg/mL). 
Cultures were then incubated at 37 °C until the optical density at 600 nm (OD
600
) reached 
0.6-0.8 (3-4 h). Protein expression was induced by adding 150 µL of 1 M isopropyl β-D-1-
thiogalactopyranoside (IPTG; Fisher Scientific) for 16 h at 18 °C. Cells were harvested at 5,000 
rpm for 20 min at 4 °C and pellet was resuspended in 30 mL of ice cold lysis buffer (100 mM 
NaH2PO4 pH 7.8, 300 mM NaCl, 0.1% NP-40, freshly added 1 mM dithiotheitol (DTT)) and 
stored at -80 °C. 
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1.70 – 1.37 (m, 8H), 1.37 – 1.21 (m, 4H). 13C NMR (125 MHz, CD3OD) δ 170.0, 155.9, 131.4, 
121.6, 114.2, 67.6, 66.7, 61.9, 60.3, 55.6, 50.2, 39.6, 35.9, 29.7, 28.7, 28.3, 28.0, 25.8, 25.3, 
25.2, 22.1 (4 peaks are missing). HRMS (ESI+) m/z calcd. for C
27
H39N7O4S [M+Na]+ 580.26819, 
found: 580.26861.
Design and cloning of H6-hNAT1 and GST-hNAT2
For the expression and purification of hNAT1 and hNAT2 in E. coli, the gene encoding hNAT1 
or hNAT2 was cloned in the pET-30A (+) vector containing a T7 promoter and a N-terminal 
histidine tag. hNAT2 was as well introduced in the pGEX4T-1 vector having a T7 promoter 
and a N-terminal GST tag. First, BamHI restriction site and TEV cleavage site (sequence: 
ENLYFQSG) were introduced at the N-terminus of the hNAT genes and NotI restriction site at 
the C-terminus. Subsequently, the BamHI-TEVsite-hNAT1-NotI or BamHI-TEVsite-hNAt2-NotI 
insert were cloned by standard techniques in the pET30A or pGEX-4T1 vector. Oligonucleotide 
primers and gBlock fragments encoding the hNAT1 gene were synthesized by Integrated DNA 
Technologies (Supplementary Table S1-3).
PCR reactions were conducted with 1× HF Buffer (New England Biolabs), 1 unit of Phusion 
polymerase, 20 ng of DNA template, 100 µM dNTP, 10 pmol of each of the primers in a total volume of 50 µL. The reaction mixtures were heated at 98 °C for 30 sec, followed by 25 cycles 
for 20 sec at 98 °C, 30 sec at 58 °C, and 2 min at 72 °C. To ensure complete extension, the 
reaction mixture was incubated at 72 °C for 4 min after the 25 cycles. The PCR products were 
purified with a QIAquick PCR purification kit (Qiagen). Subsequently, the PCR products and 
the plasmid vector were digested with 2 units of each restriction enzyme for 1 h at 37 °C. 
The digestion products were isolated with a QIAquick gel extraction kit (Qiagen). The vector 
DNA (50 ng) was ligated with one of the hNAT1 inserts (30 ng) with T4 Ligase (New England 
Biolabs) o/n at 16 °C. After heat inactivation of T4 Ligase (20 min at 65 °C), supercompetent 
Top 10 cells were transformed with the ligation mix (25 ng vector) and selected for the 
correct antibiotic resistance. The plasmids from positive colonies were isolated with the 
Miniprep DNA purification system (Qiagen) and sequences were verified by automated DNA 
sequencing (RadboudUMC sequence facility Nijmegen, the Netherlands).
Expression	and	purification	of	the	tagged	hNAT1	and	hNAT2	enzymes
The gene encoding hNAT1 or hNAT2 was cloned into a pET30a plasmid containing a 
hexahistidine (H
6
) tag (see section “Design and cloning of H
6
-hNAT1”). The pET-30 hNAT 
expression vectors were transformed into E. coli BL21 Rosetta(DE3) pLysS cells and selected 
for chloramphenicol and kanamycin resistance, the pGEX-4T1 vector encoding hNAT2 
was as well transformed into E. coli BL21 Rosetta (DE3) pLysS cells though selected for 
chloramphenicol and ampicillin. A single colony was inoculated in LB-medium (100 mL) 
supplemented with chloramphenicol (25 µg/mL) and kanamycin (50 µg/mL) or ampicillin 
(100 µg/mL) and grown o/n at 37 °C, 200 rpm. 20 mL of o/n culture was used to inoculate 
TB-medium (1 L) supplemented with kanamycin (50 µg/mL) or ampicillin (100 µg/mL). 
Cultures were then incubated at 37 °C until the optical density at 600 nm (OD
600
) reached 
0.6-0.8 (3-4 h). Protein expression was induced by adding 150 µL of 1 M isopropyl β-D-1-
thiogalactopyranoside (IPTG; Fisher Scientific) for 16 h at 18 °C. Cells were harvested at 5,000 
rpm for 20 min at 4 °C and pellet was resuspended in 30 mL of ice cold lysis buffer (100 mM 
NaH2PO4 pH 7.8, 300 mM NaCl, 0.1% NP-40, freshly added 1 mM dithiotheitol (DTT)) and 
stored at -80 °C. 
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After the H
6
-hNAT1/H
6
-hNAT2 or GST-hNAT2 bacterial lysate was thawed at 37 °C, cells 
were further lysed by ultrasonic disruption (3× 30 sec) using a Soniprep 150 (MSE) with 
a 9.5 mm probe. The cell lysate was clarified by centrifugation (4 °C, 30 min, 13,000 rpm) 
and the supernatant was incubated for 1 h at 4 °C with 500 µL Ni-NTA agarose beads (50% 
suspension, GE Healthcare) for histidine-tagged proteins or 500 µL glutathione sepharose 
(50 % suspension, GE Healthcare) in case of GST-hNAT2. The suspension was then loaded 
onto a column and washed three times with 3 mL of histidine wash buffer (100 mM NaH2PO4 
pH 7.8, 300 mM NaCl, 10 mM imidazole, 0.1% NP-40, and freshly added 1 mM DTT) or GST 
wash buffer (100 mM NaH2PO4 pH 7.8, 300 mM NaCl, 0.1% NP-40, and freshly added 1 mM 
DTT). Subsequently, the proteins were eluted in six fractions of 1 mL histidine elution buffer 
(50 mM NaH2PO4 pH 7.8, 300 mM NaCl, 250 mM imidazole, and freshly added 1 mM DTT) or 
GST elution buffer (50 mM NaH2PO4 pH 7.8, 300 mM NaCl, and freshly added 10 mM reduced 
GSH and 1 mM DTT). All fractions of the affinity purification were analyzed on SDS-PAGE gel 
by colloidal staining and western blot. The western blot was stained against anti-His mouse 
(1:3,000; Amersham Pharmacia Biotech), anti-GST mouse (1:3,000; X) and anti-hNAT rabbit 
(1:1,000; Abcam), visualized by goat anti-mouse IRDye 680 LT (1:5,000; Li-Cor) and goat anti-
rabbit IRDye800 CW (1:5,000; Li-Cor), and measured on the Odyssey® CLx.
The elution fractions were combined and dialyzed at 4 °C using Amicon® Ultra-15 Centrifugal 
Filter (10,000 NMWL; Merck Millipore) against storage buffer (20 mM Tris-HCl pH 7.8, 
100 mM NaCl, 1 mM EDTA, and freshly added 1 mM DTT). The protein concentration was 
determined at 280 nm (ε = 44,600 M-1c-1) and concentrated to 1 mg/mL using the centrifugal 
filters. Fractions containing hNAT1 or hNAT2 were flash frozen at 1 mg/mL with 5% glycerol 
and stored at -80 °C for maximal two months. The mass of the H
6
-hNAT1 was confirmed by 
electron spray ionization time-of-flight (ESI-TOF) on a JEOL AccuTOF with Agilent (1100 
series HPLC). ESI-TOF: H
6
-NAT 40,138 Da, found 40,138 Da.
An attempt was made to purify the stored H
6
-hNAT1 further by size-exclusion chromatography 
using a Superdex200 column. After the column was prewashed with storage buffer without 
DTT, 100 µL of 1 mg/mL H
6
-hNAT1 was loaded on the column, that collected fractions of 250 
µL in a 96-well plate at 4 °C. Afterwards, 2.5 µL of 5× sample buffer was added to 10 µL of each 
fraction and boiled for 10 min at 96 °C. 5 µL of each fraction was loaded on 12 % SDS-PAGE gel 
and stained by a standard silver stain protocol.
Preparation for the LC-MS/MS sample – To 5 µL of 2 mg/mL H
6
-hNAT1 (10 µg), 100 µL of 8 M 
Urea/100 mM NH
4
HCO3 (prepared fresh) was added and incubated for 30 min at rt. The free 
cysteines were then reduced with 0.6 µL of 1 M DTT for 30 min at 37 °C and alkylated with 3.5 
µL of 0.5 M iodoacetamide for 30 min at rt in the dark. The sample was then diluted to 1 mL 
with 10 mM NH
4
HCO3 pH 8 (prepared fresh) and incubated o/n with 30 ng of trypsin enzyme 
at 37 °C. The reaction was stopped by adding 5 µL of pure formic acid (95-97%) to adjust the 
pH (pH 3), and prepared and measured in Leiden by dr. Bobby I. Florea.
In vitro labeling using recombinant hNAT enzymes
Tagging of proteins by recombinant H
6
-hNAT1 or GST-hNAT2 was started by adding 2 µL of 500 µM of 1 mM AHA or AAA probe 1-10 (dissolved in DMSO as 50 mM stocks; concentration 
as indicated in Figure legends) to 18 µL of H
6
-hNAT1 enzyme (1 mg/mL). After incubation for 
different time points at 30 °C, the reaction was stopped by adding 2 µL MQ and 3 µL of blockers, containing 1 µL of 25 mM N-hydroxy-N-phenylacetamide217 (500 mM stock in DMSO), 1 µL of 
250 mM aniline (diluted in DMSO), and 1 µL of 2,5 M imidazole (for a final concentration of 1 
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mM N-hydroxy-N-phenylacetamide217, 10 mM aniline, and 100 mM imidazole).
SPAAC reaction with labeled proteins using probes 1-6 – To block reduced cysteines, samples 
were alkylated by adding 3 µL of 500 mM iodoacetamide (prepared fresh, 50 mM final) and 2 
µL of MQ (final volume 30 µL) for 30 min on ice. Then, the SPAAC reaction was performed for 2 h on ice by adding either 5 µL of 70 µM DBCO-Cy5.5 11 (10 mM stock in DMSO; 10 µM final; 
dibenzocyclooctyne-Cyanine5.5; Jena Bioscience) to the samples (total volume of 35 µL). In 
case of the optimizing reactions, different concentrations of 2 µL DBCO-Cy5.5 11 were used: 50 µM, 500 µM or 5 mM for DBCO-Cy5.5 11.
CuAAC reaction with labeled proteins using probes 1-6 – As for the SPAAC reaction, the CuAAC 
reaction was performed for 2 h on ice by adding first 8 µL of CuAAC mastermix and then 2 µL 
of 175 mM sodium ascorbate (prepared fresh). The CuAAC mastermix contained 2 µL of 35 
mM 2-(4-((bis((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)amino)methyl)-1H-1,2,3-triazol-
1-yl)acetic acid (BTTAA; dissolved in MQ; Jena Bioscience), 1 µL of 35 mM CuSO
4
, and 5 µL of 
70 µM Cy5.5-alkyne 12 (10 mM stock in DMSO; Cyanine5.5-alkyne; Jena Bioscience), resulting 
in final concentrations of 2 mM BTTAA, 1 mM CuSO
4
, 10 µM Cy5.5-alkyne 12, and 10 mM 
sodium ascorbate.
Visualizing labeled proteins using probes 1-10 – All samples were prepared for SDS-PAGE 
gel after the NAT labeling reaction optionally followed by bioorthogonal click chemistry by adding 10 µL of 5× sample buffer to all samples for a total volume of 50 µL. Samples (7.5 µL) 
were directly loaded and analyzed on 10 % SDS-PAGE gel. 
In-gel fluorescence of the SDS-PAGE gel of the SPAAC and CuAAC reactions were measured 
at 700 nm on the Odyssey® CLx (LI-COR®), whereas in-gel fluorescence of BODIPY labeled 
samples was measured at 488 nm on the Typhoon Trio+ (GE Healthcare Life Sciences) followed 
by colloidal staining of the proteins as a loading control. In case of SDS-PAGE gels loaded with 
biotinylated samples, SDS-PAGE gel was transferred to nitrocellulose by standard western 
blotting. Protein loading was first visualized by Ponceau S staining, which was removed by 
several washes with demi water. After blocking the blot with 3 % BSA in 1× PBS overnight at 
rt, the blot was stained against biotin using streptavidin IR-Dye 800 CW (1:3,000; LI-COR) for 
1 h at rt and measured on the Odyssey® CLx.
Enrichment of biotinylated hNAT1
SPAAC reaction using DBCO-biotin 13 – 9 µL of hNAT1 (1 mg/mL) was incubated with 1 µL 
of DMSO, or 1 µL of AHA probe 1 or AAA probe 2 (10 mM stock in DMSO) for 1 h at 30 °C. 
Subsequently, the excess of probe was removed by a precipitation protocol: 1) add 400 µL 
methanol, vortex briefly; 2) add 100 µL chloroform, vortex briefly; 3) add 300 µL MQ, vortex 
briefly 4) Centrifuge for 2 min at 9,000 rpm, remove the upper layer; 5) Add 300 µL methanol 
and mix gently; 6) Centrifuge for 2 min at 9,000 rpm, remove the supernatant, and air-dry the 
pellet for maximal 5 min. The protein pellet was then resuspended in 25 µL of freshly prepared 
6 M urea and 25 mM NH
4
-HCO3 and incubated for 15 min at rt. Subsequently, all cysteines 
were reduced by incubating the sample with 0.5 µL of 0.5 M DTT at 65 °C for 15 min followed 
by blocking of the cysteines by adding 2.5 µL of freshly prepared 500 mM iodoacetamide for 
30 min at rt in the dark. After blocking cysteines, the protein samples were precipitated again 
using the similar protocol as described above, resuspended in 20 µL of 0.5 % SDS and diluted in a total volume of 110 µL with streptavidin binding buffer (50 mM Tris-HCl pH 7.5, 150 mM 
NaCl). The SPAAC test reactions were performed for 2 h at 4 °C using 50 µL of 1 mM, 2 mM 
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mM N-hydroxy-N-phenylacetamide217, 10 mM aniline, and 100 mM imidazole).
SPAAC reaction with labeled proteins using probes 1-6 – To block reduced cysteines, samples 
were alkylated by adding 3 µL of 500 mM iodoacetamide (prepared fresh, 50 mM final) and 2 
µL of MQ (final volume 30 µL) for 30 min on ice. Then, the SPAAC reaction was performed for 2 h on ice by adding either 5 µL of 70 µM DBCO-Cy5.5 11 (10 mM stock in DMSO; 10 µM final; 
dibenzocyclooctyne-Cyanine5.5; Jena Bioscience) to the samples (total volume of 35 µL). In 
case of the optimizing reactions, different concentrations of 2 µL DBCO-Cy5.5 11 were used: 50 µM, 500 µM or 5 mM for DBCO-Cy5.5 11.
CuAAC reaction with labeled proteins using probes 1-6 – As for the SPAAC reaction, the CuAAC 
reaction was performed for 2 h on ice by adding first 8 µL of CuAAC mastermix and then 2 µL 
of 175 mM sodium ascorbate (prepared fresh). The CuAAC mastermix contained 2 µL of 35 
mM 2-(4-((bis((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)amino)methyl)-1H-1,2,3-triazol-
1-yl)acetic acid (BTTAA; dissolved in MQ; Jena Bioscience), 1 µL of 35 mM CuSO
4
, and 5 µL of 
70 µM Cy5.5-alkyne 12 (10 mM stock in DMSO; Cyanine5.5-alkyne; Jena Bioscience), resulting 
in final concentrations of 2 mM BTTAA, 1 mM CuSO
4
, 10 µM Cy5.5-alkyne 12, and 10 mM 
sodium ascorbate.
Visualizing labeled proteins using probes 1-10 – All samples were prepared for SDS-PAGE 
gel after the NAT labeling reaction optionally followed by bioorthogonal click chemistry by adding 10 µL of 5× sample buffer to all samples for a total volume of 50 µL. Samples (7.5 µL) 
were directly loaded and analyzed on 10 % SDS-PAGE gel. 
In-gel fluorescence of the SDS-PAGE gel of the SPAAC and CuAAC reactions were measured 
at 700 nm on the Odyssey® CLx (LI-COR®), whereas in-gel fluorescence of BODIPY labeled 
samples was measured at 488 nm on the Typhoon Trio+ (GE Healthcare Life Sciences) followed 
by colloidal staining of the proteins as a loading control. In case of SDS-PAGE gels loaded with 
biotinylated samples, SDS-PAGE gel was transferred to nitrocellulose by standard western 
blotting. Protein loading was first visualized by Ponceau S staining, which was removed by 
several washes with demi water. After blocking the blot with 3 % BSA in 1× PBS overnight at 
rt, the blot was stained against biotin using streptavidin IR-Dye 800 CW (1:3,000; LI-COR) for 
1 h at rt and measured on the Odyssey® CLx.
Enrichment of biotinylated hNAT1
SPAAC reaction using DBCO-biotin 13 – 9 µL of hNAT1 (1 mg/mL) was incubated with 1 µL 
of DMSO, or 1 µL of AHA probe 1 or AAA probe 2 (10 mM stock in DMSO) for 1 h at 30 °C. 
Subsequently, the excess of probe was removed by a precipitation protocol: 1) add 400 µL 
methanol, vortex briefly; 2) add 100 µL chloroform, vortex briefly; 3) add 300 µL MQ, vortex 
briefly 4) Centrifuge for 2 min at 9,000 rpm, remove the upper layer; 5) Add 300 µL methanol 
and mix gently; 6) Centrifuge for 2 min at 9,000 rpm, remove the supernatant, and air-dry the 
pellet for maximal 5 min. The protein pellet was then resuspended in 25 µL of freshly prepared 
6 M urea and 25 mM NH
4
-HCO3 and incubated for 15 min at rt. Subsequently, all cysteines 
were reduced by incubating the sample with 0.5 µL of 0.5 M DTT at 65 °C for 15 min followed 
by blocking of the cysteines by adding 2.5 µL of freshly prepared 500 mM iodoacetamide for 
30 min at rt in the dark. After blocking cysteines, the protein samples were precipitated again 
using the similar protocol as described above, resuspended in 20 µL of 0.5 % SDS and diluted in a total volume of 110 µL with streptavidin binding buffer (50 mM Tris-HCl pH 7.5, 150 mM 
NaCl). The SPAAC test reactions were performed for 2 h at 4 °C using 50 µL of 1 mM, 2 mM 
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or 50 mM of DBCO-biotin 13 (50 mM stock in DMSO; Dibenzylcyclooctyne-S-S-PEG3-Biotin; 
DBCO-S-S-PEG3-biotin; Jena Bioscience). To the SPAAC mix, 40 µL of 5× sample buffer without 
reducing reagents was added (final volume 200 µL) and 50 µL was loaded on a 1.5 mm 10 % 
SDS-PAGE gel.
Optimization conditions tested for enrichment of the SPAAC reaction – Extra wash steps 
were included in the protein precipitation method to remove the excess of unreacted AHA 
probe using pure MeOH. Instead of dialyzing and concentrating the samples by the protein 
precipitation method, proteins were dialyzed and concentrated at 4 °C using Amicon® 
Ultra-0.5 Centrifugal Filter (10,000 NMWL; Merck Millipore). Before dialysis to the 
streptavidin binding buffer using the 10 kDa filter, storage buffer was added to the protein 
to dilute the DMSO concentration and we included extra wash steps to remove AHA probe 
using stringent conditions (2 % SDS). We reduced cysteines also directly after removal of 
AHA probe by incubating the sample with 2.5 µL of freshly prepared 500 mM iodoacetamide 
for 30 min at rt in the dark. In between the iodoacetamide treatment and the SPAAC reaction, 
we have tested whether an extra protein precipitation step helped to remove the excess 
iodoacetamide and performed the SPAAC reaction in storage buffer or 1× PBS. Besides testing 
the SPAAC reaction using various amounts of DBCO-biotin 13, we have also tested DBCO-PEG4-
biotin (Sigma Aldrich) in parallel at a molar ratio of 1:2 AHA probe:DBCO-biotin. Note: none of 
these optimization conditions did improve the SPAAC reaction.
CuAAC reaction using biotin-alkyne 14 – 18 µL of hNAT1 (1 mg/mL) was incubated with 2 µL 
of storage buffer, 2 µL of DMSO, or 2 µL of AHA probe 1 or AAA probe 2 (10 mM or 1 mM stock 
in DMSO) for 1 h at 30 °C. The excess of probe was removed by dialyzing the samples to RIPA 
buffer using Amicon® Ultra-0.5 mL Centrifugal Filter (3,000 NMWL; Merck Millipore) and 
then to MQ. To 19 µL of the labeled hNAT1 sample, 24 µL of MQ and 11 µL CuAAC mastermix 
was added: 6 µL of 50 mM CuSO
4
, 3 µL of 200 mM BTTAA, and 2 µL of 50 mM biotin-alkyne 
14 or 5 mM Cy5.5-alkyne 12. The CuAAC reaction was then initiated by adding 6 µL of 500 
mM sodium ascorbate. Final concentrations were then 5 mM CuSO
4
, 10 mM BTTAA, 1.5 mM 
biotin-alkyne 14 or 0.15 mM Cy5.5-alkyne 12, and 50 mM sodium ascorbate. After reaction 
o/n in the fridge, 5 µL of 5× of sample buffer was added to 16 µL of the CuAAC hNAT1 mix in a total volume of 25 µL and loaded 10 µL of this sample mix on 10 % SDS-PAGE gel.
For both the SPAAC and CuAAC experiments, the SDS-PAGE gel was transferred to 
nitrocellulose by standard western blotting. Protein loading was first visualized by Ponceau S 
staining, which was removed by several washes with demi water. After blocking the blot with 
3 % BSA in 1× PBS overnight at rt, the blot was stained against biotin using streptavidin IR-
Dye 800 CW (1:3,000; LI-COR) for 1 h at rt and measured on the Odyssey® CLx.
Biotinylation of hNAT1 using AHA probe 9 – 36 µL of H
6
-hNAT1 (1 mg/mL) with 4 µL DMSO, or 
4 µL of 0.5 mM, 5 mM, or 50 mM AHA probe 9 or 50 mM AAA probe 10 (50 mM stock in DMSO) for 1 h at 30 °C. The samples were dialyzed to the streptavidin binding buffer using Amicon® 
Ultra-0.5 Centrifugal Filter with a cut-off of 10 kDa (Merck Milipore) and concentrated to 50 
µL. Of the concentrated sample, 2.5 µL was taken and 2 µL of 5× sample buffer and 5.5 µL MQ 
was added (input samples on gel). In addition, 10 µL of streptavidin magnetic beads slurry 
(Thermo Fisher Scientific) were three times washed with the streptavidin binding buffer and 
diluted sample (300 µL) was added to the beads shaking for 1 h at rt. After the flow through 
was collected, the flow through was concentrated using the amicon ultra spin filters to 50 µL and 10 µL of 5× sample buffer was added. The streptavidin beads were washed three times 
with 500 µL of streptavidin wash buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 M urea). 
To elute the proteins from the beads, 30 µL of 1× sample buffer was added. All samples were 
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boiled for 10 min at 98 °C and loaded on 10 % SDS PAGE (5 µL of the flow through and 2.5 µL 
of the input and bead fractions) followed by silver staining to visualize the protein loading.
Optimization conditions tested for enrichment of biotinylated hNAT1 – Similar for the SPAAC 
optimization, we dialyzed and concentrated the samples at 4 °C using Amicon® Ultra-0.5 
Centrifugal Filter (10,000 NMWL; Merck Millipore) instead of the precipitation protocol. Next 
to the streptavidin binding buffer, we have tested the following binding buffers: (A) 1× PBS, 
(B) 1× PBS with 0.1-2 % SDS, (C) RIPA lysis buffer (Thermo Fisher). In addition, streptavidin 
was incubated o/n instead of 2 h at 4 °C and tested also the incubation of the sample with 
streptavidin at 37 °C for 2 h. We have tested several washing buffers for the streptavidin 
beads, including (A) 1× PBS with 0.1-2 % SDS and (B) 2× 1 mL RIPA lysis buffer, 1× 1 mL of 1 
M KCl (prepared fresh), 1× 1 mL 0.1 M Na2CO3 (prepared fresh), 1× 1 mL 2 M Urea, 10 mM 
Tris-HCl pH8.0, and 2× 1 mL RIPA lysis buffer. Note: none of these optimization conditions did 
improve the enrichment of biotinylated proteins.
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boiled for 10 min at 98 °C and loaded on 10 % SDS PAGE (5 µL of the flow through and 2.5 µL 
of the input and bead fractions) followed by silver staining to visualize the protein loading.
Optimization conditions tested for enrichment of biotinylated hNAT1 – Similar for the SPAAC 
optimization, we dialyzed and concentrated the samples at 4 °C using Amicon® Ultra-0.5 
Centrifugal Filter (10,000 NMWL; Merck Millipore) instead of the precipitation protocol. Next 
to the streptavidin binding buffer, we have tested the following binding buffers: (A) 1× PBS, 
(B) 1× PBS with 0.1-2 % SDS, (C) RIPA lysis buffer (Thermo Fisher). In addition, streptavidin 
was incubated o/n instead of 2 h at 4 °C and tested also the incubation of the sample with 
streptavidin at 37 °C for 2 h. We have tested several washing buffers for the streptavidin 
beads, including (A) 1× PBS with 0.1-2 % SDS and (B) 2× 1 mL RIPA lysis buffer, 1× 1 mL of 1 
M KCl (prepared fresh), 1× 1 mL 0.1 M Na2CO3 (prepared fresh), 1× 1 mL 2 M Urea, 10 mM 
Tris-HCl pH8.0, and 2× 1 mL RIPA lysis buffer. Note: none of these optimization conditions did 
improve the enrichment of biotinylated proteins.
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Activation of arylhydroxamic acid probes 
for proximal protein labeling in living cells
4
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Abstract
The human arylamine N-acetyltransferase (hNAT) activates arylhydroxamic acid (AHA) probes via the N,O-acetyl transfer reaction resulting in nitrenium ions, which react fast, 
covalently, and under neutral conditions with nucleophilic residues residing in DNA, RNA, 
and proteins. The purpose of this thesis is to exploit this unique N,O-acetyl transfer reaction 
of the hNAT enzyme for labeling proteins in close proximity of the enzyme. In Chapter 3, we 
demonstrated the use of recombinant hNAT to activate electron-rich AHA probes resulting 
in labeling of the hNAT protein itself. As a next step towards the NAT labeling strategy, we here explore the use of the NAT enzyme to label proximal proteins either in vitro or in living 
cells using the synthetic AHA probes described in Chapter 3. We observed strong labeling 
of proteins when these were mixed with the recombinant hNAT enzyme in the presence of 
the electron-rich AHA probe. In addition, incubating living cells with synthetic AHA probes 
also resulted in protein labeling as demonstrated by the analysis of cell lysates. Together, this chapter provides important information about the level of proximal protein labeling by the hNAT enzyme in vitro as well as in cultured mammalian cells for the further development of a 
NAT-based proximity dependent labeling strategy.
4.1 Introduction
Eukaryotes and prokaryotes express arylamine N-acetyltransferase (NAT), a xenobiotic 
metabolic enzyme, which catalyzes N-, and O-acetylation of arylamines and N-hydroxylated 
arylamines.121,123,230 Humans express the two homologues, human NAT1 (hNAT1) and human 
NAT2 (hNAT2), which vary in tissue distribution and substrate specificity.136,147,197,198 hNAT1 
is widely expressed in the body, including endocrine tissues, blood cells, neural tissue, as 
well as kidney, gut and liver.145–149 In contrast, the expression of hNAT2 is restricted mainly 
to the kidney, gut and liver.145–149 Although hNAT1 and hNAT2 are 81 % identical in amino 
acid sequence, several allelic variants exist resulting in phenotypic differences.131,132 The 
substitutions of the hNAT enzymes are categorized in two classes: mutations causing an 
unstable protein and mutations that affect the activity of the folded protein.134,135,146 These 
allelic variants of hNAT1 and hNAT2 result in reduced enzymatic activity causing the slow 
acetylation phenotype, a decreased rate of acetylation, in contrast to the phenotype expressing 
wild type NAT only (called rapid acetylators).134,135,146
Until today, it is still debated whether the effect of the mutations on the functional NAT activity 
and on the expression level of the hNAT enzymes play a role in cancer susceptibility.136,231 
For example, several studies show that estrogen receptor-positive breast cancer and other 
endocrine tumors do highly overexpress hNAT1, but not hNAT2.232–234 The cause of the 
upregulated hNAT1 gene is not fully understood. Studies showed that the extremely high level 
of hNAT1 in the human breast cancer cell line ZR75 is not caused by a gene duplication or to 
a mutated hNAT1.235 Others suggested that the upregulation of hNAT1 is due to differences in 
the upstream region of the highly complex hNAT1 gene.235
Interestingly, other mammalian species also express two NAT isoenzymes with similar 
expression and substrate profiles as the hNAT variants.129,130 As for humans, rabbits express 
rabbit NAT1 and NAT2 having similarities with hNAT1 and hNAT2, respectively. In case of 
mice, mouse NAT1 is the equivalent of hNAT1 and mouse NAT2 is homologous to hNAT1.137,138 
Studies evaluating the role of the mouse NAT2 enzyme demonstrated that this rodent enzyme 
has many similarities to the hNAT1.142–144 Therefore, murine model systems can be very helpful 
to unravel the functional role of the hNAT1 enzyme. The same nomenclature of the mice NAT enzymes is used for the eukaryotic NAT enzymes expressed by rat134,135 and hamster140,141, especially the hamster NAT enzymes have been extensively investigated for the metabolism 
of carcinogens. Altogether, these animal models have contributed to understand the basis of pharmacogenetic variation and the molecular effects of different polymorphisms of the NAT 
enzymes.
In addition to the direct acetylation of arylamines, the NAT enzymes also catalyze the N,O-acetyl transfer of N-acetyl-N-hydroxy arylamine (arylhydroxamic acid; AHA) resulting in a 
N-acetoxy-arylamine intermediate.170 These N-acetoxy ester metabolites are highly unstable and undergo spontaneous heterolytic N-O bond cleavage resulting in arylnitrenium ions, 
which are highly reactive towards nucleophilic residues residing in DNA, RNA, and proteins 
with rates approaching the diffusion limit (Figure 1C).176,184,185,194 We envisioned that we could 
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Eukaryotes and prokaryotes express arylamine N-acetyltransferase (NAT), a xenobiotic 
metabolic enzyme, which catalyzes N-, and O-acetylation of arylamines and N-hydroxylated 
arylamines.121,123,230 Humans express the two homologues, human NAT1 (hNAT1) and human 
NAT2 (hNAT2), which vary in tissue distribution and substrate specificity.136,147,197,198 hNAT1 
is widely expressed in the body, including endocrine tissues, blood cells, neural tissue, as 
well as kidney, gut and liver.145–149 In contrast, the expression of hNAT2 is restricted mainly 
to the kidney, gut and liver.145–149 Although hNAT1 and hNAT2 are 81 % identical in amino 
acid sequence, several allelic variants exist resulting in phenotypic differences.131,132 The 
substitutions of the hNAT enzymes are categorized in two classes: mutations causing an 
unstable protein and mutations that affect the activity of the folded protein.134,135,146 These 
allelic variants of hNAT1 and hNAT2 result in reduced enzymatic activity causing the slow 
acetylation phenotype, a decreased rate of acetylation, in contrast to the phenotype expressing 
wild type NAT only (called rapid acetylators).134,135,146
Until today, it is still debated whether the effect of the mutations on the functional NAT activity 
and on the expression level of the hNAT enzymes play a role in cancer susceptibility.136,231 
For example, several studies show that estrogen receptor-positive breast cancer and other 
endocrine tumors do highly overexpress hNAT1, but not hNAT2.232–234 The cause of the 
upregulated hNAT1 gene is not fully understood. Studies showed that the extremely high level 
of hNAT1 in the human breast cancer cell line ZR75 is not caused by a gene duplication or to 
a mutated hNAT1.235 Others suggested that the upregulation of hNAT1 is due to differences in 
the upstream region of the highly complex hNAT1 gene.235
Interestingly, other mammalian species also express two NAT isoenzymes with similar 
expression and substrate profiles as the hNAT variants.129,130 As for humans, rabbits express 
rabbit NAT1 and NAT2 having similarities with hNAT1 and hNAT2, respectively. In case of 
mice, mouse NAT1 is the equivalent of hNAT1 and mouse NAT2 is homologous to hNAT1.137,138 
Studies evaluating the role of the mouse NAT2 enzyme demonstrated that this rodent enzyme 
has many similarities to the hNAT1.142–144 Therefore, murine model systems can be very helpful 
to unravel the functional role of the hNAT1 enzyme. The same nomenclature of the mice NAT enzymes is used for the eukaryotic NAT enzymes expressed by rat134,135 and hamster140,141, especially the hamster NAT enzymes have been extensively investigated for the metabolism 
of carcinogens. Altogether, these animal models have contributed to understand the basis of pharmacogenetic variation and the molecular effects of different polymorphisms of the NAT 
enzymes.
In addition to the direct acetylation of arylamines, the NAT enzymes also catalyze the N,O-acetyl transfer of N-acetyl-N-hydroxy arylamine (arylhydroxamic acid; AHA) resulting in a 
N-acetoxy-arylamine intermediate.170 These N-acetoxy ester metabolites are highly unstable and undergo spontaneous heterolytic N-O bond cleavage resulting in arylnitrenium ions, 
which are highly reactive towards nucleophilic residues residing in DNA, RNA, and proteins 
with rates approaching the diffusion limit (Figure 1C).176,184,185,194 We envisioned that we could 
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Figure 1 – Overview of labeling by the endogenously expressed NAT enzyme using AHA probes.
A) On cellular level, incubating cells expressing the NAT enzyme with AHA probes will result in labeling of cellular 
proteins. B) Illustration of protein labeling by NAT using AHA probes. C) Activation of AHA probes on molecular level. After the N,O-acetyl transfer reaction by the NAT enzyme, an acetoxy-ester intermediate is formed, which undergoes spontaneously heterolytic N-O bond cleavage. The produced nitrenium ions are highly reactive towards nucleophiles. 
Labeled proteins are visualized by direct fluorescence (labeled AHA probes) or by bioorthogonal chemistry (azide 
labeled AHA probes).
As a first step towards the PDL NAT strategy, we examined NAT labeling in Chapter 3 by 
subjecting recombinant hNAT1 to synthetic AHA probes. We synthesized three different azide-
functionalized AHA probes 1, 3, and 5, varying in the electron donating and withdrawing 
properties to assess the electronic factors on the labeling efficiency by recombinant hNAT 
(Figure 2A). A set of structurally similar control probes was also synthesized, arylacetamide 
(AAA) probes 2, 4, and 6, lacking the hydroxy function that is essential for the N,O-acetyl 
transfer by hNAT and hence impedes nitrenium ion formation. The incorporated azide was 
used as a handle to visualize tagged proteins using bioorthogonal chemistry, including 
copper-free strain-promoted alkyne-azide cycloaddition (SPAAC) and copper(I)-catalyzed 
alkyne-azide cycloaddition (CuAAC) using the fluorescent DBCO-Cy5.5 11 and Cy5.5-alkyne 
12, respectively (Figure 2B and C).
hNAT1 efficiently activated the electron-rich AHA probe 1, whereas less pronounced labeling 
was seen by the recombinant enzyme using the intermediate electron-donating AHA probe 3 
and the more electron-poor AHA probe 5. The specificity of the reaction was demonstrated 
by the minimal background level of labeling observed with AAA probes 2, 4, and 6. The 
difference in the labeling efficiency using the various AHA probes is likely due to a discrepancy 
in binding affinity of the probes to the hNAT1 enzyme or the influence of electronic factors on 
the stability of the acetoxy-ester or nitrenium ion intermediates.
4
exploit this unique N,O-acetyl transfer capacity of the NAT enzymes for the development of 
a novel proximity-dependent labeling (PDL) strategy in order to rapidly visualize proteins in 
living systems by enzymatically activating a small molecule, which will then covalently label 
the enzyme and proteins in close vicinity of the enzyme.
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Figure 1 – Overview of labeling by the endogenously expressed NAT enzyme using AHA probes.
A) On cellular level, incubating cells expressing the NAT enzyme with AHA probes will result in labeling of cellular 
proteins. B) Illustration of protein labeling by NAT using AHA probes. C) Activation of AHA probes on molecular level. After the N,O-acetyl transfer reaction by the NAT enzyme, an acetoxy-ester intermediate is formed, which undergoes spontaneously heterolytic N-O bond cleavage. The produced nitrenium ions are highly reactive towards nucleophiles. 
Labeled proteins are visualized by direct fluorescence (labeled AHA probes) or by bioorthogonal chemistry (azide 
labeled AHA probes).
As a first step towards the PDL NAT strategy, we examined NAT labeling in Chapter 3 by 
subjecting recombinant hNAT1 to synthetic AHA probes. We synthesized three different azide-
functionalized AHA probes 1, 3, and 5, varying in the electron donating and withdrawing 
properties to assess the electronic factors on the labeling efficiency by recombinant hNAT 
(Figure 2A). A set of structurally similar control probes was also synthesized, arylacetamide 
(AAA) probes 2, 4, and 6, lacking the hydroxy function that is essential for the N,O-acetyl 
transfer by hNAT and hence impedes nitrenium ion formation. The incorporated azide was 
used as a handle to visualize tagged proteins using bioorthogonal chemistry, including 
copper-free strain-promoted alkyne-azide cycloaddition (SPAAC) and copper(I)-catalyzed 
alkyne-azide cycloaddition (CuAAC) using the fluorescent DBCO-Cy5.5 11 and Cy5.5-alkyne 
12, respectively (Figure 2B and C).
hNAT1 efficiently activated the electron-rich AHA probe 1, whereas less pronounced labeling 
was seen by the recombinant enzyme using the intermediate electron-donating AHA probe 3 
and the more electron-poor AHA probe 5. The specificity of the reaction was demonstrated 
by the minimal background level of labeling observed with AAA probes 2, 4, and 6. The 
difference in the labeling efficiency using the various AHA probes is likely due to a discrepancy 
in binding affinity of the probes to the hNAT1 enzyme or the influence of electronic factors on 
the stability of the acetoxy-ester or nitrenium ion intermediates.
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Besides the azide-functionalized AHA probes, we prepared two electron-rich probes that were 
pre-conjugated to a fluorescent BODIPY (AHA probe 7) or a biotin (AHA probe 9) for easy 
and quick visualization of the labeled proteins (Figure 2A). The recombinant hNAT activated 
both AHA probe 7 and AHA probe 9 resulting in strong labeling compared to the structurally 
similar control probes, AAA probe 8 and AAA probe 10 (Figure 2A). 
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Figure 2 – Overview of the structures of AHA and AAA probes and the bioorthogonal chemistry reactions.
A) AHA probes 1, 3, 5, 7, and 9 and AAA probes 2, 4, 6, 8, and 10 were synthesized as described in Chapter 3. Labeling by 
the hNAT enzyme using azide-functionalized probes is visualized by the SPAAC (B) or CuAAC (C) reaction.
As a follow-up study of hNAT labeling in vitro, we examine in this chapter the labeling of 
proximal proteins, using the similar synthetic AHA probes, by hNAT in living cells. We first 
investigated proximity labeling by spiking additional proteins into purified recombinant 
hNAT1 samples. Subsequently, we incubated living cells with AHA probes to evaluate protein 
labeling by the endogenous NAT enzyme. Labeling in cells is of interest as we are able to 
establish (i) the cell permeability of AHA probes, (ii) the optimal conditions to label proteins 
by AHA probes in cultured cells and (iii) the level of labeling observed in different human cell 
lines. 
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4.2 Results and Discussion
4.2.1 Protein labeling by recombinant hNAT1
Tagging	of	purified	proteins	using	AHA	probe	1
In order to evaluate the tagging of proximal proteins by hNAT, we examine the labeling of three 
additional proteins that were spiked into a sample of purified recombinant hNAT1 (Figure 
3A). In Chapter 3, we demonstrated that incubating hNAT1 with the azide-functionalized AHA probe 1 followed by visualization using the SPAAC or CuAAC reaction with a Cy5.5 fluorophore 
conjugate resulted in strong hNAT1 labeling, as evidenced by fluorescence scanning of the 
SDS-PAGE gel. Of these, the SPAAC reaction resulted in the strongest signal compared to the 
CuAAC reaction. Therefore, we used a similar set up and evaluated protein labeling by the 
recombinant hNAT enzyme visualized by the SPAAC reaction using the DBCO-Cy5.5 11. 
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Figure 3 – In vitro protein labeling by recombinant H6-hNAT1 using AHA probe 1.
A) Schematic representation. B) H
6
-hNAT1 was incubated with AHA probe 1 or AAA probe 2 followed by SPAAC using 
DBCO-Cy5.5 11 in presence or absence of the three selected proteins BSA, GFP-Cys (GFP*), and FKBP (proteins) or cell 
lysate derived from HEK-293T cells. In-gel fluorescence of the SDS-PAGE gel is shown. As a reference, the SDS-PAGE gel 
was stained with Coomassie Brilliant Blue.
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For this experiment, we selected three recombinant proteins with distinct sizes, bovine 
serum albumin (BSA), ± 69 kDa, cysteine-modified green fluorescent protein (GFP-Cys), ± 
32 kDa, and the FK506 binding protein (FKBP), ± 15 kDa, and incubated these proteins with 
recombinant hNAT1 and AHA probe 1. We observed strong labeling of all proteins, whereas 
no protein labeling was observed in the absence of hNAT1 or when using AAA probe 2 
(Figure 3B). The amount of labeled hNAT1 was similar in absence or presence of the three 
selected proteins, possibly because the cysteine in the catalytic active site of the enzyme 
is predominantly labeled by AHA probes as shown previously by Wang and coworkers.149 
Looking at the intensity of protein labeling of the three added proteins, recombinant GFP-Cys 
was the most efficiently labeled protein compared to BSA and FKBP. Thomas and coworkers 
demonstrated that nitrenium ions rapidly react with tryptophan and methionine residues (> 109 M-1 s-1) and with tyrosine, cysteine, lysine, histidine, and arginine residues (107-108 M-1 s-1).182 Notably, the reactivity of a given protein depends on structural factors and the number 
of readily accessible reactive amino acids.182 The relatively strong labeling of GFP-Cys might be 
the result of the cysteine at the C-terminus of the protein that is readily available for labeling, 
whereas the cysteines of BSA and FKBP are not positioned at the termini of these proteins 
(Supplementary Table S1).
Lysate labeling by the recombinant hNAT1 and endogenous enzymes
Next, we incubated HEK-293T cell lysate with AHA probe 1 in presence or absence of the 
recombinant hNAT1 (Figure 3B). We observed labeling of many lysate proteins using AHA probe 1 while only weak signals were obtained with AAA probe 2 (Figure 3B). Cell lysate 
incubated with AHA probe 1 without recombinant hNAT1 also resulted in protein labeling, 
albeit at a lower level (Figure 3B), which is likely due to the presence of endogenous hNAT1 
and hNAT2. As observed earlier, the most intensely labeled protein is the H
6
-hNAT1 enzyme 
itself and this is consistent with the reaction of the activated AHA probe 1 with the nucleophilic 
residues in close vicinity of the hNAT1 active site.
4.2.2 Labeling in living cells by AHA probes
Fast cell labeling by BODIPY AHA probe 7
In order to explore labeling by the endogenously expressed NAT enzymes in living cells, 
we investigated protein tagging by incubating cells with BODIPY AHA probe 7. As direct 
visualization of the labeled proteins by this fluorescent probe is less time consuming and labor 
intensive, we used this probe to optimize the reaction conditions and to measure tagging in 
multiple cell lines (Figure 4). First, we assessed the amount of protein labeling by varying the 
concentration of AHA probe 7 in cultures of mouse fibroblasts (NIH 3T3 cells), which express 
mainly mouse NAT2 (the homologue of hNAT1).
4
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Efficient protein labeling was observed with 100 µM of AHA probe 7 after one hour, whereas 
incubating cells with AAA probe 8 resulted only in weak background signal (Figure 4B). About 
five times less intense labeling was observed with a ten-fold lower concentration of AHA probe 7 (10 µM) and a similar signal reduction was observed with AAA probe 8 (Figure 4B). 
Because the signal-to-noise ratio was not affected by the probe concentration, we continued 
using the higher concentration (100 µM) of AHA probe 7. 
Decreasing the labeling time of AHA probe 7 from one hour to 15 minutes resulted in an 
equal level of fluorescently tagged proteins (Figure 4B). In fact, labeling was observed almost 
directly after adding AHA probe 7 and marginally increased with longer incubation times 
(Figure 4C). This suggests that AHA probe 7 is either completely activated in a very short time or that the hNAT enzymes are inactivated by covalent addition of the reactive intermediate 
to the catalytic cysteine. The latter phenomenon was also observed by Wang and coworkers, 
who used the hydroxamic acid of 4-aminobiphenyl (N-OH-4-AABP), which inhibits NAT by 
covalently binding the catalytic cysteine after activation (Chapter 2; Figure 4).172 The fast 
labeling with AHA probe 7 indicates that this probe easily enters the cells and is quickly 
activated by the endogenous enzymes. 
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Figure 4 – Tagging of proteins in living cells using BODIPY AHA probe 7.
(A) Schematic representation of protein labeling in living cells. (B-C) SDS-PAGE analysis of protein labeling in NIH-3T3 
cells using AHA probe 7 and AAA probe 8 at different concentrations in time (100 µM of probe was used in C). (D) 
Analysis of protein labeling with AHA probe 1 or AAA probe 2 at 1 hour in different cell lines. 3T3 = NIH 3T3; MCF = 
MCF-7; HEK = HEK-293; In-gel fluorescence of the SDS-PAGE gel is shown. As a reference, the SDS-PAGE gel was stained 
with Coomassie Brilliant Blue or transferred to western blot, which was stained with an antibody against actin to detect 
actin, which was used as a loading control.
Protein tagging in different cell lines
We next incubated five different cell lines with BODIPY probes 7 and 8, and explored the level of protein labeling as the concentrations of endogenous NAT enzyme may differ among cell 
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lines (Figure 4D). Besides the NIH 3T3 cells used above, we selected the human breast cancer 
cell Michigan Cancer Foundation-7 (MCF-7), the human cervical cancer HeLa cell line, the 
human embryonic kidney cell line HEK-293, and cells originating from human liver cancer 
(HepG2). As mentioned earlier in the introduction, the hNAT1 is widely expressed in many 
tissues, whereas hNAT2 expression is restricted mainly to the gut and liver. Therefore, we 
hypothesized that the mouse NIH 3T3 cell line expresses mouse NAT2 (the homologue of 
hNAT1), that the selected human cell lines all express hNAT1, and that the liver cancer cell 
line expresses both hNAT1 and hNAT2. Moreover, high levels of hNAT1 were expected in the 
MCF-7 cell line, because estrogen receptor-positive breast cancer cells have been reported to 
overexpress hNAT1.232–234
As shown in Figure 4D, the human cell lines incubated with AHA probe 7 all showed strong 
protein labeling, while the NIH-3T3 cells showed a less intense signal. Unexpectedly, the 
intensity of the signals obtained with AAA probe 8 was relatively high in some cells, especially 
in the HepG2 cells (Figure 4D). Because the hNAT enzymes cannot activate the acetamide 
probes due to the lack of the hydroxy group, other enzymatic activities may be responsible for 
the activation of this probe. The acetamide probes might be hydroxylated by cytochrome P450 
(CYP) enzymes resulting in the essential hydroxamic acid moiety.236 The CYP enzymes are 
highly expressed in the liver compared to other tissues, such as the kidney and the lung.237,238 
Therefore, we hypothesize that the CYP enzymes are responsible for hydroxylation of AAA probe 8 leading to strong protein labeling by the NAT enzymes and explaining the enhanced 
labeling observed in HepG2 cells compared to the other cell types when using this probe.
Based on the relative fluorescence levels of BODIPY probes 7 and 8, we concluded that protein 
tagging by endogenous NAT was most optimal in the HEK-293 cells (Figure 4D). Because 
of this observation, we chose to use a derivative of the HEK-293 cells containing the SV40 
T-antigen (HEK-293T) for subsequent experiments. Like its parent HEK-293, HEK-293T cells 
are very efficiently transfectable with DNA. Due to the expression of SV40 large T antigen 
in HEK-293T cells, transfected plasmid DNAs carrying the SV40 origin of replication can 
replicate and transiently maintain a high copy number. This can greatly increase the amount 
of recombinant protein produced in these cells.
Analysis of in-cell labeling by confocal microscopy
To investigate the subcellular distribution and labeling of endogenous NAT, we next analyzed 
labeling in the HEK-293T cells by confocal microscopy using BODIPY probes 7 and 8 (Figure 
5A). In agreement with observations made with cell lysates, AHA probe 7 efficiently labeled 
the HEK-293 cells in a probe dependent manner (Figure 5A). Importantly, incubations with AAA probe 8 resulted in only very weak labeling (Figure 5A). According to literature, the hNAT enzyme is mainly expressed in the cytosol127 and therefore we expected to mainly label 
proteins in the cytoplasm. Indeed, at a subcellular level, the staining was confined to the 
cytoplasm with most intense signals in the perinuclear region (Figure 5A).
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Figure 5 – Confocal microscopy of labeling by the tagged AHA probes in living cells.
A) HEK-293T incubated with probes 7 or 8, or no probe (-) (green) were fixed and stained by DAPI (grey) to visualize the 
nucleus. B) HEK-293T cells incubated with probes 9 or 10, or no probe (-) were fixed and stained by the streptavidin-488 
conjugate (green) and DAPI (grey) to visualize the nucleus. Scale bar = 10 µm.
4.2.3 NAT-mediated biotinylation of proteins in living cells
To investigate whether the activation of the biotin-conjugated probes would lead to 
biotinylation of proteins in HEK-293T cells, we incubated the cells with AHA probe 9 and AAA probe 10 for one hour. We envisioned that the biotinylated proteins could be easily detected 
by fluorophore-conjugated streptavidin and recovered using streptavidin beads for further 
mass spectrometry analysis. In contrast to the labeling efficiency in living cells by AHA probe 
7, we did not observe extensive protein tagging by AHA probe 9 compared to AAA probe 
10 or cells incubated without any probe, neither in the lysate by western blotting nor by 
confocal microscopy (Figure 5B and Supplementary Figure S1). In all samples, the relatively 
strong signals obtained after incubation with probes 9 and 10 were similar to those observed 
for non-treated cells stained with streptavidin. These results indicate that the biotinylation 
observed by the streptavidin staining is the result of endogenously biotinylated proteins. 
Since the hNAT1 enzyme is able to activate biotinylated AHA probe 9 resulting in protein labeling in vitro (Chapter 3), the absence of protein biotinylation in living cells might be 
explained by difficulties of biotinylated probes to enter the cells or by hydrolysis of the probe 
by the biotinidase enzyme. Biotin is a water-soluble vitamin B and functions as a cofactor 
for biotin-dependent enzymes (e.g. carboxylases) making biotin essential for many cellular 
processes.74,75 However, cells are unable to synthesize biotin de novo and therefore actively 
transport free biotin over the plasma membrane for cellular uptake.76 Nutrients in food 
contain free forms of biotin or protein-bound biotin, which is converted to free biotin by 
the action of biotinidase. This enzyme catalyzes the hydrolysis of esters and amides77, and is 
highly expressed in human kidney and breast tissues.148,149 AHA probe 9 might be hydrolyzed 
by the biotinidase enzyme, and thereby prevent protein biotinylation by the endogenous NAT 
enzyme. 
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4.2.4 NAT-mediated azide-tagging of proteins in living cells
As we did not observe an increased protein labeling with biotin probes 9 and 10, we were 
interested in the activation of the azide-functionalized probes 1-6 in living cells to allow a 
two-step purification procedure of the labeled proteins. After cellular labeling in the HEK-
293T cells using these probes, we verified protein labeling by the analysis of protein lysates 
using click chemistry with Cy5.5-labeled reagents (Figure 6). As we have observed in Chapter 
3 that AHA probe 1 was activated more efficiently in cell lysate compared to AHA probes 3 and 5, we used this probe to examine the optimal click chemistry conditions to visualize the 
labeled proteins by the SPAAC (DBCO-Cy5.5 11) or CuAAC (Cy5.5-alkyne 12) reaction.
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Figure 6 – Protein labeling in living cells using probes 1-6.
A) HEK-293T cells were incubated probes 1 or 2, or no probe (-). Cells were lysed and visualized by SPAAC or CuAAC 
using ± 10 µg of cell lysate and the Cy5.5-alkyne 12 or the DBCO-Cy5.5 11, respectively. B) Similar as in A, HEK-293T 
cells were incubated with probes 1-6. C) SDS-PAGE gel of the time response of labeling in HEK-293T cells visualized by 
the CuAAC reaction using Cy5.5-alkyne 12. In-gel fluorescence of the SDS-PAGE gel is shown. As a reference, the SDS-
PAGE gel was transferred to western blot and stained with an antibody against actin to detect actin, which was used as 
a loading control.
We incubated HEK-293T cells with AHA probe 1 for one hour and performed, the 
bioorthogonal ligations with DBCO-Cy5.5 11 or with Cy5.5-alkyne 12 after cell lysis (Figure 
6A). We observed more intense protein labeling when using DBCO-Cy5.5 11 compared to 
Cy5.5-alkyne 12, while fluorescent proteins were not observed after incubations with AAA Activation of arylhydroxamic acid probes for proximal protein labeling in living cells  91
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probe 2 or in the absence of probes (Figure 6A). The absence of click compounds or reagents 
did not lead to detectable background signals of fluorescent proteins (Figure 6A). Remarkably, 
untreated cells incubated with DBCO-Cy5.5 11 resulted in strong aspecific labeling by the 
SPAAC reaction that was not observed by the CuAAC reaction (Figure 6A). Likely, the high 
background by the SPAAC reaction was due to the presence of nucleophilic residues in the 
lysate, which were not blocked by the iodoacetamide treatment. This aspecific labeling by the 
SPAAC reaction could not be reduced by optimizing the iodoacetamide treatment of the lysate 
(data not shown). For this reason, we used the CuAAC reaction with the Cy5.5-alkyne 12 in 
subsequent experiments to visualize the labeled proteins in living cells. 
To assess the effect of the electron density on labeling by the azide-functionalized probes 
in living cells, we incubated the HEK-293T cells with AHA probes 1, 3, and 5 as well as AAA probes 2, 4, and 6 for one hour, after which the protein lysate was subsequently subjected to 
the CuAAC reaction (Figure 6B). Although we previously observed less pronounced labeling 
with AHA probes 3 and 5 compared to AHA probe 1 using recombinant hNAT1 protein 
described in Chapter 3, we now observed efficient protein labeling for all probes indicating that probes 3 and 5 are efficiently activated in living cells (Figure 6B).
Interestingly, the incubations with AHA probes 1, 3, and 5 resulted in a different fluorescent 
labeling pattern as shown in the SDS-PAGE gel (Figure 6B). For example, two intense bands 
around 50 kDa (identity unknown) were obtained for active probe 1, while at this position 
less prominent bands were observed for probe 3 and 5. Possibly, the variation in intensity and band pattern is the result of activation of the probes by other enzymes next to the NAT 
enzymes, such as sulfotransferases.239 Sulfotransferases catalyze the transfer of the sulfuryl 
moiety from the 3’-phosphoadenosine 5’-phosphosulfate (PAPS) donor to acceptor substrates 
bearing hydroxy- or amino- groups, including N-arylhydroxamic acids.240–242 The sulfation of 
N-arylhydroxamic acids by sulfotransferases results in short-lived electrophilic sulfuric acid 
ester metabolites, which lead to the formation of nitrenium ions after cleavage of the sulfuryl 
group (Supplementary Figure S2).243,244 Since the nitrenium ions will react fast and covalently 
with proximal proteins of the activating enzyme, labeling of the surrounding proteins by NAT 
or sulfotransferases will result in a different labeling pattern.Another explanation for the distinct protein labeling patterns might be a difference in the stability or reactivity of the N-acetoxy ester intermediate in living cells of the three AHA 
probes after activation by the NAT enzyme. Activating the electron-rich AHA probe 1 will likely result in a more unstable N-acetoxy ester intermediate than the less electron-donating 
AHA probe 3 and even more electron-withdrawing AHA probe 5. The distinct stability of 
these probes might influence the reactivity towards residues residing in proteins. In addition, 
probe stability likely plays a role in the diffusion radius of the probes from the NAT enzyme. 
Due to the stability, the N-acetoxy ester intermediate will diffuse with different distances from 
the NAT enzyme before producing the reactive nitrenium ions. In this way, the diffusion rate of 
each probe will lead to labeling of different proteins by the NAT enzyme.
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We observed protein labeling using AHA probe 1 within one minute and this increased up to 
4-5 minutes (Figure 6C). This suggests that AHA probe 1 easily enters the cell and is quickly 
activated by the endogenous enzymes. Furthermore, the relative labeling signals did not 
increase after 5 minutes (Figure 6C), which can be explained by either complete activation of this probe or by inactivation of the NAT enzyme by covalent addition of the reactive 
intermediate to the catalytic cystein.149
Analysis of azide protein-tagging in HEK-293T cells by confocal microscopy
To investigate the subcellular distribution of the labeled proteins, we studied HEK-293T cells 
incubate with the azide-functionalized probes 1-6 by confocal microscopy. After incubation 
with these probes, cells were fixed and subjected to the CuAAC reaction using a commercially 
available fluorescent alkyne, Fluor488-alkyne 15 (Figure 7A). In contrast to the level of 
protein labeling observed in the lysate above, the incubation of HEK-293T cells with AHA probe 1 resulted in only very weak cytosolic labeling (Figure 7B). Higher levels were observed 
in all cells incubated with AHA probe 3 (Figure 7B). AHA probe 5 did not result in any labeling 
(Figure 7B), similar to what was observed for all control probes. There is no clear explanation 
for these observations and this must be further investigated.
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Figure 7 – Confocal microscopy of labeling in living cells by AHA and AAA probes 1-6.
A) Schematic representation. B) HEK-293T cells incubated with the probes 1-6 were fixed and stained by the CuAAC 
reaction using Fluor488-alkyne 15 (green) and DAPI (grey) to visualize the nucleus. Scale bar = 10 µm.
As expected, the staining pattern obtained with AHA probes 1 and 3 was mainly cytoplasmic 
(Figure 7B). In this case a more diffuse distribution was obtained compared to the staining 
pattern observed for AHA probe 7 (Figure 5A). These results indicate that AHA probes can be 
activated inside living cells by endogenous hNAT, although we cannot exclude the involvement 
of other enzymes that can activate these probes. Activation of arylhydroxamic acid probes for proximal protein labeling in living cells  93
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4.3 Concluding Remarks
As a follow-up study to develop the PDL NAT strategy, the purpose of this chapter was to 
explore the ability of the hNAT enzyme to label proximal proteins via the unique N,O-acetyl 
transfer reaction using synthetic AHA probes. After demonstrating in Chapter 3 the self-
labeling of recombinant hNAT1 with the electron-rich AHA probe 1, we now demonstrate 
that proteins in the vicinity of recombinant hNAT1 enzyme are also labeled. Compared to the 
other proteins present in the sample, hNAT1 was most strongly labeled supporting the idea 
that the activated AHA probes favor reactions with nucleophilic residues in close proximity of 
the hNAT1 active site.
We observed cellular labeling in the cytosol of living HEK-293T cells with BODIPY labeled 
AHA probe 7 as well as with the azide-functionalized AHA probes 1 and 3, as evidenced by 
confocal microscopy. Labeling by AHA probes 1 and 7 was already measured within minutes, 
suggesting that these probes easily enter the cell and are quickly activated by endogenous 
enzymes. Moreover, strong labeling with BODIPY AHA probe 7 was also observed in three 
other human cell lines (MCF-7, HeLa, and HepG2) while less in the mouse NIH 3T3 cell line. 
These results indicate that the synthetic AHA probes can be activated inside living cells by 
endogenous hNAT.After applying these hydroxamic acid probes in living cells to assess protein labeling by 
endogenous enzymes, our next aim is to study the compartmentalized protein labeling 
by targeting the hNAT enzyme to defined subcellular regions (e.g. cytosol or nucleus), as 
described in Chapter 5.
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4.5 Supplementary Figures and Tables
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Supplementary Figure S1 – Lysate labeling in HEK-293T cells by AHA probe 9 and AAA probe 10.
Biotinylation was visualized on western blot stained with the streptavidin-800 conjugate. An antibody against actin to 
detect actin was used as a loading control.
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Supplementary Figure S2 – Schematic representation of N-arylhydroxamic acid sulfation by sulfotransferases.241
After sulfotransferases (SUT) catalyze the transfer of the sulfuryl moiety to the hydroxy group of the N-arylhydroxamic 
acid, the electrophilic sulfuric acid ester metabolite will result in nitrenium ion formation.
Supplementary Table S1 – Amino acid sequences of recombinant proteins BSA, GFP-Cys, and FKBP.
 
 
 
BSA (69.3 kDa)
M K W V T F I S L L L L F S S A Y S R G V F R R D T H K S E I A H R F KD L G E E H F K G L V L I A F S Q Y L Q Q C P F D E H V K L V N E L T EF A K T C V A D E S H A G C E K S L H T L F G D E L C K V A S L R E T YG D M A D C C E K Q E P E R N E C F L S H K D D S P D L P K L K P D P NT L C D E F K A D E K K F W G K Y L Y E I A R R H P Y F Y A P E L L Y YA N K Y N G V F Q E C C Q A E D K G A C L L P K I E T M R E K V L A S SA R Q R L R C A S I Q K F G E R A L K A W S V A R L S Q K F P K A E F VE V T K L V T D L T K V H K E C C H G D L L E C A D D R A D L A K Y I CD N Q D T I S S K L K E C C D K P L L E K S H C I A E V E K D A I P E NL P P L T A D F A E D K D V C K N Y Q E A K D A F L G S F L Y E Y S R RH P E Y A V S V L L R L A K E Y E A T L E E C C A K D D P H A C Y S T VF D K L K H L V D E P Q N L I K Q N C D Q F E K L G E Y G F Q N A L I VR Y T R K V P Q V S T P T L V E V S R S L G K V G T R C C T K P E S E RM P C T E D Y L S L I L N R L C V L H E K T P V S E K V T K C C T E S LV N R R P C F S A L T P D E T Y V P K A F D E K L F T F H A D I C T L PD T E K Q I K K Q T A L V E L L K H K P K A T E E Q L K T V M E N F V AF V D K C C A A D D K E A C F A V E G P K L V V S T Q T A L A
 
GFP-Cys (32.3 kDa)
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Supplementary Table S2 – Amino acid composition of recombinant proteins BSA, GFP-Cys, and FKBP.
amino acid
Ala
Arg
Asn
Asp
Cys
Gln
Glu
Gly
His
Ile
Leu
Lys
Met
Phe
Pro
Ser
Thr
Trp
Tyr
Val
# amino acids
in BSA
47
26
14
40
35
20
59
17
17
15
65
60
5
30
28
32
35
3
21
38
13
10
13
25
3
8
18
27
17
12
22
23
9
13
12
15
20
1
9
19
# amino acids
in GFP-Cys
# amino acids
in FKBP
5
7
2
6
1
6
8
20
10
5
9
8
6
5
8
11
7
1
4
11
4.6 Supplementary Information
Synthetic procedures
The synthesis of AHA and AAA probes 1-10 is described in the Supplementary Information of 
Chapter 3 (“Synthetic procedures”).
Protein labeling by recombinant H6-hNAT1
hNAT1 was purified similarly as described in the Supplementary Information of Chapter 3 
(“Design and cloning of tagged hNAT1 hNAT2 enzymes” and “Expression and purification of 
the tagged hNAT1 and hNAT2 enzymes”) by standard cloning of pET30A encoding H
6
-hNAT1 
and expression of H
6
-hNAT1 in E. coli followed by Ni2+ NTA purification.
Protein labeling by recombinant hNAT1 was shown using the recombinant proteins: BSA (±69 
kDa; Sigma-Aldrich), GFP-Cys (± 32 kDa; gift from the Biomolecular Chemistry department, 
Radboud University), FKBP (± 15 kDa)242. The protein lysate was prepared by lysing HEK-
293T cells in RIPA lysis buffer (5 mg/mL; Thermo Fisher Scientific). Proteins were mixed 
by adding 5 μL of H
6
-hNAT1 enzyme (1 mg/mL) with 0.5 μL BSA (20 mg/mL), 5 μL GFP-Cys 
(323 µg/mL), and 1 μL FKBP (5 mg/mL), or adding the similar amount of enzyme to 13.5 μL 
of lysate (5 mg/mL). The reaction was started by adding 2 μL of 1 mM probe (dissolved in 
DMSO) in a total volume of 20 µL and incubated for 1 h at 30 °C. The reaction was stopped by 2 µL of MQ and 3 µL blockers , containing 1 µL of 25 mM N-hydroxy-N-phenylacetamide 
(500 mM stock in DMSO; synthesized using a literature procedure217), 1 µL of 250 mM aniline 
(diluted in DMSO), and 1 µL of 2,5 M imidazole for a final concentration of 1 mM N-hydroxy-
N-phenylacetamide, 10 mM aniline, and 100 mM imidazole.
Labeled proteins were visualized by the SPAAC reaction using DBCO-Cy5.5 11. First, the 
reduced cysteines were alkylated by adding 3 µL of 500 mM iodoacetamide (prepared 
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fresh, 50 mM final) and 2 µL MQ to the sample (final volume 30 µL) for 30 min on ice. Then, 
the SPAAC reaction was performed for 2 h on ice by adding 5 µL of 70 µM DBCO-Cy5.5 11 
(dissolved in DMSO; 10 µM final) to the samples (total volume of 35 µL). Finally, 10 µL of 5× 
sample buffer and 5 µL of MQ was added to all samples for a total volume of 50 µL. Samples 
(5 µL) were directly loaded and analyzed on 10 % SDS-PAGE. In-gel fluorescence of the SDS-
PAGE was measured on the Odyssey® CLx followed by colloidal staining of the proteins.
Mammalian cell culture
The NIH 3T3 cell line (passage number unknown) was cultured in DMEM supplemented 
with 10% heat-inactivated despeciated bovine serum (DBS), whereas the MCF-7, HeLa, HEK-
293, and HEK-293T cell lines (passage number < 25) were cultured in DMEM supplemented 
with 10% heat-inactivated fetal bovine serum (FBS). The HepG2 cell line (passage number 
unknown) was cultured in EMEM (Thermo Fisher Scientific) supplemented with 10 % FBS. 
Media of all cell lines were supplemented as well with 100 U/mL penicillin, and 100 µg/mL 
streptomycin and cells were grown at 37 °C under 5 % CO2. All cell lines were grown for 24-48 
h before labeling experiments were performed on polystyrene microplates (in case of a 6-well 
with 2 mL of 80,000 cells/mL).
Protein labeling in living cells by endogenous NAT
Probe incubation – After cells were grown for 24-48 h, protein labeling was initiated by 
changing the medium to 2 mL of pre-warmed culture medium for a 6-well containing 10 or 100 µM of the probe 1-10 (1 or 10 mM stocks dissolved in DMSO) for 1 h or a specific time 
in case of the time series at 37 °C under 5 % CO2. The excess of probes was removed and 
cells were briefly washed three times by 2 mL of 1× PBS. Next, cells were scraped in ice cold 
RIPA lysis buffer (Thermo Fisher Scientific), containing 1× protease inhibitor (Roche). The 
concentration of the samples was measured by the PierceTM BCA protein assay kit (Thermo 
Fisher Scientific) and the samples were diluted to 2 mg/mL.
SPAAC with the azide-labeled lysates – Before the SPAAC reaction was started, lysates (20 μL 
of 2 mg/mL) were first alkylated for 30 min on ice by adding 5 μL of 250 mM iodoacetamide 
(prepared fresh, 50 mM final). Subsequently, 5 μL of 40 μM dibenzocyclooctyne-Cyanine5.5 
11 (dissolved in DMSO; 10 µM final; DBCO-Cy5.5, Jena Bioscience) was added to perform the 
SPAAC reaction for 2 h on ice.
CuAAC reaction with the azide-labeled lysates – The CuAAC reaction was performed using 
Cyanine5.5-alkyne 12 (Cy5.5-alkyne, Jena Bioscience). To the lysate (20 μL of 2 mg/mL), 8 μL 
of a CuAAC mastermix was added, consisting of 2 μL of 20 mM BTTAA (Click Chemistry Tools), 1 μL of 10 mM CuSO
4
, and 5 μL of 40 μM Cy5.5-alkyne 12 (dissolved in DMSO). The CuAAC 
reaction was started by adding 2 μL of 100 mM sodium ascorbate (prepared fresh). The final 
concentrations of the CuAAC reaction components in the lysates were 2 mM BTTAA, 1 mM 
CuSO
4
, 10 μM Cy5.5-alkyne 12, and 10 mM sodium ascorbate. The samples were incubated for 
2 h on ice and the CuAAC reaction was stopped by adding 5 μL of 350 mM EDTA (50 mM final). 
Preparing labeled samples for SDS-PAGE – 5× sample buffer was added to the 40-50 µg prepared 
lysate samples and samples were boiled for 10 min at 96 °C. About 10-20 µg of each lysate was 
directly loaded on 12 % SDS-PAGE. 
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Visualizing labeled proteins on SDS-PAGE – BODIPY labeled lysates were visualized by in-gel 
fluorescence of the SDS-PAGE measured on the Typhoon Trio+ (GE Healthcare Life Sciences) 
at 488 nm followed by colloidal staining of the proteins or transferred to western blot and 
stained against actin (see below by staining for “biotinylated lysates”).
Biotinylated lysates were first transferred from SDS-PAGE to nitrocellulose by standard 
western blotting. After blocking the blot with 3 % BSA in 1× PBS overnight (o/n) at room 
temperature (rt), blots were first stained for 1 h at rt against anti-actin mouse (1:7,500; Sigma-
Aldrich). Secondary anti-mouse IRDye 680 RD (1:5,000; LI-COR) was used to visualize stained 
actin, and streptavidin IRDye 800 CW (1:3,000; LI-COR) was used to measure biotinylated 
proteins. Secondary staining was performed for 1 h at rt and measured on the Odyssey® CLx 
at 800 nm.
Azide-tagged lysates were followed by the SPAAC or CuAAC reaction, which was measured 
by in-gel fluorescence of the SDS-PAGE on the Odyssey® CLx at 700 nm followed by transfer 
to nitrocellulose by standard western blotting. Lysates were stained against anti-actin (see 
above) and visualized by goat anti-mouse (see above) and measured on the Odyssey® CLx 
at 800 nm.
Visualizing lysate labeling by confocal microscopy
Probe incubation – HEK-293 or HEK-293T cells were grown on glass coverslips in a 48-well 
plate for 24-48 h on a 48-well containing 500 µL of 80,000 cells/mL). The adherence of these 
cells was improved by pre-treatment of the glass coverslips with poly-L-lysine (0.1 mg/mL; 
Sigma-Aldrich) for 5 min and washed three times with 1× PBS. After discarding the growth 
medium, cells grown on coverslips were rinsed with 1× PBS followed by probe labeling. Pre-
warmed culture medium was supplemented with 100 µM of the probe 1-10 (10 mM stock in 
DMSO). Cells were labeled by 500 µL of the culture medium containing the probe for 1 hour at 
37 °C under 5 % CO2. The excess of probes was removed and cells were briefly washed three times by 1× PBS.
Fixing and permeabilizing cells – After probe labeling, cells were directly fixed for 15 min at room temperature using 500 µL of 3.7 % formaldehyde in 1× PBS. Cells were briefly washed 
with 1× PBS and permeabilized with 500 µL ice cold methanol for 5 min. After two brief washes 
with 1× PBS, cells were blocked with 500 µL of 3 % BSA in 1× PBS for 1 h at rt or o/n at 4 °C.
Probe staining – BODIPY labeled samples were directly visualized by the confocal microscope 
at 488 nm.
Biotinylation was visualized by staining blocked cells using streptavidin conjugated to a 
fluorophore for 1 h at rt using Streptavidin-F488 (1:3,000; Thermo Fisher Scientific).
Azide-tagging in cells was visualized by a CuAAC reaction after blocking in 3 % BSA in 1x 
PBS. The CuAAC reaction was performed for 2 h at rt using 300 µL of CuAAC mix, containing 
2 mM BTTAA, 1 mM CuSO
4
, 10 µM rhodamine110-PEG4-alkyne 14 (10 mM stock in DMSO; 
Fluor488-alkyne, Sigma-Aldrich), and 10 mM sodium ascorbate (added last) in 1× PBS. After 
the CuAAC, the cells were washed two times with 1× PBS, once with PBST (1× PBS, 0.1 % w/v 
Tween-20 (MP Biomedicals), and once with 3 % w/v BSA in 1× PBS for at least 5 min. Note: 
images from Figure 5 and 7B are originating from Figure 3, 4, and 6 in Chapter 5, the nuclear 
targeted hNAT1 experiments, by selecting for non-transfected cells in the image.
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DAPI staining – Cells were stained with 500 µL of 4′,6-Diamidine-2′-phenylindole 
dihydrochloride (DAPI, 1 µg/mL; Sigma-Aldrich) for 5 min in 1× PBS followed by three washes 
in 1× PBS. Finally, coverslips were mounted using Mowiol®4-88 mounting medium (Sigma-
Aldrich).
Confocal imaging – The samples were imaged on a Leica SP_8 confocal microscope 63× 
magnification with 1.0 digital zoom. Images were processed using ImageJ64 software.
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Subcellular labeling by a spatially-
restricted arylamine N-acetyltransferase
5Part of this Chapter is published in:Kleinpenning, F.; Eising, S.; Berkenbosch, T.; Garzero, V.; Schaart, J. M.; Bonger, K. M. ACS Chem. Biol. 2018, 13 (8), 1932–1937.
Abstract
The mapping of proteins at a specific subcellular region is effective to gain detailed insight in 
local cell dynamics and can be achieved by proximity-dependent labeling (PDL) techniques. 
The PDL approach is based on enzymatically activating small molecules resulting in reactive 
probes that tag proteins in close proximity of the enzyme. The biotin ligase (BirA) and 
ascorbate peroxidase (APEX) approaches are widely applied, but these PDL methods lack 
either temporal resolution (BirA) or require the use of potentially cell physiology-disturbing 
cofactors (APEX). Therefore, we set out to develop a novel PDL strategy using the arylamine 
N-acetyltransferase (NAT), which activates an arylhydroxamic acid (AHA) functionality into a 
nitrenium ion. The nitrenium ions react fast and under neutral conditions with nucleophilic 
residues of neighboring proteins and result in covalent adducts. We anticipated efficient 
proximal protein tagging upon this unique N,O-acetyl transfer reaction and subcellular labeling 
by spatially-restricting the NAT enzyme in the cell. The NAT enzyme was first successfully targeted to either the nucleus or cytosol by ectopically expressing fusion proteins containing 
a nuclear localization signal (NLS) or a nuclear export signal (NES). More importantly, the cells overexpressing the nuclear or cytosolic NAT enzyme resulted in selective tagging of 
proteins in the same compartment upon incubating the transfected cells with AHA probe 1 
within minutes. We conclude that with this chemoenzymatic labeling strategy based on the 
NAT enzyme, fast and covalent protein labeling can be achieved at a subcellular level without 
the need for potentially cell physiology-disturbing cofactors.
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5.1 Introduction
Proper cell functioning relies on the expression of proteins at the correct time and at the right 
location. The function, amount, and localization of proteins determines the cellular response 
of essentially all intracellular processes, including cell signaling, cellular transport, enzymatic 
catalysis, and cell division. In order to maintain cellular homeostasis, proteins often assemble 
into larger complexes establishing molecular machineries carrying out specific cellular 
processes.2,13,199 The ability to dynamically track proteins in their native cellular environment 
is crucial to understand the function of proteins. Several methods have been developed to 
rapidly profile protein-protein interactions (PPIs) in a living system by tagging a protein of 
interest (POI) as well as the interacting biomolecules of the POI. These so-called proximity-
dependent labeling (PDL) strategies15,16,18 are based on an enzymatic conversion of a small 
molecule into a reactive species that reacts with nucleophilic residues in proteins in close 
proximity of the enzyme, after which the labeled proteins are recovered and identified by 
mass spectrometry.53,54,66 The biotin ligase (BirA) and the ascorbate peroxidase (APEX) 
are two enzymes that are often used for PDL based strategies.19,200,201 These two enzymatic 
approaches are reviewed in detail in Chapter 1, and their properties are highlighted shortly 
below.
One of the first PDL systems is based on a gain-of-function mutant of the BirA enzyme 
(R118G; also called BirA*), which biotinylates proximal proteins via the formation of the 
reactive intermediate 5’-AMP-biotin by conjugating biotin and ATP.118,245 After the diffusion 
of 5’-AMP-biotin from the binding pocket of the BirA* enzyme, the intermediate reacts 
with primary amines of nearby proteins.118,245 Genetic fusion of the BirA* enzyme to a POI 
ensures biotinylation of vicinal proteins when expressed in mammalian cells.63 Recently, two 
improved BioID systems (BioID267 and TurboID68) were developed resulting in enhanced 
biotinylation and decreased labeling times compared to the first BioID approach, respectively. 
The adaptations of the BirA* enzyme were necessary to overcome background labeling by the 
BirA enzyme using endogenous biotin as well as to overcome long labeling times required 
for the BioID strategy (24 hours).63,80 While the temporal resolution using BioID2 is still 
limited (requiring at least 16 hours)67, biotinylation was observed within 10 minutes using 
the TurboID system.68
Another PDL approach with high temporal and spatial resolution is based on the APEX 
enzyme. In the presence of 1 mM of hydrogen peroxide, APEX oxidizes biotin-phenol 
generating reactive biotin-phenoxy radicals.80,101 The free phenoxy radicals are short-lived 
and react within 1 ms to electron-rich amino acids, including tyrosine, tryptophan, cysteine, 
and histidine.80,101 APEX labels only proteins in close proximity of this enzyme with a labeling 
radius of less than 20 nm.80,101 The biotinylated proteins can be enriched using streptavidin 
and subsequently purified and analyzed by mass spectrometry. The catalytic efficiency of the 
APEX system was further improved via a yeast screening technique resulting in a more active 
APEX variant (A134P mutant; APEX2), allowing the efficient enrichment of endogenous 
mitochondrial and endoplasmic reticulum (ER) membrane proteins.103 APEX2 is currently 
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widely applied to identify novel protein candidates.98,109,246 One potential drawback is that the 
APEX approach requires exposure of the cell to high levels of hydrogen peroxide (1 mM) in 
order to oxidize the biotin-phenol. Subjecting cells to such high levels of peroxide can cause 
adverse effects, such as the induction of a cellular stress response.115–117
In this research, we aim to establish a novel PDL strategy based on the human arylamine 
N-acetyltransferase (hNAT; Figure 1A), to preserve fast labeling times for proximal labeling 
and to avoid the use of potential cell disturbing cofactors (such as hydrogen peroxide).121–123 
Chapter 2 includes detailed information about the hNAT enzymes, hNAT1 and hNAT2. Both enzymes N- and O-acetylate a variety of arylamine substrates136,144,147,197 and catalyze the N,O-acetyl transfer of N-acetyl-N-hydroxy arylamine (arylhydroxamic acid; AHA probes) into 
N-acetoxy arylamine (Figure 1B).170 Depending on the aryl substituents, these N-acetoxy-esters undergo fast heterolytic N-O bond cleavage into nitrenium ions,184,185 which are 
highly reactive towards nucleophilic residues residing in DNA, RNA, and proteins with rates 
approaching the diffusion limit.189,203
In Chapter 3 and 4 we explored the activation of synthetic AHA probes and the subsequent labeling of neighboring proteins by the bacterially expressed recombinant hNAT enzyme and 
by hNAT enzymes expressed in cultured cells. Our findings suggested that the unique N,O-acetyl transfer capacity of hNAT for protein labeling can be used for subcellular labeling in 
living cells. To demonstrate the applicability of hNAT as a PDL tool, we genetically-targeted the 
hNAT enzyme to a specific cellular region and incubated the transfected cells with synthetic 
AHA probes to examine subcellular protein labeling using these AHA probes.
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Figure 1 – Overview of subcellular labeling by the targeted hNAT enzyme using AHA probes.
A) As an example, NAT is genetically fused to the nuclear localization signal (NLS) resulting in nuclear NAT expression. 
The localized enzyme activates AHA probes, which react with nucleophilic residues in biomacromolecules and labeling 
is then visualized either directly (labeled probe) or by bioorthogonal chemistry (azide labeled probe). B) Mechanism of 
activating AHA probes by NAT.
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5.2 Results and Discussion
5.2.1 Design of the spatially-restricted hNAT constructs
To exploit the NAT enzyme for the PDL strategy, we first equipped the hNAT1 and hNAT2 
enzymes with localization tags to specific subcellular regions. One of the first localization 
signals, the nuclear localization signal (NLS), was discovered in 1984 by Smith and 
coworkers.247 The nuclear accumulation of proteins containing a NLS was mediated by a short 
basic sequence of amino acids, such as Pro-Lys-Lys-Lys-Arg-Lys-Val. The NLS is recognized by 
an importin, which binds strongly to proteins containing an NLS, and this complex enters the 
nucleus through the nuclear pore.248 In the nucleus, Ran-GTP binds to the importin-protein 
complex, causing the release of the NLS-protein from importin due to a decrease in affinity 
of importin for the NLS-protein.248 We selected this widely applied NLS sequence as a nuclear 
localization tag for the hNAT enzymes.
Besides expressing proteins in the nucleus, we additionally aim to localize the proteins to 
the cytosol by introducing a nuclear export signal (NES). NES-tagged proteins are recognized 
and bound by exportins, which transport the cargo protein through the nuclear pore to the 
cytoplasm by simultaneous binding of exportin to Ran-GTP and the NES-protein.249 Most 
commonly, the NES consists of several hydrophobic residues, such as leucine, which are 
recognized by the export complex.250 One of the NES motifs is derived from the rev protein of 
the human immunodeficiency virus type 1 (HIV-1) (Leu-Gln-Leu-Pro-Pro-Leu-Glu-Arg-Leu-
Thr-Leu-Asp)251–253, which was fused to hNAT to spatially restrict the enzyme in the cytosol 
of the cell. 
Many other organelle-targeting tags exist (see the database by Negi and coworkers254), such 
as the signals localizing proteins in the mitochondria, peroxisome, or endoplasmic reticulum 
(ER). The N-terminal mitochondrial tag consists of an amphipathic helix, an alternating 
pattern of hydrophobic and positively charged amino acids, that is cleaved once the targeting 
of the protein is complete.255 Two types of targeting peptides directing proteins to the 
peroxisome have been described, including the C-terminal peroxisomal targeting signal 1 
(PTS1), consisting of only three amino acids, and the N-terminal peroxisomal targeting signal 
2 (PTS2) that contains nine amino acids.256 Localizing proteins towards the ER requires an 
N-terminal signal sequence to transport the protein to the ER257,258 and a retention motif at the 
C-terminus to retain the localized protein in the ER.259–261
To investigate whether localization tags can be fused to either the N-terminus or C-terminus of 
hNAT without affecting its enzymatic activity and whether the localization tags are functional 
in this context, we genetically incorporated the NLS and the NES sequences at either the 
N-terminus or C-terminus of the hNAT1 enzyme (Figure 2A). In addition, we marked the 
enzymes with the HA epitope, derived from the surface glycoprotein hemagglutinin (HA) of 
the human influenza virus, which can be visualized using anti-HA-tag antibodies. We also 
generated constructs containing the ER signal sequence at the N-terminus with or without 
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the C-terminal KDEL sequence, the mitochondrial and the peroxisomal sequence at the 
N-terminus to demonstrate the general use of localizing the hNAT1 enzyme in subcellular 
compartments (Figure 2A).
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Figure 2 – Targeting of the hNAT1 enzyme towards the nucleus and cytosol.
A) Design of the HA-hNAT constructs, containing the C- or N-terminal NES or NLS sequences. B-C) After transfection 
of HEK-293T for 36 hours with the indicated HA-hNAT1 constructs, cells were fixed and stained with antibodies. B) 
Antibodies against the HA-tag (red) or the hNAT enzyme (green) were used; nuclei were stained by DAPI (grey). C) 
Antibodies against the HA-tag (green), against the organelle markers COX-IV, catalase, or PDI (red) were used; nuclei 
were stained by DAPI (grey). Mito = mitochondrial tag; PTS2 = peroxisomal targeting signal 2, ss = signal sequence; KDEL 
= C-terminal ER retention signal. Scale bar = 25 µm.
5.2.2 Targeting the hNAT enzyme to subcellular compartments
Transient transfection of HEK-293T cells with the plasmids encoding NLS- or NES-HA-hNAT1 resulted in high expression levels and accumulation of the hNAT1 enzyme in the nucleus and 
cytosol, respectively (Figure 2B). Moreover, the same subcellular distribution of the hNAT1 
enzyme was observed by fusing the NLS- and NES-tag to the C-terminal region. The spatial 
restriction of the enzyme was confirmed by confocal microscopy. An overlay of the images 
showed identical distributions for the HA and hNAT signal, indicating that the HA epitope can 
be used to visualize HA-tagged hNAT enzymes and that the level of endogenous hNAT is very 
low. 
Targeting of hNAT1 to the mitochondria, peroxisome, and ER resulted in high levels of the 
ectopically expressed enzyme, as visualized by the HA-tag, in the corresponding organelle, 
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which was confirmed by organelle-specific markers (Figure 2C). The inner membrane of the 
mitochondria was visualized by antibodies against the COX-IV enzyme, which is a subunit of 
the cytochrome c oxidase (COX) enzyme complex.262 To highlight the peroxisomes, we selected 
the catalase enzyme, which protects the cell from oxidative damage by reactive oxygen 
species (ROS).263 The ER was visualized by antibodies against the disulfide isomerase (PDI), 
which catalyzes the formation and cleavage of disulfide bonds between cysteine residues 
within proteins when they fold in the ER.264 The staining of these three organelle markers 
completely overlapped with that of the corresponding targeted hNAT1 enzyme, indicating the accumulation of the tagged hNAT1 enzyme at the intended subcellular location.
Unfortunately, transfection of HEK-293T cells with the hNAT2 constructs containing the NLS 
or NES tag, or merely the HA-tag did not result in high expression levels (data not shown). 
Since none of the cells after transfection with the hNAT2 constructs demonstrated detectable 
expression levels, we suspect that this enzyme is lethal for these cells. To our knowledge, there 
is only one study that developed transgenic mice expressing either hNAT1 or hNAT2, which 
suppressed the endogenous protein levels of mouse NAT2 or mouse NAT1, respectively.265,266 
In addition, a study showed that only low levels of expression of the hNAT1 enzyme in mouse 
embryonic stem cells was achieved, whereas overexpression of this enzyme could not be 
detected.267 The failure to achieve high expression of either the hNAT1 or hNAT2 enzyme 
suggests that overexpression of NATs may be detrimental for the cell. We did not observe any 
visible cellular toxicity when transfecting cells with targeted HA-hNAT1. However, we were 
not able to detect cells overexpressing the HA-hNAT2 enzyme.
Importantly, and as mentioned above, we were not able to detect the expression of endogenous 
hNAT in HEK-293T cells, as evidenced by immunostaining of non-transfected cells and cells 
expressing NES-HA-hNAT1 with the anti-hNAT antibody (Supplementary Figure S1). The 
signal of hNAT staining in non-transfected HEK-293T cells was similar to the background 
signal of the secondary antibody only (Supplementary Figure S1). In contrast, strong signals of 
the enzyme were observed in the NES-HA-hNAT1 expressing cells by the anti-hNAT antibody. 
This indicates that the endogenous hNAT expression levels are low compared to the levels of 
the localized hNAT1 enzyme in the cell.
5.2.3 Activation of labeled AHA probes by NLS-hNAT
In Chapter 3, we designed a synthetic AHA probe containing the BODIPY fluorescent group 
(AHA probe 7) for direct visualization of the labeled proteins by fluorescence microscopy 
(Figure 3A). A structurally similar control probe containing the BODIPY functionality was 
also synthesized (AAA probe 8), lacking the hydroxy group that is essential for the N,O-acetyl 
transfer reaction by the hNAT enzyme. We demonstrated that recombinant hNAT1 activated 
AHA probe 7, resulting in strong labeling, whereas only marginal labeling was observed with AAA probe 8 (Chapter 3). In addition, subjecting living cells to AHA probe 7 also resulted in 
strong protein labeling by the endogenous enzymes, while cells incubated with AAA probe 8 
were only weakly labeled (Chapter 4). 
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Figure 3 – Cellular labeling by BODIPY AHA probe 7 in HEK-293T transfected NLS-HA-hNAT1 cells.
A) Structures of AHA probe 7 and AAA probe 8. The hydroxy function of AHA probe 7 required for the hNAT labeling 
reaction is highlighted in grey. B) HEK-293T cells transfected with NLS-HA-hNAT1 incubated without a probe (-) or with probes 7 or 8 (green). Cells were then fixed and immune-stained against the HA-tag (red) and nuclear staining by DAPI 
(grey). Scale bar = 25 µm. 
We evaluated the NAT-based PDL using 7 and 8 by incubating living cells that overexpress 
hNAT1 in the nucleus. Unexpectedly, we observed strong labeling in the area around the 
nucleus using AHA probe 7, while no signal was observed in the nucleus (Figure 3B). The background signal measured for AAA probe 8 was almost equal to the cells that were not 
subjected to any probe (Figure 3B). Since AHA probe 7 did result in strong labeling compared to AAA probe 8, we assumed that endogenous hNAT enzymes activated AHA probe 7 resulting 
only in cytosolic labeling. Our results are supported by earlier reported experiments showing 
nuclear exclusion of BODIPY derivatives, which is likely due to charges residing within the 
BODIPY molecule.268 Because of this perinuclear effect, these BODIPY probes cannot be used 
for further subcellular experiments.
As an alternative for AHA probe 7, we synthesized in Chapter 3 probes conjugated to a biotin 
moiety (AHA probe 9 and AAA probe 10, Figure 4B), which can be visualized by a fluorescent-
conjugated streptavidin (Figure 4B). We observed strong protein labeling of recombinant 
hNAT1 with AHA probe 9, while no labeling was observed using AAA probe 10 (Chapter 
3). This specific labeling was not observed in living HEK-293T cells and the high detected background labeling for both 9 and 10 using a fluorescent streptavidin conjugate, likely 
resulted from the endogenous biotinylated biomolecules (Chapter 4).
We were interested if an enhanced biotinylation signal could be obtained by overexpressing 
NLS-HA-hNAT1. Incubating cells with AHA probe 9, AAA probe 10 or without probe resulted 
in biotinylation signals in all samples (Figure 4C), which is likely a result of endogenously 
biotinylated proteins rather than labeling by the hNAT enzymes. However, a very faint nuclear 
biotinylation is visible in cells expressing hNAT1 in the nucleus when using AHA probe 9, 
which was not observed for transfected cells incubated with AAA probe 10 or not subjected 
to any probe. This indicates that, since AHA probe 9 was activated by recombinant hNAT1, the 
absence of biotinylation in living cells might be explained by difficulties of the biotinylated 
probe to enter the cells. 
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Figure 4 – Biotinylation by AHA probe 9 in HEK-293T transfected NLS-HA-hNAT1 cells.
A) Schematic overview. B) Structures of biotinylated AHA probe 9 and AAA probe 10. The hydroxy function of AHA probe 
9 required for the hNAT labeling reaction is highlighted in grey. C) HEK-293T cells transfected with NLS-HA-hNAT1 were 
incubated with no probe (-) or probes 9 or 10. Cells were then fixed and biotinylation was detected by streptavidin-488 
conjugate (green), the NLS-HA-hNAT1 was detected with anti-HA antibody (red), and nuclear staining by DAPI (grey). 
Scale bar = 25 µm.
5.2.4 Subcellular labeling by localized hNAT1 using AHA probe 1
Because the conjugated BODIPY and biotin probes are not suitable for subcellular labeling in 
living cells, we next tested if a two-step labeling procedure using AHA probe 1 can be employed 
(Figure 5A). AHA probe 1 and the corresponding AAA probe 2 both contain an azide moiety at the para position of the arylhydroxamic acid via an electron-rich linker (Figure 5B). The 
azide functionality can be used as a handle to conjugate a fluorescent alkyne moiety using 
bioorthogonal chemistry, including the strain-promoted alkyne-azide cycloaddition (SPAAC; 
see Chapter 3 and 4) and the copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC; Figure 
5C), to visualize the labeled proteins by fluorescent microscopy.267,268
In Chapter 3 and 4, we observed strong protein labeling when incubating recombinant 
hNAT1 with AHA probe 1. Although labeling was more efficiently visualized by the SPAAC 
reaction than the CuAAC reaction, the CuAAC reaction in the labeled lysate was more specific 
compared to the SPAAC reaction (Chapter 4). Therefore, we subjected AHA probe 1 in living cells expressing nuclear localized hNAT1 and visualized the labeled proteins on formaldehyde 
fixed cells by means of a CuAAC reaction with a Fluor488-alkyne 15 (Figure 5A). To our delight, 
we observed enhanced subcellular protein labeling in the nucleus in cells overexpressing the 
NLS-HA-hNAT1 as evidenced by fluorescent microscopy (Figure 5D). The labeling intensity 
correlated with the hNAT1 expression levels. Cells that were not transfected with the NLS-HA-
hNAT1 did not show protein labeling. Furthermore, the staining of transfected cells treated 
with AAA probe 2 was similar to that of transfected cells that were subjected to the CuAAC 
reaction, but not treated with any probe. 
5
A
B
visualizing
with Strep488
NAT NAT
nuclear
labeling
NLS-HA-hNAT1
10
9
-
overlay
C
DAPI Strep488HA
9
N
O
OH
O
N
NN
6
NH
O
S
NH
HN
O
H
H
3
10
N
O
H
O
N
NN
6
NH
O
S
NH
HN
O
H
H
3
Subcellular labeling by a spatially-restricted arylamine N-acetyltransferase  109
5
Figure 5 – Nuclear labeling by AHA probe 1 in HEK-293T transfected NLS-HA-hNAT1 cells.
A) Schematic overview. B) Structures of AHA probe 1 and AAA probe 2. The hydroxy function of AHA probe 1 required for 
the hNAT labeling reaction is highlighted in grey. C) Illustration of the CuAAC reaction. D-E) HEK-293T cells transfected 
with NLS-HA-hNAT1 were incubated without probe (-) or with probes 1 or 2. Cells were then fixed and stained by 
the CuAAC reaction using the Fluor488-alkyne 15 (green). The localized NAT enzyme was detected using the anti-HA 
antibody (red) and nuclear staining by DAPI (grey). E) The CuAAC conditions were optimized by varying concentrations 
of CuAAC ingredients (see as well Supplementary Figure S2 for other conditions). Copper = CuSO
4
; BTTAA = 2-(4-((bis((1-
tert-butyl-1H-1,2,3-triazol-4-yl)methyl)amino)methyl)-1H-1,2,3-triazol-1-yl)acetic acid. Scale bar = 25 µm.
Optimization of experimental conditions
We aimed to improve the labeling signal by testing alternative fixing methods and CuAAC 
reaction conditions (Figure 5E and Supplementary Figure S2). In Figure 5D, we fixed the 
cells by formaldehyde, a crosslinking agent that reacts with proteins and nucleic acids in the 
cell. Subsequently, the cell membrane was permeabilized by a brief methanol treatment to 
allow relatively large molecules to enter (e.g. dyes or antibodies). Other methods to fix and 
permeabilize the cells include dehydration and precipitation of proteins as well as nucleic 
acids using organic solvents, such as acetone. Although the dehydration fixatives are more 
effective at preserving the nucleic acid content than aldehyde-based fixatives, organic solvents 
often result in the loss of cytosolic organelles and nuclear content (reviewed by Hobro and 
Smith).269 Changing the formaldehyde fixing method to an acetone/methanol treatment in 
nuclear hNAT1 expressing HEK-293T cells decreased the relative amount of labeling observed 
in these cells (Supplementary Figure S2). The decrease of the fluorescent CuAAC signal is 
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likely due to the loss of cellular content by dehydrating the cells using acetone compared to 
the crosslinking formaldehyde agent.
After having established the most optimal method for fixing the cells, we opted for the 
most optimal CuAAC conditions. The CuAAC can be varied in the amounts of copper(II)
sulfate, sodium ascorbate, the type of copper ligand as well as the alkyne reagent. We first 
established the most optimal concentration of the Fluor488-alkyne 15 (1 µM, 5 µM or 10 µM) 
for visualization of labeled proteins (Supplementary Figure S2). Cells expressing high levels 
of the NLS-HA-hNAT1 enzyme incubated with AHA probe 1 were less intensively stained 
when the relatively low Fluor488-alkyne 15 concentration of 1 µM was used compared to 5 µM and 10 µM. Performing the CuAAC reaction with 10 µM Fluor488-alkyne 15 resulted 
in slightly stronger signals compared to cells incubated with 5 µM. We expect that further 
raising the Fluor488-alkyne 15 concentration will not increase signal intensities, because the 
difference between 5 µM and 10 µM of the fluorophore did marginally affect the observed 
labeling. Subsequent CuAAC optimizing conditions were therefore performed using 10 µM of 
Fluor488-alkyne 15.
Sodium ascorbate is required for the reduction of copper(II)sulfate to the required Cu(I) 
species. Increasing the ratio of sodium ascorbate to copper sulfate (1:1, 2.5:1, and 10:1) 
resulted in a slightly improved signal (Supplementary Figure S2). Therefore, a 10-fold molar 
excess of sodium ascorbate to the copper sulfate was selected for subsequent experiments.
The Cu(I) oxidation state of the species in solution can be stabilized by a water-soluble 
chelating ligand, thereby accelerating the cycloaddition reaction.270,271 Additionally, the ligand 
in the CuAAC reaction also reduces the concentration of the toxic copper ions and prevents 
damage of biomolecules associated with the Cu(I)-mediated formation of reactive oxygen 
species. Several tris(triazolylmethyl)amine-based ligands have been developed, including the 
water-soluble THPTA, BTTAA, and BTTES ligands (structures are shown in Supplementary 
Figure S3). BTTAA is used effectively for bioconjugation in cells with suppressed cell 
cytotoxicity compared to THPTA and BTTES, mainly because the BTTAA ligand allows the 
use of lower copper concentrations.209 Furthermore, the BTTAA ligand increases the CuAAC 
kinetic rates compared to the THPTA and BTTES ligands.209 Because of the advantages of the 
BTTAA, we selected this ligand for the CuAAC reaction to visualize nuclear labeling in cells 
expressing NLS-HA-hNAT1.
Notably, performing the CuAAC reaction without the BTTAA ligand resulted in strong 
aspecific background labeling in the NLS-HA-hNAT1 expressing HEK-293T cells as well as in 
non-transfected HEK-293T cells (Figure 5E). According to the literature, the CuAAC reaction 
using sodium ascorbate initially resulted in protein adduct formation, crosslinking, and 
precipitation, which is likely caused by the dehydroascorbate oxidation product.272 By adding 
a ligand to the CuAAC reaction, the generated reactive oxygen species will be intercepted and 
quickly reduced without compromising the CuAAC reaction rate.272 In our experiments, a 
ratio of BTTAA:copper sulfate of 1:1 was already sufficient to reduce aspecific labeling that 
was observed for the CuAAC reaction in absence of the ligand (Figure 5E). Increasing the 
5
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BTTAA:copper sulfate ratio (2:1 or 5:1) further increased specific nuclear labeling. Since the 
5:1 and 2:1 BTTAA:copper sulfate ratio resulted in similar labeling intensities, we used the 
lower concentrations in future experiments to visualize the labeled proteins. 
Finally, the concentration of the copper sulfate was determined by lowering the concentration 
of copper sulfate while keeping the ratio of BTTAA ligand and sodium ascorbate the same 
(copper sulfate:BTTAA:sodium ascorbate 1:2:10) and adding 10 µM Fluor488-alkyne 15 
(Supplementary Figure S2). Nuclear labeling was not detected in NLS-HA-hNAT1 expressing 
cells using a five- or ten-fold lower copper sulfate concentration compared to the CuAAC 
reaction using 1 mM of copper sulfate. Although higher concentrations of the copper 
sulfate were not tested, we used the following conditions for the CuAAC reaction in the 
paraformaldehyde fixed cells: 1 mM copper sulfate, 2 mM BTTAA ligand, 10 µM Fluor488-alkyne 15, and 10 mM sodium ascorbate.
5.2.5 Cellular labeling by AHA and AAA probes 1-6
Besides AHA probe 1 and AAA probe 2, we previously synthesized in Chapter 3, two additional 
sets of azide-functionalized probes varying in the electron donating and withdrawing 
properties (compounds 3-6, Figure 6A). We hypothesized that the electronic factors of the linker at the para position of the AHA active group influences the rate of heterolytic N-O bond cleavage into nitrenium ions of the N-acetoxy arylamine intermediate.184,185 In addition, the 
linker may also be involved for efficient binding of the substituents to the hNAT enzyme.138,150
Previously, we reported the use of AHA and AAA probes 1-6 in vitro for protein tagging using 
the recombinant enzyme (Chapter 3) and subsequently measured the activation of these 
probes in living cells (Chapter 4). Incubating recombinant hNAT1 with AHA probe 1 resulted 
in strong protein labeling, whereas less pronounced labeling was observed for AHA probes 3 and 5 (Chapter 3). In contrast to labeling by recombinant hNAT1, in HEK-293T cells efficient 
protein labeling was observed using either AHA probe 1, 3, or 5 (Chapter 4). Comparing the 
in vitro results with labeling in cells, we hypothesized that labeling by AHA probes in cells is 
not only the result of activation by endogenous hNAT1, but also of other endogenous enzymes 
(e.g. hNAT2 or sulfotransferases239). Since AHA probes 3 and 5 did result in protein labeling 
in living cells, we tested also their applicability in HEK-293T cells expressing the NLS-HA-
hNAT1.
Strong nuclear labeling was observed in HEK-293T cells overexpressing nuclear hNAT1 that 
were incubated with AHA probe 1, while no labeling was observed using AHA probes 3 and 5 
(Figure 6B). Both non-transfected cells and cells expressing nuclear targeted hNAT1 incubated 
with AHA probe 3 resulted in enhanced cellular labeling, mainly in the cytosol, which was 
not observed in cells incubated with AAA probe 4. Cytosolic labeling was observed with AHA probes 1 and 5, but the intensity was much lower than that observed for AHA probe 3. 
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Figure 6 – Cellular labeling by probes 1-6 in HEK-293T transfected NLS-HA-hNAT1 cells.
A) Schematic presentation and structures of the probes 1-6. B) After incubating the transfected HEK-293T with probes 
1-6, cells were fixed and stained by the CuAAC reaction using Fluor488-alkyne 15 (green). The NLS-HA-hNAT1 was 
detected using the anti-HA antibody (red), and nuclear staining by DAPI (grey). Scale bar = 25 µm.
The nuclear labeling results using the azide-functionalized probes (Figure 6) are consistent 
with the in vitro labeling experiments using recombinant hNAT1 (Chapter 3). This suggests 
that AHA probes 3 and 5 are either not activated by the hNAT1 enzyme (mentioned above) 
or the electronic factors influence the stability of the acetoxy ester intermediate after NAT 
activation. As hypothesized in Chapter 4, the acetoxy ester intermediate of AHA probe 1 will 
be less stable than the less electron-donating AHA probe 3 and AHA probe 5. Consequently, the acetoxy ester intermediate of the electron poor probes 3 and 5 might even diffuse from 
the nucleus resulting in the overall labeling of the NLS-HA-hNAT1 transfected cells, whereas 
AHA probe 1 will probably react fast with amino acid residues residing in the NLS-HA-hNAT1 
and proteins in vicinity of the enzyme.
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 Figure 7 – Time response of nuclear labeling by NLS-HA-hNAT1 using probes 1-6 in living cells.
HEK-293T transfected cells were incubated with AHA probes 1, 3, or 5 for specific time points, or with AAA probes 2, 4, and 6 for 60 minutes. Cells were fixed and stained by the CuAAC reaction using Fluor488-alkyne 15 (green). NLS-HA-
hNAT1 was detected using the anti-HA antibody (red); nuclei were stained by DAPI (grey). Scale bar = 50 µm.
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In order to further evaluate labeling by AHA and AAA probes 1-6 and to assess the cell 
permeability of these probes, we monitored labeling by these probes in living cells expressing 
the nuclear-restricted hNAT1 at different time points (Figure 7). HEK-293T cells were 
transfected with the NLS-HA-hNAT1 followed by incubating the cells with the probes for 
various periods of time. Cells were fixed and the labeling was visualized by the CuAAC reaction 
using the Fluor488-alkyne 15.
Initial nuclear labeling was observed within five minutes and the intensity of labeling 
increased over time using AHA probe 1. The cytosolic labeling observed for the three azide-functionalized probes 1, 3, and 5 increased slowly by incubating the transfected HEK-293T 
cells for longer time periods. In agreement with previous experiments, AHA probe 3 resulted 
in stronger cytosolic signals than AHA probes 1 and 5. Cytosolic labeling was notable after 
thirty minutes in non-transfected and transfected cells and still increased after one hour. The 
rate of labeling by the endogenous enzymes was rather slow compared to the nuclear labeling 
observed within minutes using AHA probe 1 in the cells overexpressing NLS-HA-hNAT1. This 
indicates that AHA probe 1 is easily distributed throughout the cell and is rapidly activated by 
the nuclear-restricted hNAT1 enzyme.
5.2.6 Cytosolic labeling in cells by NES-hNAT1
The general use of the hNAT1 enzyme for subcellular labeling was tested by targeting the 
hNAT1 enzyme to the cytosol using the NES tag. HEK-293T cells transfected with the cytosolic 
targeted hNAT1 (NES-HA-hNAT1) were incubated with the probes 1 and 2 followed by the 
CuAAC reaction (Figure 8). In agreement with the results observed for NLS-HA-hNAT1, 
enhanced labeling in the cytosol was observed using AHA probe 1 in cells expressing NES-
HA-hNAT1. Again, no specific labeling was observed upon incubation with AAA probe 2.
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Figure 8 – Cytosolic labeling in HEK-293T cells expressing NES-HA-hNAT1 using AHA probe 1.
A) Schematic overview. B) After incubating the transfected HEK-293T with the probes 1 or 2, cells were fixed and stained 
by the CuAAC reaction using Fluor488-alkyne 15 (green). NES-HA-hNAT1 was detected using the anti-HA antibody (red) 
and nuclei were stained by DAPI (grey). Scale bar = 25 µm.
Altogether, these results showed nuclear and cytosolic labeling using AHA probe 1 by 
genetically incorporating the NLS or NES at the N-terminus of HA-hNAT1. Importantly, AHA probe 1 did not lead to detectable labeling of the corresponding compartments in cells 
expressing HA-hNAT1 carrying the NLS or NES at the C-terminus (data not shown). According 
to literature, the C-terminal domain of the hNAT enzymes contributes to substrate recognition 
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and is essential to control the enzymatic acetylating activity.198,273,274 This conserved region 
seems to form an active-loop buried inside the enzyme and important for the hydrogen 
bonding network of the catalytic hNAT core.164 Because hNAT is correctly localized by the 
C-terminal NLS and NES signals, we hypothesize that introducing the C-terminal NLS or 
NES results in the misfolding of the C-terminal domain, which interferes with the enzymatic 
activity of the enzyme, but exposes functional targeting signals. Therefore, the hNAT1 enzyme 
does not seem to be suitable for subcellular mapping of organelles or proteins that require a 
C-terminal signaling motif for correct localization.
We also investigated labeling in cells expressing hNAT1 in the mitochondria, peroxisome, or 
ER. We were not able to detect labeling in one of these organelles using AHA probe 1 compared 
to the background signal observed for AHA probe 2 (data not shown). Possibly, the localized 
hNAT1 enzyme is not active in the peroxisome and the ER. Endogenous hNAT1 is mainly 
expressed in the cytosol, which maintains a reducing environment.127 Both the peroxisome and 
the ER have an oxidizing environment275–277, which might lead to the oxidation of the reduced 
Cys68 in hNAT1 resulting in the inactivation of the enzyme. In contrast, the mitochondria maintain a reducing environment278 and we anticipate that hNAT1 is active in this organelle. It 
is more likely that labeling by hNAT1 was not observed in the mitochondria due to low uptake 
of AHA probes in this organelle or the low labeling efficiency by the localized enzyme.
5.3 Concluding Remarks
In this chapter, we set out to develop a novel enzymatic PDL strategy using the hNAT enzyme 
based on the unique N,O-acetyl transfer reaction of synthetic AHA probes resulting in the 
formation of highly reactive arylnitrenium ions, which covalently attach to nucleophilic 
residues residing in DNA, RNA, and proteins. For our studies, we envisioned that protein 
tagging by this unique N,O-acetyl transfer capacity of hNAT can be applied for subcellular 
labeling by subjecting cells expressing the hNAT enzyme at a specific cellular region of interest 
to AHA probes.
Fusing the NLS and NES sequences to the N- or C-termini of the HA-hNAT1 or hNAT2 
enzyme, indeed resulted in the accumulation of hNAT1 in the nucleus or cytosol of HEK-
293T cells transfected with the hNAT1 constructs. However, we were not able to detect 
cells expressing the hNAT2 enzyme, which led us to hypothesize that the overexpression 
of hNAT2 is detrimental for the viability of the cells. Incubating NLS-HA-hNAT1 or NES-HA-
hNAT1 expressing cells with AHA probe 1 resulted in strong nuclear and cytosolic labeling, 
respectively, while protein labeling using this probe was not observed in cells expressing 
HA-hNAT1 containing a C-terminal NLS- or NES-tag. In addition, we were not able to detect 
labeling in the peroxisome, the ER, and the mitochondria using AHA probe 1. Furthermore, 
nuclear labeling was not observed in cells expressing the NLS-tagged hNAT1 incubated with 
AHA probes 3, 5, 7 or 9.
In summary, with ectopically expressed localized hNAT1, we show fast protein labeling at a 
subcellular level, while avoiding the use of potentially cell-disturbing cofactors. The unique 
N,O-acetyl transfer feature by the hNAT1 enzyme activated AHA probe 1 into highly reactive 
nitrenium ions, resulting in defined labeling in the nucleus or cytosol within minutes in 
living cells. Labeled proteins were modified with an alkyne fluorophore by means of a CuAAC 
reaction and visualized by fluorescent confocal microscopy. The electronic properties of the 
probes seem important for the subcellular use, as local labeling was only observed for the 
electron-rich AHA probe 1 and not for the more electron-deficient AHA probes 3 and 5. We 
anticipate that this enzymatic NAT labeling approach is suitable for a PDL proteomics setup 
with high spatial and temporal resolution to identify and characterize subcellular protein 
assemblies.
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Figure S1 – Localization of the hNAT1 enzyme to the cytosol in living cells.
HEK-293T cells were either not transfected or transfected with the NES-HA-hNAT1 and fixed, followed by immunostaining 
against the HA-tag (red), against the hNAT enzyme (green), and nuclear staining by DAPI (grey). Background labeling 
by each secondary antibody was determined by single staining with the Alexa Fluor conjugated antibodies goat anti-
mouse-633 (m633) or goat anti-rabbit-488 (p488) only. In addition, NES-HA-tagged hNAT1 was as well stained only 
for HA or the hNAT enzyme to examine photobleaching of the fluorophores in each of the channels. Scale bar = 25 µm. 
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Figure S3 – Structures of the water-soluble ligands BTTA, THPTA, and BTTES.
BTTAA = 2-[4-{(bis[(1-tert-butyl-1H-1,2,3-triazol-4-yl)methyl]amino)methyl}-1H-1,2,3-triazol-1-yl]acetic acid, THPTA 
= tris[(1-hydroxy- propyl-1H-1,2,3-triazol-4-yl)methyl]amine, BTTES = 2-[4-{(bis[(1-tert-butyl-1H-1,2,3-triazol-4-yl)
methyl]amino)- methyl}-1H-1,2,3-triazol-1-yl]ethyl hydrogen sulfate. 
Table S1 - Plasmids used for expression of tagged hNAT1 in mammalian cells. 
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NN
N
N
N N
N
N
N
N
HO
HO
OH
THPTA
O
OH
N N
N
N
N
N
NN
N
N
BTTAA BTTES
N N
N
N
N
N
NN
N
N
O
S
OH
OO
name
HA-hNAT1
NES-HA-hNAT1
HA-hNAT1-NES
NLS-HA-hNAT1
HA-hNAT1-NLS
mito-HA-hNAT1
PTS2-HA-hNAT1
ss-HA-hNAT1-
KDEL
HA-hNAT2
NES-HA-hNAT2
HA-hNAT2-NES
NLS-HA-hNAT2
HA-hNAT2-NLS
promoter/vector
CMV/pcDNA3
CMV/pcDNA3
CMV/pcDNA3
CMV/pcDNA3
CMV/pcDNA3
CMV/pcDNA3
CMV/pcDNA3
CMV/pcDNA3
CMV/pcDNA3
CMV/pcDNA3
CMV/pcDNA3
CMV/pcDNA3
CMV/pcDNA3
details
HA-tag sequence: YPYPDVPDYA
nuclear export signal (NES) sequence:
LQLPPLERLTLD19
nuclear localization signal (NLS) sequence:
PKKKRKVDPKKKRKVDPKKKRK19
mitochondrial signal peptide (mito)
sequence: MLATRVFSLVGKRAISTSVCVRAH19
peroxisomal targeting signal 2 (PST2)
sequence: GARLQVVLGHLA75
signal sequence (ss):
ETDTLLLWVLLLWVPGSTGD19
C-terminal ER retention sequence: KDEL19
features
BamHI-HA-hNAT1-
STOP-XhoI
BamHI-NES-HA-
hNAT1-STOP-XhoI
BamHI-HA-hNAT1-
NES-STOP-NotI
BamHI-NLS-HA-
hNAT1-STOP-XhoI
BamHI-HA-hNAT1-
NLS-STOP-XhoI
BamHI-mito-HA-
hNAT1-STOP-XhoI
BamHI-PST2-HA-
hNAT1-STOP-XhoI
BamHI-ss-HA-
hNAT1-KDEL-
STOP-NotI
BamHI-HA-hNAT2-
STOP-XhoI
BamHI-NES-HA-
hNAT2-STOP-XhoI
BamHI-HA-hNAT2-
NES-STOP-NotI
BamHI-NLS-HA-
hNAT2-STOP-XhoI
BamHI-HA-hNAT2-
NLS-STOP-XhoI
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Table	S2	-	Oligonucleotide	sequences	used	for	amplification	of	the	hNAT1	gene,	including	targeting	or	tags.
primer name
BamHI-HA-
hNAT1/2
BamHI-NES-
HA
BamHI-NLS-
HA
BamHI-mito-
HA
BamHI-PTS2-
HA
BamHI-ss-HA
hNAT1-STOP-
XhoI
hNAT1-NES-
STOP-NotI
hNAT1-NLS-
STOP-XhoI
hNAT1-KDEL-
STOP-NotI
hNAT2-STOP-
XhoI
hNAT2-NES-
STOP-NotI
hNAT2--NLS-
STOP-XhoI
details comments
forward primer encoding BamHI restriction
site, Kozak sequence, the HA-tag, and
overlapping with hNAT1/2
forward primer encoding BamHI restriction
site, Kozak sequence, the NES-tag, and
overlapping with the HA-tag
forward primer encoding BamHI restriction
site, Kozak sequence, the NLS-tag, and
overlapping with the HA-tag
forward primer encoding BamHI restriction
site, Kozak sequence, the mito-tag, and
overlapping with the HA-tag
forward primer encoding BamHI restriction
site, Kozak sequence, the PTS2-tag, and
overlapping with the HA-tag
forward primer encoding BamHI restriction
site, Kozak sequence, the ss-tag, and
overlapping with the HA-tag
reverse primer encoding XhoI restriction
site, a STOP codon, and overlapping with
hNAT1
reverse primer encoding XhoI restriction
site, a STOP codon, the NES-tag, and 
overlapping with hNAT1
reverse primer encoding XhoI restriction
site, a STOP codon, the NLS-tag, and 
overlapping with hNAT1
reverse primer encoding NotI restriction
site, a STOP codon, the KDEL sequence,
and overlapping with hNAT1
reverse primer encoding XhoI restriction
site, a STOP codon, and overlapping with
hNAT2
reverse primer encoding XhoI restriction
site, a STOP codon, the NES-tag, and 
overlapping with hNAT2
reverse primer encoding XhoI restriction
site, a STOP codon, the NLS-tag, and 
overlapping with hNAT2
ATATAT GGATCC GCCACC ATG TATC
CGTACGACGTACCGGATTATGC GACGCG
TGACATTGAAGCATAT
ATATAT GGATCC GCCACC ATG CTGC
AGCTGCCGCCACTGGAACGTCTGACGCTG
GAT TATCCGTACGACGTACCGG
ATATAT GGATCC GCCACC ATG CCGA
AGAAGAAACGTAAGGTTGACCCGAAAAAGA
AGCGCAAGGTGGACCCAAAGAAAAAGCGT
AAAGTG TATCCGTACGACGTACCGG
ATATAT GGATCC GCCACC ATG CTGG
CGACGCGTGTGTTCAGCCTGGTTGGCAAA
CGTGCGATCTCGACCTCCGTGTGCGTGCG
CGCGCAT TATCCGTACGACGTACCGG
ATATAT GGATCC GCCACC ATG GGCG
CCCGGCTGCAGGTGGTCCTGGGCCACCTG
GCC TATCCGTACGACGTACCGG
ATATAT GGATCC GCCACC ATG GAGA
CAGACACACTCCTGCTATGGGTACTGCTG
CTCTGGGTTCCAGGTTCCACTGGTGAC
TATCCGTACGACGTACCGG
ATATAT CTCGAG CTA AATAGTAAAAA
ATCTATCACCATGTTTGG
ATATAT CTCGAG CTA ATCCAGCGTCA
GACGTTCCAGTGGCGGCAGCTGCAG AAT
AGTAAAAAATCTATCACCATGTTTGG
ATATAT CTCGAG CTA CACTTTGCGTT
TCTTCTTTGGGTCCACCTTGCGCTTCTTC
TTCGGGTCAACCTTACGTTTCTTCTTCGG
AATAGTAAAAAATCTATCACCATGTTTGG
ATATAT GCGGCCGC CTA CAGTTCATC
TTT AATAGTAAAAAATCTATCACCATGT
TTGG
ATATAT CTCGAG CTA AATAGTAAGGG
AGCCATCACCAG
ATATAT CTCGAG CTA ATCCAGCGTCA
GACGTTCCAGTGGCGGCAGCTGCAG AAT
AGTAAGGGAGCCATCACCAG
ATATAT CTCGAG CTA CACTTTGCGTT
TCTTCTTTGGGTCCACCTTGCGCTTCTT
CTTCGGGTCAACCTTACGTTTCTTCTTCG
G AATAGTAAGGGAGCCATCACCAG
5.6 Supplementary Information
Synthetic procedures
The synthesis of AHA and AAA probes 1-10 is described in the Supplementary Information of 
Chapter 3 (“Synthetic procedures”). 120 Chapter 5
Cloning of targeted hNAT1 constructs
Genes encoding hNAT1 or hNAT2 without or with a targeting sequence were cloned by 
standard techniques in the pcDNA3 vector containing the CMV promoter for expression in 
mammalian cells. Supplementary Table S1 summarizes the plasmids used for hNAT expression 
in mammalian cells. 
Oligonucleotide primers and a gBlock fragment encoding the hNAT1 or hNAT2 gene were 
synthesized by Integrated DNA Technologies (see Chapter 3). PCR reactions were conducted 
with 1× HF Buffer (New England Biolabs), 1 unit of Phusion polymerase, 20 ng of DNA template, 
100 µM dNTP, 10 pmol of each of the primers in a total volume of 50 µL. The reaction mixtures 
were heated at 98 °C for 30 sec, followed by 25 cycles for 20 sec at 98 °C, 30 sec at 58 °C, and 2 
min at 72 °C. To ensure complete extension, the reaction mixture was incubated at 72 °C for 4 
min after the 25 cycles. The PCR products were purified with a QIAquick PCR purification kit 
(Qiagen). Subsequently, the PCR products and the plasmid vector were digested with 2 units of 
each restriction enzyme for 1 h at 37 °C. The digestion products were isolated with a QIAquick 
gel extraction kit (Qiagen). The vector DNA (50 ng) was ligated with one of the hNAT1 inserts 
(30 ng) with T4 Ligase (New England Biolabs) overnight (o/n) at 16 °C. After heat inactivation 
of T4 Ligase (20 min at 65 °C), supercompetent Top 10 cells were transformed with the 
ligation mix (25 ng vector) and selected for the correct antibiotic resistance. The plasmids 
from positive colonies were isolated with the Miniprep DNA purification system (Qiagen) 
and sequences were verified by automated DNA sequencing (RadboudUMC sequence facility 
Nijmegen, the Netherlands).
Mammalian cell culture and transfection
The HEK-293T cell line (passage number < 25) was cultured in DMEM supplemented with 
10 % heat-inactivated fetal bovine serum (FBS) and supplemented with 100 U/mL penicillin, 
and 100 µg/mL streptomycin. Cells were grown at 37 °C under 5 % CO2 for 24-48 h before 
labeling experiments were performed on polystyrene microplates (in case of a 6-well with 
2 mL of 80,000 cells/mL). For imaging experiments, cells were grown on 10 × 10-mm glass 
coverslips in 48-wells (approximately 300 µL of 80,000 cells mL-1). To improve the adherence 
of the HEK-293T cells, glass coverslips were pre-treated with poly-L-lysine (0.1 mg mL-1; Sigma-Aldrich) for 5 min and washed three times with 1× PBS. Cells were transfected at 
60-80 % confluency using either the standard TransXI-T2® dynamic delivery system protocols 
(MĬrus) or by polyethylenimine (PEI, Sigma-Aldrich, 1 mg/mL in 1× PBS) with the targeted 
hNAT1 constructs in a pcDNA3 vector containing the CMV promoter added at a 3:1 ratio of 
TransXI-T2 or PEI (µg):total DNA (µg). After 36 h of transfection, cells were labeled and/or 
directly fixed followed by immune-staining.
HEK-293T immune-staining and confocal microscopy
(Non)-transfected HEK-293T cells were grown for 48 h on pre-coated coverslips in a 48-well 
plate. After discarding the growth medium, cells grown on coverslips were rinsed with 1× 
PBS followed by labeling (see protocol ‘Subcellular labeling for confocal microscopy’) and/or 
directly fixed for 15 min at room temperature (rt) using 500 µL 3.7 % v/v formaldehyde in 1× 
PBS. Cells were briefly washed with 1× PBS and permeabilized with 500 µL ice cold methanol 
for 5 min. After two brief washes with 1× PBS, cells were blocked with 500 µL of 3 % w/v BSA 
in 1× PBS o/n at 4 °C. In case cells were fixed and permeabilized with acetone/methanol, cells 
were incubated for 20 min with ice-cold acetone/methanol (1:1).
5
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The primary antibodies were diluted in 3 % w/v BSA in 1× PBS, 1:1,000 for anti-HA mouse 
(Sigma-Aldrich), 1:500 for anti-hNAT rabbit, 1:1000 anti-COX-IV rabbit (GeneTex), 1:100 anti-
Catalase rabbit (GeneTex), 1:250 anti-PDI rabbit (gift from the department of Cell Biology 
from the RadboudUMC). The cells were incubated with 300 µL of the antibodies for 1 h at 
rt, followed by three washes with 1× PBS for of at least 5 min each. Secondary Alexa Fluor 
conjugated antibodies goat anti-mouse-633, goat anti-mouse-488, goat anti-rabbit-555 and goat 
anti-rabbit-488 (Invitrogen) were diluted 1:300 in 3 % w/v BSA in 1× PBS. As well, 300 µl of 
the secondary antibodies was applied on the coverslips for 1 h at rt following three washes 
with 1× PBS of at least 5 min each. Next, cells were stained with 300 µL 4′,6-Diamidine-2′-
phenylindole dihydrochloride (DAPI, 1 µg/mL; Sigma-Aldrich) for 5 min in 1× PBS. Finally, 
coverslips were mounted using Mowiol®4-88 mounting medium (Sigma-Aldrich) and the 
samples were imaged on a Leica SP_8 confocal microscope 63× magnification with 1.0 digital 
zoom. Images were processed using ImageJ64 software.
Subcellular labeling visualized by confocal microscopy
Probe incubation of cells on coverslips – Transfected HEK-293T cells were grown for 48 
h on pre-coated coverslips in a 48-well plate (see protocol mammalian cell culture and 
transfections). Next, the cells were incubated with 300 µL pre-warmed medium containing 100 µM of probe 1-10 (10 mM stock in DMSO) for a specific time at 37 °C under 5 % CO2. 
Labeling was halted by three brief washes of 300 µL blocking solution, containing 0.6 µL of 
500 mM N-hydroxy-N-phenylacetamide (dissolved in DMSO), 3 µL 1 M aniline (diluted in 
DMSO), and 30 µL of 1 M imidazole in 1× PBS (for a final concentration of 1 mM N-hydroxy-N-
phenylacetamide, 10 mM aniline, and 100 mM imidazole). 
Visualizing probe labeling – After labeling in the living HEK-293T, the cells were fixed and 
permeabilized (as described above in immune fluorescence and confocal microscopy) and 
labeling was visualized. Next, BODIPY labeled cells were directly immune-stained and 
visualized by confocal microscope (488 nm for BODIPY probe). Biotinylated cells were 
blocked using 3 % BSA-1x PBS o/n at 4 °C after fixation and permeabilization. These cells 
were stained with the primary antibody against the HA-tag and with the secondary antibody 
and the Streptavidin-F488 for 1 h at rt (1:3,000; Thermo Fisher Scientific). Biotinylation was 
visualized at 488 nm by the confocal microscope. Azide-labeled cells were directly subjected 
to the CuAAC reaction after fixing the cells. The CuAAC reaction was performed for 2 h at rt using 300 µL of CuAAC mix. The standard CuAAC mix contained 2 mM BTTAA, 1 mM CuSO
4
, 10 µM rhodamine110-PEG
4
-alkyne (Fluor488-alkyne 15, dissolved in DMSO, Sigma-Aldrich), 
and 10 mM sodium ascorbate (added last) in 1× PBS. The cells were washed two times with 1× PBS, once with PBST (1× PBS, 0.1 % w/v Tween-20 (MP Biomedicals), and once with 3 % 
w/v BSA in 1× PBS for at least 5 min. Finally, the HA-tag of the hNAT1 enzyme and the nucleus 
were visualized by immune fluorescence (see immune fluorescence and confocal microscopy 
for details) and samples were imaged on the confocal microscope.
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Adopting a bump-hole strategy to establish 
an orthogonal hNAT1-ligand pair
566666
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Abstract
The aim of the study described in this chapter was to optimize the human arylamine 
N-acetyltransferase (hNAT) proximity-dependent labeling (PDL) strategy by limiting the 
background labeling by the endogenous hNAT enzymes (as observed in Chapter 5). We 
employed a bump-hole procedure to create a hNAT mutant that recognizes bulky substrates, 
which are not capable of binding to the wild type enzyme. Guided by the crystal structure of 
the hNAT enzyme, we selected two amino acids of the hNAT1 enzyme, Phe37 and Ile106, and 
mutated these amino acids to a valine or alanine/glycine (F37V, I106A, I106G, or the double 
mutant F37V, I106A), thereby creating a cavity in the substrate binding pocket. All recombinant 
hNAT1 variants were active, as shown by the ability to N-acetylate the 4-aminoazobenzene 
(4-AAB) substrate using acetyl coenzyme A (acetyl-CoA) as acetyl source. Both 2-ethylaniline 
(2-EA) and 2-isopropylaniline (2-iPA) competed with the N-acetylation of 4-AAB by hNAT1 
(I106A) and hNAT1 (I106G), whereas this was not observed for wild type hNAT1. We envision 
that the hNAT PDL efficiency can be improved by combining hNAT1 (I106G) with a newly 
designed 2-ethyl or 2-isopropyl substituted hydroxamic acid in cells concomitant with the 
lack of labeling by the endogenous enzymes.
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6.1 Introduction
In Chapter 5, we have established a novel enzymatic proximity-dependent labeling (PDL) method based on the human arylamine N-acetyltransferase 1 (hNAT1; more details of 
the hNAT enzymes are described in Chapter 2). This strategy is based on the activation of 
N-acetyl-N-hydroxy arylamines (N-arylhydroxamic acids; AHA probes) in cells expressing 
spatially-restricted hNAT1. The activated AHA probes undergo fast heterolytic N-O bond 
cleavage into nitrenium ions depending on the aryl substituents.184,185 The nitrenium ions 
then react with nucleophilic residues residing in proteins in close vicinity of the localized 
enzyme.189,203 As discussed in Chapter 5, we observed nuclear and cytosolic labeling by 
incubating cells expressing hNAT1 in these cellular compartments with a synthetic electron-
rich AHA probe, as evidenced by microscopy imaging. However, labeling was also observed in 
lysates of cells subjected to AHA probes, irrespective of the presence of ectopically expressed 
hNAT1 (Chapter 4 and 5). This background labeling is likely due to AHA probe activation by 
the endogenous hNAT enzymes.Although the NAT proximity labeling approach has potential to visualize the proteome at a 
subcellular level, it is beneficial to circumvent the observed background labeling in the lysate 
caused by endogenous enzymes. To overcome this issue, we applied a bump-hole approach 
to change the substrate selectivity of the hNAT enzyme (Figure 1).279,280 The substrate binding 
site is enlarged by site-directed mutagenesis to accommodate a bulky substrate that cannot 
bind wild-type hNAT due to steric clashes. Consequently, the bulkier ligand will only bind to the designed mutant thereby eliminating activation and labeling by endogenous hNAT 
enzymes. 
6
mutagenesis
(hole)
synthesis
ligand
WT
(bump)
WT
WT mutant mutant mutant
orthogonal pair
Figure 1 – Schematic representation of the bump-hole strategy used to create a cavity in the hNAT enzyme and 
a bump on the arylamine substrate.
The wild type enzyme (WT) is modified by mutagenesis in order to enlarge the substrate binding site and the ligand is 
substituted with a bulky group. The mutant recognizes both the original and bulky ligand, whereas the wild type enzyme 
only binds to the original substrate. In this way, an orthogonal mutant-ligand pair is developed.
The bump-hole strategy was successfully applied to create chemical probes with single-
target selectivity for the Bromodomain and Extra-Terminal domain (BET) family. This family 
consists of four BET proteins, Brd2, Brd3, Brd4, and Brdt, which play an important role in the 
transcriptional regulation of genes involved in controlling cell growth and cell-cycle.281 Small-
molecule inhibitors have been developed that target the bromodomains of the BET proteins, 
though these inhibitors were not selective for the individual BET family members.281 Baud and 
coworkers successfully created an ethyl derivative of an existing small-molecule BET inhibitor 
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(I-BET/JQ1), which is up to 540-fold more selective for the BET mutant, having a leucine 
replaced by an alanine in the binding pocket, relative to the wild-type bromodomains.281 The 
design of the orthogonal bromodomain/ligand pair allowed to dissect the role of individual 
bromodomains in the binding of chromatin by the BET proteins.
In order to design a mutant hNAT1 enzyme and a complementary orthogonal ligand, the 
nature of the mutation and the nature of the bump should be balanced. Larger holes in the 
binding pocket of the enzyme will likely enhance the chances of binding of the bumpy ligand, 
but the enlarged binding pocket might also disrupt the structure and/or function of the 
enzyme. Therefore, it is important to develop an orthogonal mutant-ligand pair for which 
the enzymatic activity is retained. In this chapter, we will discuss in more detail the binding 
pocket of hNAT1 and hNAT2 in order to select proper residues for mutation. Next, the mutants 
are generated by site-directed mutagenesis, followed by expression and purification of the 
enzymes. Finally, we will measure their N-acetylation activity and explore the possibility 
to compete with the N-acetylation reaction by adding a variety of arylamine substrates at 
different molar ratios.
6.2 Engineering a hole in the substrate binding pocket of 
the hNAT enzyme
6.2.1 General structure and acetylation reaction of the hNAT enzymes
Humans express two homologues of the NAT enzyme, human NAT 1 (hNAT1) and human NAT 2 
(hNAT2), which catalyze the acetyl coenzyme A (acetyl-CoA)-dependent N- and O-acetylation 
of many arylamines (Figure 2A).136,138,147 Both enzymes contain a well-conserved protease-
like catalytic triad (Cys68-His107-Asp122) buried in a deep cleft (Chapter 2, Figure 7B).150 
In the absence of a ligand, Cys68 is reduced and interacts with His107, forming a thiolate-
imidazolium ion pair (Figure 2B). Asp122 is required for catalysis and structural stability of 
the hNAT enzymes (Figure 2B).150 The arrangement of these three residues is maintained by 
other highly conserved amino acids in or close to the catalytic site of the hNAT enzymes.150
The acetylation reactions by the hNAT enzymes follow a ping-pong bi-bi mechanism, in 
which the acetyl-CoA is released before the acceptor substrate binds to the enzyme (Figure 
2C).140,141,161 The acetyl group is first transferred from acetyl-CoA by the NAT enzyme to the 
sulfhydryl group of the Cys68 of the enzyme itself. Binding of an arylamine substrate to the 
acetylated NAT enzyme will then result in the transfer of the acetyl group from the enzyme 
to the arylamine substrate, leading to a deacetylated enzyme and an acetylated arylamine 
ligand.
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Figure 2 – Overview of the overall structure and acetylation reaction by the NAT enzymes.
A) Acetyl-CoA dependent N- and O-acetylation by the NAT enzyme. B) Schematic representation of the catalytic triad 
Cys68-His107-Asp122 in NAT enzymes. C) Acetylation of arylamine acceptors (green) by NAT enzymes follow a ping-
pong bi-bi mechanism using for example acetyl-CoA as acetyl donor (red).
6.2.2	 Substrate	specificity	of	the	hNAT	enzymes
In order to design a good mutant-ligand pair of the hNAT enzyme recognizing substituted AHA 
probes, we investigated the substrate specificities of several substituted anilines for hNAT1 
and hNAT2 in relation to the amino acid composition of both enzymes. Other investigators 
have already compared the hNAT enzymatic activities with a wide range of aniline substrates by measuring the binding constants and N-acetylation reaction rates.138,197 hNAT1 and hNAT2 
have distinct substrate specificities as a result of minor differences in the amino acid sequence, 
despite the conserved arrangement of the catalytic site in both enzymes.
Aniline (ANL) is acetylated by both the hNAT1 and hNAT2 enzymes (Table 1) and interacts 
with hydrophobic residues residing in the active site of these enzymes, forming ring-stacking 
pi-pi interactions.150 The affinity of ANL for hNAT1 is about 4.5-fold higher than that for hNAT2, 
whereas the ANL acetylation rate of hNAT2 is about 2.5-fold faster than of hNAT1 (Table 
1).196,197 Interestingly, 3-alkyl substituted anilines have enhanced affinity for both hNAT1 and hNAT2 compared to ANL (Table 1), indicating that this position of the aromatic ring 
contributes to favorable binding interactions with for example Ser215, Leu209, and Phe217, 
residues that are present in both enzymes (Figure 4A).197 In addition, 3,5-dimethylaniline (3,5-
DMA) likely interacts with Phe125 in hNAT1, which is not present in hNAT2(Ser125) (Figure 
3B).197 The interaction between 3,5-DMA with Ser125 is compensated in hNAT2 by additional 
hydrophobic interactions with Phe93, which cannot occur in hNAT1 (Val93) (Figure 3B), and 
explains possibly the enhanced selectivity of hNAT2 for this substrate (Table 1).197
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Table	1	–	Binding	affinity	(Km) and catalytic rate (kcat,app) for ANL substrates of the hNAT enzymes.
A) Structures of the ANL-based substrates. B) Binding affinity and catalytic rate were based on the decrease in absorbance 
of the acetyl donor (p-nitrophenyl acetate) in presence of various concentrations of the arylamine substrates. Results are 
based on three experiments and expressed as the means ± standard deviation. a not determined. The rate of N-acetylation of 2-EA (20 mM) by hNAT1 was 2.2 µmol mg-1 min-1. b n.d., not determined. N-acetylation was not detectable at a 2,6-
DMA concentration of 50 mM. Source: Liu et al.197
A
NH2
ANL
NH2
R1
R2
R3
R5
R4
2-MA R1 = CH3
2-EA R1 = CH2-CH3
2,6-DMA R1 = R5 = CH3
3-EA R2 = CH3
3,5-DMA R2 = R4 = CH3
4-MA R3 = CH3
4-EA R3 = CH2-CH3
HO
OHO
NH2
PAS
ANL
PAS
4-ABP
2-MA
2-EA
2,6-DMA
3-EA
3,5-DMA
4-MA
4-EA
hNAT1 hNAT2
2,490 ± 140
59 ± 9.2
191 ± 13
2,320 ± 170
n.d.a
n.d.b
576 ± 27
742 ± 27
483 ± 28
205 ± 20
Km,app 
(µM)
281 ± 5.1
591 ± 32
243 ± 5.4
12 ± 0.83
n.d.a
n.d.b
310 ± 7.0
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256 ± 5.6
111 ± 8.1
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(s-1)
B
[kcat/Km (hNAT1)]/
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2,000
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0.35
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In contrast to 3-akyl substituted anilines, anilines with increased hydrophobicity at the fourth 
position of the carbon ring (e.g. 4-methylaniline (4-MA) and 4-ethylaniline (4-EA); Figure 
3A) have higher binding affinity for hNAT1 compared to that for hNAT2.197 This preference of 
hNAT1 might be explained by hydrophobic interactions with the side chain methyl group of 
Val216, which is not available in hNAT2 (Ser216; Figure 3B).197
Substantially lower N-acetylation levels of 2-alkyl substituted anilines were observed for 
the hNAT enzymes compared to the 3- and 4-alkyl substituted anilines.197 N-acetylation of 
2-methylaniline (2-MA; Figure 3A) was about 22 times slower by hNAT1 than that of ANL, 
about 7 times in case of hNAT2.197 In addition, hNAT2 N-acetylated 2-ethylaniline (2-EA; 
structure is shown in Figure 3A) about 12 times slower than ANL, whereas N-acetylation of 2-EA by hNAT1 could not be determined. N-acetylation of 2,6-dimethylaniline (2,6-DMA; 
Figure 3A) could not be determined for both hNAT1 or hNAT2.197 These slower reaction rates 
for 2-alkyl substituted anilines might be a result of steric clashes within the catalytic site, 
and/or steric hindrance between the 2-alkyl substituent and amino acid side chains residing 
in the substrate binding pocket of the hNAT enzymes.196,197 For example, the smaller Ser125 in hNAT2 cause possibly less hindrance for binding of 2-MA or 2-EA compared to hNAT1 
(Phe125) and might explain the more favorable N-acetylation of these substrates by hNAT2.196
6
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Figure 3 – Structural information about the hNAT1 and hNAT2 binding pocket and bump-hole candidates.
A-B) The catalytic binding pocket of hNAT1 (pdb file: 2pqt) is shown in grey, hNAT2 (pdb file: 2pfr in blue, hNAT1 
mutants (pdb file: 2pqt) in yellow, and Cys68 in hNAT1 covalently binding acetanilide (Cys68-acetanilide) in red. A) 
Zoom in of the catalytic binding pocket of hNAT1 and hNAT2. B) Zoom in of hNAT1 and hNAT1 mutants F37V and I106G. 
C) Structures of the amino acids mutated in hNAT1 (yellow) and the bulkier aniline substrates (green).
6.2.3 Design of a hole in the hNAT enzyme
When creating a mutant hNAT1 enzyme to recognize bulkier substrates, conserved amino acids 
of the catalytic triad cannot be exchanged. In addition, Phe125 in hNAT1 is critical for the size 
of the substrate binding pocket and forms favorable π-π stacking with p-aminosalicylic acid 
(PAS; Figure 3A).150 The interaction between Phe125 in hNAT1 and PAS plays an important 
role in the correct positioning of the substrate for catalysis (Figure 3B).150 We hypothesized 
that the principle of π-π stacking interactions extends to other arylamine substrates with 
similar structures, and therefore Phe125 was excluded for mutation. The binding of PAS to the hNAT1 enzyme is also a result of interactions with the backbone 
carbonyl of the isoleucine positioned at 106 (a valine in hNAT2).136,150,198 We noticed that the 
Ile106 is located around the 2-alkyl substituent of the arylamines (Figure 3C) and might as 
well be a possible candidate for the bump-hole strategy by mutating the amino acid to alanine 
or even glycine (I106A or I106G, respectively). 
We envisioned further that exchanging Phe37 in the binding pocket of hNAT to an aliphatic 
amino acid can provide sufficient space for a bulkier ligand. Since Phe37 is not known to 
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play a role in catalysis and is not required for orienting the substrate, we decided to mutate 
this amino acid to a valine (F37V) in order to create a cavity in the binding pocket of the 
hNAT1 enzyme (Figure 3C). Furthermore, a larger hole in the binding pocket of hNAT1 can 
be created by combining the F37 and I106, which are positioned opposite to each other. We 
hypothesized that the depicted mutations (F37V, I106A, or I106G) result in sufficient space 
for 2-alkyl substituted ligands, such as 2-EA, 2-isopropylaniline (2-iPA), or possibly 2,6-DMA 
(Figure 3D).
6.3 Results
6.3.1 Producing recombinant hNAT1 and hNAT2 enzymes
In order to determine the effect of the point mutations on the activity of the NAT enzyme and 
binding affinity for arylamines, we first expressed and purified the mutant hNAT1 enzymes as 
well as wild type hNAT1 and hNAT2. In Chapter 3, the hNAT1 and hNAT2 enzymes equipped 
with a histidine- or glutathione S-transferase-tag (H
6
-hNAT1 or GST-hNAT2) were expressed in Escherichia coli (E. coli) and purified from bacterial lysates.
Similar to the previously described wild type hNAT1 construct, the mutant hNAT1 enzymes 
were equipped with a histidine-tag (H
6
-hNAT1 proteins) to facilitate purification of the enzymes from E. coli. The mutations F37V, I106G, I106A, and F37V, I106A were introduced 
by site-directed mutagenesis and the constructs were subsequently expressed in E. coli using 
similar conditions as for wild type hNAT1. The H
6
-tagged mutant enzymes were then purified using Ni2+ NTA chromatography resulting in relatively pure mutant hNAT1 fractions (Figure 
4). The total protein concentration for each enzyme was determined at 280 nm and the 
elution fractions were then concentrated to 2 mg/mL. Since we measured the total protein 
concentration of the samples, the concentration of wild type hNAT1 slightly differed from that 
of the hNAT1 mutants. Although the concentration of hNAT2 was lower than hNAT1 due to 
the difference in purity of these samples, we did not correct for this during the activity assays.
Electrospray ionization time-of-flight (ESI-TOF) mass spectrometry was used to verify the 
expected molecular weight of the mutant H
6
-hNAT1 enzymes (Supplementary Figure S2). Next 
to confirming the theoretical size of the enzymes, a second peak (+ 178 Da) was measured in 
the mutant samples, which was previously also observed for wild type hNAT1. This peak is 
likely caused by posttranslational gluconoylation of the N-terminal H
6
-tag.217,218
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Figure	4	–	Expression	and	purification	of	H6-tagged mutant hNAT1 enzymes.
A-F) Elution fractions loaded on SDS-PAGE. The molecular weight of each mutant was confirmed by mass spectrometry 
(Supplementary Figure S2, respectively). The SDS-PAGE gels were stained with Coomassie Brilliant Blue. In each panel 
the left lane contains molecular weight markers.
6.3.2 N-acetylation of 4-aminoazobenzene by (mutant) hNAT enzymes
N-acetylation of 4-AAB by the H6-hNAT1 
To determine the influence of the introduced mutations on the enzymatic activity of hNAT1, 
we used a spectrophotometric kinetic assay to measure N-acetylation by the recombinant 
mutant and wild type hNAT enzymes (Figure 5A).128 The 4-aminoazobenzene hNAT substrate 
(4-AAB) was used as the acceptor that is acetylated in the presence of the acetyl donor, acetyl-
CoA. Upon N-acetylation of the 4-AAB substrate, the absorbance maximum of 4-AAB (386 nm) 
will shift to that of the corresponding N-acetylated 4-aminoazobenzene product (Ac-4-AAB; 
348 nm).128 We will follow the decrease in relative absorbance of the 4-AAB NAT substrate 
(4-AAB; 386 nm) in time to measure the N-acetylation reaction rate of the recombinant wild 
type and mutant hNAT enzymes.
As shown in Figure 5B, the transfer of the acetyl group from acetyl-CoA to the substrate 4-AAB 
was completed after approximately five minutes when catalyzed by hNAT1. Importantly, 
no decrease in the relative absorbance was measured by incubating the 4-AAB acceptor 
in presence or absence of hNAT1, and without the acetyl-CoA donor (Figure 5B). However, adding hNAT1 to the substrate 4-AAB without the presence of acetyl-CoA resulted in a lower relative absorbance compared to the 4-AAB only (Figure 5B). The difference in relative absorbance of 4-AAB in presence or absence of hNAT1 is likely the effect of the binding of this 
substrate to the catalytic pocket of the enzyme.
The final relative absorbance reached after N-acetylation of 4-AAB by hNAT1 is higher than that of Ac-4-AAB (set at 0). The final relative absorbance of Ac-4-AAB was not affected by 
incubating this substrate with hNAT1 without acetyl-CoA (Figure 5B), indicating that the 
presence of hNAT1 does not influence the absorbance of Ac-4-AAB. In case of the hNAT1 
reaction, the acetyl-CoA donor was added in a two-fold molar excess compared to 4-AAB. 
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Since the N-acetylation reaction is reversible, there will be an equilibrium between acetyl-CoA and N-acetylated 4-AAB by hNAT1 depending on the specificities for these substrates. Likely, the difference in relative absorbance of the Ac-4-AAB reaction product formed by hNAT1 and the Ac-4-AAB substrate is the result of this reaction equilibrium. Incubating 4-AAB with 
acetyl-CoA in the absence of the enzyme did not result in any spontaneous N-acetylation of 
4-AAB (data not shown). Altogether, these results show that acetyl-CoA is an essential acetyl source for the enzymatic N-acetylation of 4-AAB by wild type hNAT1.
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Figure 5 – N-acetylation of 4-AAB by hNAT wild type or mutant enzymes using acetyl-CoA as donor source.
hNAT1 = H
6
-hNAT1; hNAT2 = GST-hNAT2; A) Schematic representation. B-C) To 4-AAB the depicted enzyme was added, 
and acetylation was started by addition of acetyl-CoA. The absorbance of 4-AAB at t=0 is set at 1 after correction for the absorbance of Ac-4-AAB. Shown is a non-linear regression fit of the relative absorbance of 4-AAB at 386 nm followed in 
time using a one phase decay model. D) The observed reaction rates (kobs) were calculated from C by using a one phase 
decay model.
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N-acetylation of 4-AAB by the H6-hNAT1 mutants and GST-hNAT2
After we successfully measured N-acetylation of 4-AAB by wild type hNAT1, the hNAT1 
mutants and GST-hNAT2 were analyzed using this assay. As observed for hNAT1, all mutant 
hNAT1 enzymes and GST-hNAT2 were able to N-acetylate 4-AAB (Figure 5C) and their 
observed reaction rates were calculated (Figure 5D). A decreased N-acetylation rate was 
measured for both the mutant hNAT1 and the hNAT2 enzymes compared to wild type hNAT1.
N-acetylation by hNAT2 was five times slower compared to hNAT1, which is not in line with the observations described in the literature for these enzymes using comparable arylamines like ANL and 4-aminobiphenyl (4-ABP); Figure 3A). The study by Liu and coworkers showed that hNAT2 has similar or higher reaction rates for ANL and 4-ABP than hNAT1.197 Therefore, 
we assumed that the slower N-acetylation by hNAT2 compared to hNAT1 is the result of a 
significant difference in the purity of these enzymes (about ten-fold less hNAT2 than hNAT1 
based on SDS-PAGE (Figure 4)). In addition, the reduced N-acetylation activity might as well 
be caused by the conjugated GST-tag used for purification of hNAT2. The GST-tag of about 25 
kDa might negatively influence the activity of hNAT2, while the smaller histidine-tag (0.8 kDa) 
will probably have less effect on the activity of the enzyme.
N-acetylation by hNAT1 (F37V) was almost similar to that of hNAT1, indicating that this 
mutation does not influence the catalytic activity of the enzyme. Furthermore, we measured 
lower N-acetylation rates for the I106 hNAT1 mutants compared to the wild type. The 
N-acetylation rate of hNAT1 (I106A) was decreased by about 1.5-fold compared to hNAT1 
(Figure 5D). This is possibly caused by the influence of this mutation in the substrate binding 
pocket (e.g. decreasing the stability of the structure or disrupting interactions residing in 
the binding pocket). It is not likely that the purity or the conjugated purification-tag of these 
enzymes affected the catalytic activity, because the purities of the elution fractions of these 
enzymes are almost similar (Figure 4) and they all contain the histidine-tag. N-acetylation of 
4-AAB by hNAT1 (I106G) as well as by the double mutant F37V, I106A was about two-fold 
slower than that of the hNAT1 (I106A) (Figure 5D). This suggests that mutating Ile106 to an 
alanine has less effect on the enzyme than replacement by a glycine. Moreover, the decrease in 
N-acetylation by hNAT1 (F37V, I106A) might be the result of the position of these mutations 
in the binding pocket. Since the F37 and I106 are located at the opposite of each other, the 
binding pocket might be less structured or interactions with the substrate might be disrupted.
6.3.3 Substrate screening for hNAT mutants
N-acetylation of 4-AAB by wild type hNAT1 in the presence of ANL
To gain information about the binding affinity of the hNAT variants for different arylamines, 
we first examined N-acetylation of 4-AAB by hNAT1 in the presence of different amounts of 
the known substrate ANL. Using a similar setup as above, we added to hNAT1 4-AAB and ANL, using three different molar ratios 4-AAB:ANL (1:1, 1:10, or 1:100), and started the reaction 
6
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by adding a two-fold excess of acetyl-CoA compared to 4-AAB (Figure 6A). If 4-AAB and ANL 
have similar specificities for hNAT1, the amount of N-acetylated 4-AAB will decrease with 50 
% when adding equal amounts of 4-AAB and ANL. Hence, a decrease of 4-AAB N-acetylation 
indicates that the added substrate acts as a competitor for the enzyme. 
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Figure 6 – N-acetylation of 4-AAB was inhibited by ANL in presence of hNAT1 and acetyl-CoA.
hNAT1 = H
6
-hNAT1; A) Schematic overview. B) 4-AAB was incubated with hNAT1, acetyl-CoA, and with or without ANL at molar ratios 4-AAB:ANL 1:1, 1:10, and 1:100. Negative controls include 4-AAB and Ac-4-AAB with or without 100-fold excess of ANL. The absorbance of 4-AAB at t=0 is set at 1 after correction for the absorbance of Ac-4-AAB. Shown 
is a non-linear regression fit of the relative absorbance of 4-AAB at 386 nm followed in time using a one phase decay 
model.
In order to determine whether ANL is a competitor, we evaluated the amount of N-acetylated 
4-AAB after the reaction reached an equilibrium. The relative absorbance of 4-AAB was 
marginally affected by adding a 100-fold excess of ANL (0.90 for 4-AAB versus 0.95 for 1:100 
4-AAB:ANL) in absence of hNAT1. Adding equal amounts of ANL and 4-AAB to hNAT1 and 
acetyl-CoA resulted in an increase in final relative absorbance of 4-AAB from about 0.1 (no 
ANL) to 0.4 and indicates a decrease of about 30 % in N-acetylation of 4-AAB (Figure 6B). This 
observation is in line with the hNAT1 specificities described in literature for a structurally similar 4-AAB substrate, 4-ABP, compared to that for ANL (Table 1).138 The catalytic rate of 
hNAT1 for these compounds is almost similar, whereas the binding affinity for 4-ABP is about 
twelve-fold higher than that for ANL (Table 1).138 This might explain that higher amounts of 
ANL than 4-AAB are required to compete fully with N-acetylation of 4-AAB using hNAT1.
Adding a 10-fold excess of ANL compared to 4-AAB resulted in significant reduction of 
N-acetylation of the 4-AAB substrate (final relative absorbance of 0.8) compared to the reaction in absence of the ANL competitor. Increasing the ANL concentration further to a 
100-fold molar excess did not result in less N-acetylation of 4-AAB compared to a 10-fold 
excess, indicating that a 10-fold excess of ANL already fully competes with the N-acetylation of 4-AAB.
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N-acetylation of 4-AAB by hNAT enzymes in presence of bulky substrates
In order to find a hNAT1 mutant that recognizes bulkier substrates, we selected three 
arylamine ligands, 2-EA, 2-iPA, and 2,6-DMA, containing different alkyl substituents at the 
2-position (Figure 3C). We evaluated the N-acetylation of 4-AAB in presence of these bulky 
arylamines by the wild type and mutant hNAT enzymes by measuring the amount of 4-AAB 
N-acetylation in presence of varying amounts of the ligand candidates (summarized in Figure 
7 and Supplementary Table S1). As seen for ANL, we hypothesize that a decrease in the 
N-acetylation of 4-AAB in the presence of a competitor is the result of interactions between 
the hNAT1 enzyme and the competitor ligand.
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Figure 7 - N-acetylation of 4-AAB by hNAT mutant enzymes was inhibited by several bulky ANL substrates.
hNAT1 = H
6
-hNAT1; hNAT2 = GST-hNAT2; F37V = H
6
-hNAT1 (F37V); I106A = H
6
-hNAT1 (I106A); F37V, I106A = H
6
-
hNAT1 (F37V, I106A); IG = H
6
-hNAT1 (I106G); Shown is the calculated plateau of the relative absorbance of 4-AAB 
after t = 30 minutes based on a one phase decay model. The absorbance of 4-AAB at t=0 is set at 1 after correction for the absorbance of Ac-4-AAB. Higher signals indicate less N-acetylation of 4-AAB. (n > 3; stars indicate the significance, 
based on p-values calculated using a t-test (p-value of ≤ 0.01 is indicated as *).
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Inhibition of 4-AAB N-acetylation by 2-EA
According to previously reported literature, anilines containing a 2-alkyl substituent have 
lower kcat/Km values compared to ANL for hNAT1 (Table 1). Liu and coworkers assumed 
that this is caused by a steric clash between the 2-alkyl group and the Phe125.197 Indeed, the N-acetylation reaction of 4-AAB was hardly affected by adding equal amounts of 2-EA 
in presence of the wild type hNAT1 (Supplementary Table S1), whereas the reaction was 
inhibited for about 30 % in presence of equal amounts of ANL. Increasing the amount of 2-EA resulted in a dose dependent increase in inhibition of 4-AAB N-acetylation up to 50% when 
using a ratio of 1:100 (Supplementary Table S1). 
In contrast to hNAT1, the study by Liu and coworkers showed that the N-acetylation rates of 2-MA and 2-EA are higher for hNAT2 (Table 1).197 This is likely explained by the smaller 
Ser125 that results in less steric hindrance to bind 2-alkyl substituted anilines compared to 
the Phe125 in hNAT1.197 In agreement with this, we observed stronger inhibition of 4-AAB 
N-acetylation by hNAT2 in presence of a 10-fold excess of 2-EA (final relative absorbance of 
0.6) compared to hNAT1 (final relative absorbance of 0.3; Figure 7 and Supplementary Table 
S1). Hence, our results demonstrated that 2-EA competes with the N-acetylation of 4-AAB by 
hNAT2 at lower molar ratios than that by hNAT1. The weaker recognition of 2-EA by hNAT1 compared to hNAT2 is probably related to the larger size of the hNAT2 substrate binding 
pocket (257 Å) than that of hNAT1 (162 Å).150
Similar to the results obtained for hNAT2, the N-acetylation of 4-AAB by hNAT1 mutants 
I106A, I106G, and F37V, I106A was also reduced in presence of a 10-fold excess of 2-EA 
(Figure 7 and Supplementary Table S1). In contrast, the N-acetylation level of 4-AAB by 
hNAT1 (F37V) was not affected in the presence of a 1:10 or 1:100 ratio of 2-EA (Figure 7 
and Supplementary Table S1). Together, these results indicate that 2-EA is competing with the N-acetylation of 4-AAB by hNAT2 and I106 hNAT1 mutants, which is not observed for 
hNAT1 and hNAT1 (F37V) at similar 2-EA molar ratios. This might be the result of enhanced 
affinity for 2-EA by hNAT2 and I106 hNAT1 mutants compared to hNAT1. Because of these 
observations and based on previously reported literature, we hypothesized that both Phe125 
and Ile106 play an important role in the binding of 2-EA by hNAT1 (Ser125 and Val106 in 
hNAT2). Thereby, substitution of Ile106 by alanine or glycine seems to favor binding of the 
2-EA substrate, whereas the F37V mutation has no effect on 2-EA binding.
Inhibition of 4-AAB N-acetylation by 2,6-DMA
In contrast to 2-EA, the N-acetylation rate and binding affinity of the bulkier 2,6-DMA substrate could not be determined for both hNAT1 and hNAT2 by previously reported 
experiments.197 Consistent with this, adding different amounts of 2,6-DMA (1:1, 1:10, or 
1:100) to the reaction did not influence the N-acetylation of 4-AAB by either wild type hNAT1 
or hNAT2 (Supplementary Table S1). This indicates that 2,6-DMA does not compete with 
4-AAB N-acetylation and possibly cannot bind to the substrate binding pocket of wild type 
hNAT1 and hNAT2. 
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Because we presumed that the single mutant F37V has no effect on the binding pocket as demonstrated by the 2-EA competitor experiment, we measured only the effect of 4-AAB 
N-acetylation by adding a 100-fold excess of 2,6-DMA. Indeed, the presence of 2,6-DMA did not reduce the amount of N-acetylation of 4-AAB by hNAT1 (F37V), indicating that this substrate does not compete with the reaction. Thereby, the substitution of Phe37 by a valine 
has no influence on the recognition of bulkier substrates by this mutant.
As observed for hNAT1 (F37V), N-acetylation of 4-AAB by hNAT1 (I106A) was not decreased 
by adding a 100-fold excess of 2,6-DMA (Figure 7 and Supplementary Table S1). Compared to 2,6-DMA, 2-EA competed more with the N-acetylation of 4-AAB by hNAT2 and the I106 
hNAT1 mutants. This is probably due to a more favorable binding of 2-EA than that of 2,6-
DMA by these enzymes. The main difference between these structures is the position of the 
2-ethyl group of 2-EA and the two methyl groups in 2,6-DMA. Likely, the cavity created in 
hNAT1 (I106A) resulted in enough space to recognize 2-EA, but not to 2,6-DMA.
Based on the crystal structure, we hypothesized that Phe37 is positioned at the opposite of 
I106 and we presumed that the mutant hNAT1 (F37V, I106A) is able to recognize 2-alkyl as 
well as 2,6-alkyl substituted anilines. However, N-acetylation of 4-AAB was not affected by 
a 100-fold excess of 2,6-DMA for this double mutant (Figure 7 and Supplementary Table 
S1). Furthermore, we substituted I106 to a glycine, which is structurally smaller than the 
alanine introduced in hNAT1 (I106A) and assumed that hNAT1 (I106G) results in a larger 
substrate binding pocket leading to enhanced affinity for 2,6-DMA. Some inhibition of 
4-AAB N-acetylation was observed for hNAT1 (I106G) at a ratio of 4-AAB:2,6-DMA 1:100, 
although there was no significant difference compared to wild type hNAT1 (Figure 7 and 
Supplementary Table S1).
Altogether, our results indicate that 2-EA is a better competitor compared to 2,6-DMA for 
hNAT1 (I106A), hNAT1 (I106G), and hNAT1 (F37V, I106A), and that the position of the alkyl 
groups on the phenyl ring is crucial for binding to these enzymes.
Inhibition of 4-AAB N-acetylation by 2-iPA
Finally, we tested the ability of the wild type and mutant hNAT enzymes to N-acetylate 4-AAB in presence of different ratios of the bulky 2-iPA substrate. We did not include hNAT1 (F37V) 
in this experiment, because we assumed that this single mutant has no effect on the binding pocket as demonstrated by the 2-EA competitor experiment. Adding equal amounts of 2-iPA 
or even higher concentrations (10-or 100-fold excess) did not influence the N-acetylation reaction of 4-AAB by hNAT1, indicating that this substrate is not competing with the reaction 
(Figure 7 and Supplementary Table S1).The N-acetylation of 4-AAB was reduced at a ratio of 1:100 4-AAB:2-iPA in presence of the 
hNAT2 enzyme (final relative absorbance around 0.6) compared to N-acetylation without this 
competitor (final relative absorbance around 0.2; Figure 7 and Supplementary Table S1). This 
is in line with reported literature data showing that hNAT2 recognizes bulkier substrates than 
6
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hNAT1 due to the larger size of the binding pocket in hNAT2 compared to hNAT1.144 Still, the 
N-acetylation of 4-AAB was stronger inhibited by 2-EA compared to 2-iPA, indicating that 
the structurally larger 2-isopropyl group of 2-iPA is suboptimal for competition with 4-AAB. 
Similar to hNAT2, the formation of Ac-4-AAB was also decreased by incubating hNAT1 
(106A) and hNAT1 (I106G) using a 100-fold excess of 2-iPA (Figure 7 and Supplementary 
Table S1). This supports our hypothesis that these mutants are able to recognize bulkier 
2-alkyl substituted anilines. Though, 2-EA is a stronger competitor compared to 2-iPA for 
these hNAT1 mutants, which is likely related to the size of these substrates.
Since 2-EA is a competing substrate for N-acetylation by the double mutant and not by hNAT1 
(F37V), we hypothesized that the enhanced inhibition in presence of 2-EA is only a result 
of the I106A mutation in case of hNAT1 (F37V, I106A). In line with this, we expected that 
N-acetylation in presence of 2-iPA as observed for hNAT1 (I106A) is similar to that for hNAT1 
(F37V, I106A), though this was not the case. The N-acetylation of 4-AAB in presence of 2-iPA 
(1:100) was not affected by hNAT1 (F37V, I106A), while the reaction was inhibited by adding 
2-EA (Figure 7 and Supplementary Table S1). We hypothesized that the cavity is large enough 
in hNAT1 (F37V, I106A) to recognize 2-EA, but not to recognize the structurally larger 2-iPA. 
The difference in observations for hNAT1 (I106A) and the double mutant might be explained 
by a less structured hNAT1 (F37V, I106A) due to the combination of the two mutations leading 
possibly to the loss of interactions within the substrate binding pocket.
6.4 Concluding remarks
In summary, we applied a bump-hole strategy to circumvent labeling in living cells by the 
endogenous hNAT enzymes in a hNAT-based PDL approach. We designed mutant hNAT1 
enzymes recognizing bumpy substrates, which are not recognized by the wild type enzymes. 
The mutants for the bump-hole strategy to establish an orthogonal mutant-ligand pair were 
based on the crystal structure of the hNAT1 and hNAT2 enzymes. We substituted Ile106 for 
an alanine or glycine (I106A or I106G, respectively), Phe37 for a valine (F37V), and combined 
F37V and I106A (F37V, I106A). These mutations were expected to create a cavity in the 
enzyme, which allows the recognition of bulkier arylamine substrates while preserving the 
catalytic activity.
After cloning and expressing the wild type hNAT enzymes and the hNAT1 mutants, all enzymes 
were able to N-acetylate 4-AAB in the presence of acetyl-CoA. Two compounds, 2-EA as well as 2-iPA, could inhibit N-acetylation of 4-AAB by hNAT1 (I106A) or hNAT1 (I106G) while no 
inhibition was observed for the wild type enzyme. We hypothesized that the substrate binding 
pocket of these mutants is enlarged compared to hNAT1, while retaining the N-acetylation 
activity and leading to enhanced affinity for the bulkier 2-EA and 2-iPA substrates. Therefore, 
combining hNAT1 (I106A/G) with a newly designed 2-ethyl or 2-isopropyl substituted AHA 
probe is promising to increase the signal-to-noise ratio of the hNAT1 labeling in cells.
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Although the orthogonal mutant-ligand pair is suitable to circumvent labeling by hNAT1, we 
expect that hNAT2 is also able to activate the 2-ethyl or 2-isopropyl AHA probes, as 4-AAB 
N-acetylation was also decreased in the presence of 2-EA and 2-iPA. In order to bypass 
labeling by both hNAT1 and hNAT2, the substrate binding pocket of hNAT1 can be further 
enlarged while using bulkier arylamines than 2-EA and 2-iPA. Alternatively, exploring 
subcellular labeling using NAT enzymes originating from other eukaryotes may be promising. 
We will elaborate on these possibilities further in the future perspectives in Chapter 7.
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Figure S1 – ESI-TOF mass spectrometry deconvoluted total mass spectrum (left) and multiply charged ion series 
(right) of the eluted H6-hNAT1 mutant proteins.
D) The mass of the depicted hNAT1 mutant was verified by ESI-TOF mass spectrometry. Expected mass A: 40,090 Da; 
Observed mass A: 40,090 Da; Expected mass B: 40,096 Da; Observed mass B: 40,098 Da; Expected mass C: 40,048 Da; 
Observed mass C: 40,049 Da; Expected mass D: 40,082; Observed mass D: 40,081; In the spectra of A-C, a second peak 
of 178 Da was observed.
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Table S1 – N-acetylation of 4-AAB by hNAT mutant enzymes was inhibited by several bulky ANL substrates.
hNAT1 = H
6
-hNAT1; hNAT2’ = GST-hNAT2; F37V = H
6
-hNAT1 (F37V); I106A = H
6
-hNAT1 (I106A); F37V, I106A = H
6
-
hNAT1 (F37V, I106A); I106G = H
6
-hNAT1 (I106G); n.d. not determined. 4-AAB N-acetylation by the hNAT enzymes was 
followed in time using different anilines. Shown is the calculated plateau of the relative absorbance of 4-AAB at t = 
30 minutes based on a one phase decay model. The absorbance of 4-AAB at t = 0 is set at 1 after correction for the absorbance of Ac-4-AAB. The standard deviation is based on n > 3. a) Reactions are based on n = 2. b) Reactions are based 
on n = 1.
6
no inhibitor
ANL
1:1
1:10
1:100
2-EA
1:1
1:10
1:100
2,6-DMA
1:1
1:10
1:100
2-iPA
1:1
1:10
1:100
Relative final absorbance (386 nm)
hNAT1
0.10 ± 0.08
0,80 ± 0.00050
0,77 ± 0.00046
0,38 ± 0.0017
0.18 ± 0.07a
0.27 ± 0.07
0.51 ± 0.07
0.20 ± 0.10a
0.17 ± 0.10
0.22 ± 0.12
0.15 ± 0.05a
0.20 ± 0.08
0.28 ± 0.11
0.24 ± 0.09
n.d.
n.d.
n.d.
0.33 ± 0.05
0.74 ± 0.02
0.84b
0.17b
0.18 ± 0.13
0.24 ± 0.09
0.16b
0.34b
0.41 ± 0.27a
I106A I106G
0.19 ± 0.04
n.d.
n.d.
n.d.
0.23 ± 0.03
0.71 ± 0.11
1.00 ± 0.19
0.19 ± 0.06
0.18 ± 0.06
0.36 ± 0.18
0.19 ± 0.05
0.21 ± 0.04
0.56 ± 0.12
F37V
0.03 ± 0.12a
n.d.
n.d.
n.d.
n.d.
0,11 ± 0.14
0.50 ± 0.08
n.d.
n.d.
0.10 ± 0.04a
n.d.
n.d.
n.d.
F37V,
I106A
0.23 ± 0.16
n.d.
n.d.
n.d.
0.30 ± 0.06
0.69 ± 0.13
0.70 ± 0.08
0.15 ± 0.04
0.37 ± 0.26
0.28 + 0.03
0.21b
0.23 ± 0.05
0.21 ± 0.06
hNAT2’
0.16b
n.d.
n.d.
n.d.
n.d.
0.65b
n.d.
n.d.
n.d.
0.22b
n.d.
n.d.
0.62b
Table S2 – Design of plasmids used for expression of mutant hNAT1 enzymes in E. coli.
name
H6-hNAT1(F37V)
H6-hNAT1(I106A)
H6-hNAT1(F37V,I106A)
H6-hNAT1(I106G)
promoter
/vector
T7/pET30A
T7/pET30A
T7/pET30A
T7/pET30A
H6-BamHI-TEVsite-hNAT1 (F37V)-STOP-NotI
H6-BamHI-TEVsite-hNAT1 (I106A)-STOP-NotI
H6-BamHI-TEVsite-hNAT1 (F37V,I106A)-STOP-NotI
H6-BamHI-TEVsite-hNAT1 (I106G)-STOP-NotI
features
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Table S3 – Oligonucleotide sequences used for the introduction of the mutations F37V, I106A, and I106G.
primer name
BamHI-TEVsite-hNAT1
hNAT1-STOP-NotI
F37V (forward)
F37V (reverse)
I106A (forward)
I106A (reverse)
I106G (forward)
I106G (reverse)
details comments
forward primer encoding BamHI
restriction site, TEV protease cleavage
site, and overlapping with hNAT1
reverse primer encoding NotI restriction
site, a STOP codon, and overlapping
with hNAT1
forward primer encoding the 
F37V mutation
reverse primer encoding the
F37V mutation
forward primer encoding the
I106A mutation
reverse primer encoding the
I106A mutation
forward primer encoding the
I106G mutation
reverse primer encoding the
I106G mutation
GATC GGATCC GAGAACTTGTAT
TTTCAGAGCGGC GACATTGAAGC
ATATCTTG
ATATAT GCGGCCGC CTA AATA
GTAAAAAATCTATCACCATGTTTG
GGCACAAG
ATCCGAGCTGTTCCC GTG GAGA
ACCTTAACATC
GATGTTAAGGTTCTC CAC GGGA
ACAGCTCGGAT
TACAGCACTGGCATG GGC CACC
TTCTCCTGCAG
CTGCAGGAGAAGGTG GCC CATG
CCAGTGCTGTA
TACAGCACTGGCATG GCG CACC
TTCTCCTGCAG
CTGCAGGAGAAGGTG CGC CATG
CCAGTGCTGTA
6.7 Supplementary information
Caution: All arylamines should be handled in accordance with NIH Guidelines for the 
Laboratory use of Chemical Carcinogens. 
Synthesis Ac-4-AAB
(E)-N-(4-(phenyldiazenyl)phenyl)acetamide (Ac-4-AAB) is synthesized following a literature 
procedure.282
Design and cloning of the hNAT1 and hNAT2 plasmids
Constructs encoding H
6
-hNAT1, H
6
-hNAT2, and GST-hNAT2 were designed and prepared as 
described in Chapter 3, Supplementary Information.
All single point mutations were prepared in two steps by site-directed mutagenesis. The first 
fragment was amplified using the hNAT1 enzyme as a template, a forward primer encoding 
the N-terminal domain of the hNAT1 enzyme and a reverse primer encoding the desired 
mutation. In addition, the C-terminal fragment was produced by a forward primer encoding 
the desired mutation and a reverse primer encoding the C-terminal domain of the hNAT1 
enzyme. All PCR reactions were conducted with 1× HF Buffer (New England Biolabs), 1 unit 
of Phusion polymerase, 20 ng of DNA template, 100 µM dNTP, 10 pmol of the forward and reverse primer in a total volume of 50 µL. The reaction mixtures were heated at 98 °C for 30 
sec, followed by 25 cycles for 20 sec at 98 °C, 30 sec at 58 °C, and 2 min at 72 °C. To ensure 
complete extension, the reaction mixture was incubated at 72 °C for 4 min after the 25 cycles. 
Each PCR product was separated on agarose (1 %) and the PCR products were isolated using 
the QIAquick gel extraction kit (Qiagen). Subsequently, the N- and C-terminal PCR products 
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were ligated by a 10-cycle PCR reaction (protocol see above) without the forward and reverse 
primer. The mutated hNAT1 construct was then amplified by a 20-cycle PCR reaction using primers encoding the N- and C-terminal domain of the hNAT1 enzyme.
In case of the double mutant, three fragments were synthesized using the hNAT1 enzyme 
as a template, a forward primer encoding the N-terminus and a reverse primer encoding 
the first mutation (1), a forward primer encoding the first mutation and a reverse primer 
encoding the second mutation (2), and a forward primer encoding the second mutation and a 
reverse primer encoding the C-terminus (3). After agarose (1 %) separation and purification 
using the Qiaquick gel extraction kit, the first two PCR products were fused by a 10-cycle PCR 
reaction (protocol see above) without the primers followed by ligating the third PCR product 
by another 10-cycle PCR reaction (protocol see above) without the primers. Finally, the entire 
PCR product was amplified by a 20-cycle PCR reaction using the forward and reverse primer 
encoding the N- and C-terminus of hNAT1, respectively.
All final PCR products were purified with a QIAquick PCR purification kit (Qiagen). 
Subsequently, the PCR products (mutants hNAT1) and the plasmid vector were digested with 
2 units of each restriction enzyme for 1 h at 37 °C. The digestion products were isolated with 
a QIAquick gel extraction kit (Qiagen). The vector DNA (50 ng) was ligated with the PCR insert 
(30 ng) with T4 Ligase (New England Biolabs) overnight (o/n) at 16 °C. After heat inactivation 
of T4 Ligase (20 min at 65 °C), supercompetent Top 10 cells were transformed with the 
ligation mix (25 ng vector) and selected for the correct antibiotic resistance. The plasmids 
from positive colonies were isolated with the Miniprep DNA purification system (Qiagen) 
and sequences were verified by automated DNA sequencing (RadboudUMC sequence facility 
Nijmegen, the Netherlands).
Expression	and	purification	of	hNAT	enzymes
Expression of wild type hNAT enzymes and hNAT1 mutants was performed as described in 
Chapter 3, Supplementary Information.  The mass of the proteins was confirmed by electron 
spray ionization time-of-flight (ESI-TOF) on a JEOL AccuTOF with Agilent (1100 series HPLC). 
ESI-TOF: H
6
-hNAT1 40,138 Da, found 40,138 Da; H
6
-hNAT1 (F37V) 40,090 Da, found 40,090 
Da; H
6
-hNAT1 (I106A) 40,096 Da, found 40,098 Da; H
6
-hNAT1 (I106G) 40,082 Da, found 
40,081;
Kinetic experiments using the hNAT enzymes
N-acetylation by the hNAT enzymes was followed by measuring the absorbance of 4-AAB at 
386 nm, a protocol developed by J. Booth.128 The kinetic measurements were carried out in a 
transparent flat-bottom 96-well plate (Greiner) in a total reaction volume of 100 µL containing 10 µL of 1 mM 4-AAB (dissolved in DMSO; Sigma-Aldrich) and 10 µL of NAT enzyme (2 mg/
mL). The reactions were started by the addition of 10 µL of 2 mM acetyl-CoA (Roche) and 
followed for 30 min with a 10 second time interval at 25 °C. Competition experiments were performed by adding 2 µL 5 mM, 50 mM, or 500 mM of the candidate substrate (dissolved in 
DMSO) to obtain a ratio 4-AAB:competitor of 1:1, 1:10, or 1:100, respectively. All candidate 
anilines were bought from Sigma-Aldrich. Kinetic experiments were followed on the 
multimode microplate reader Spark® 10M (Tecan) and analyzed by Prism7 using a one phase 
decay model (Graphpad).
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Summary and future perspectives
7
7.1 Summary
The concept of labeling proteins by a proximity-dependent labeling (PDL) strategy is an 
interesting approach to identify protein-protein interactions (PPIs) with high temporal and 
spatial resolution in living cells. The PDL system is based on the activation of small molecules 
by an enzyme resulting in reactive probes, which tag proteins in close proximity of the 
enzyme.15,16,18 The labeled proteins are then recovered and subsequently identified by mass 
spectrometry.53,54,66 Currently applied approaches employ the biotin ligase (BioID) and the 
engineered ascorbate peroxidase (APEX) enzymes, which are described in more detail in 
Chapter 1.19,200,201 In this thesis, we have expanded these existing PDL methods by introducing the human arylamine N,O-acetyltransferase 1 (hNAT1) approach. Table 1 shows a comparison 
of the existing PDL methods with the NAT strategy.
BirA catalyzes the conjugation of biotin and ATP, resulting in a reactive 5’-AMP-biotin 
intermediate. 5’AMP-biotin dissociates from the enzyme and covalently reacts with primary 
amines residing in proteins.118,245 The BirA enzyme was evolved over the years to improve the 
labeling reaction rate as well as the background labeling caused by endogenous biotin.67,68 
TurboID is the most active BirA variant reported to date and labels proximal proteins orders 
of magnitude faster compared to the BirA forerunners BioID, BioID2, and miniTurboID (10 
minutes versus hours of labeling, respectively).68 miniTurboID yields less background labeling 
in the absence of exogeneous biotin compared to TurboID.68
The APEX enzyme activates biotin-phenol in the presence of hydrogen peroxide generating 
reactive biotin-phenoxy radicals, which react with electron-rich amino acids (e.g. tyrosine 
and tryptophan).80,101,102 The activity of APEX was also improved by the development of 
APEX2 (containing an A134P APEX mutation), which enables the superior enrichment of the 
endogenous labeled proteins.103 Although APEX2 is used to identify novel protein candidates in living cells98,109,246, one potential drawback is the need of high levels of hydrogen peroxide, 
which can cause adverse effects such as a cellular stress response.115–117
In order to avoid the use of hydrogen peroxide and still preserve fast labeling times for 
proximal protein identification, we set out to develop a novel PDL strategy using the hNAT 
enzyme (reviewed in Chapter 2). Humans express two homologues of the NAT enzyme, hNAT1 
and hNAT2, which acetylate a variety of arylamine substrates.136,144,147,197 In addition, these enzymes catalyse the N,O-acetyl transfer of N-acetyl-N-hydroxy arylamine (arylhydroxamic 
acid; AHA) to the N-acetoxy arylamine intermediate.170 This unstable intermediate undergoes fast heterolytic N-O bond cleavage depending on the aryl substituents.184,185 The resulting 
nitrenium ions react fast and covalently under neutral conditions with nucleophilic residues 
of neighbouring macromolecules, including proteins.189,203
We started our research by synthesizing a set of AHA molecules varying in the electronic 
density of the arylring (Figure 1) to test the ability of the hNAT enzymes to activate AHA probes and to explore the labeling of proteins by the resulting activated N-acetoxy arylamine and 
nitrenium ion intermediates. As described in Chapter 3, we showed that incubating purified 
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enzyme
size (kDa)
variants
labeling substrates
half-life of generated
reactive species
labeling time
labeling radius
organisms used
main advantage
major challenge
biotin ligase
(BirA)
27-35
BioID63, BioID267,
TurboID68, miniTurbo68
100 µM exogenous
biotin, endogenous ATP
biotin-AMP, minutes
10 minutes - 24 hours
10-30 nm
mammalian cells,
xenograft tumors in
mice,Trypanasoma
brucei, Toxoplasma
gondii, Dictyostelium
discoideum, 
Plesmodium berghei
can be applied in vivo
long labeling times
and/or endogenous
biotinylation
ascorbate peroxidase
(APEX)
27
APEX80,101, APEX2103,
split APEX2112
500 µM biotin-phenol,
1 mM hydrogen peroxide
radicals < 1 milliseconds
1 minute
biotin-phenol is incubated
30-60 minutes in advance
20 nm
mammalian cells,
Schizosaccharomyces
pombe, Saccharomyces
cerevisiae, Drosophila
melanogaster
high temporal and spatial
resolution
cellular toxicity due to high
levels of hydrogen
peroxide
arylamine N-acetyl-
transferase (NAT)
34
hNAT1283
100 µM arylhydroxamic
acid
nitrenium ions,
femtoseconds
5-30 minutes
unknown
mammalian cells
high temporal
resolution, no need for
cofactor
protein labeling by
endogenous enzymes
hNAT1 or hNAT2 with synthetic AHA probes resulted in the strongest activation of AHA probe 1. In contrast, AHA probes 3 and 5 were hardly activated by the hNAT1 enzyme. Likely, the stability of the reactive N-acetoxy arylamine intermediate of AHA probe 1 is decreased 
compared to AHA probes 3 and 5 due to the electron-rich oxygen, which contributes to the 
resonance structures of the nitrenium ion.188 Therefore, AHA probe 1 might result in faster 
nitrenium ion formation than that of AHA probes 3 and 5 leading to more intense hNAT1 
labeling. We concluded that the electron density on the aromatic ring proved important for 
activation as strong labeling was only observed with AHA probe 1.
In Chapter 4, we assessed protein labeling in living cells by the endogenous hNAT enzymes 
using the same AHA probes as used in Chapter 3. After incubating living cells with the electron-
rich AHA probes and analysis of the cell lysates by SDS-PAGE, we observed protein labeling 
in different cell lines, including the human embryonic kidney cell line HEK-293. Interestingly, 
AHA probes 3 and 5 also resulted in protein labeling in living cells. These results indicate that 
the synthetic AHA probes can enter the cell and are activated by endogenous hNAT, although 
we cannot exclude activation by other enzymes, e.g. sulfotransferases238.
Table 1 – Overview of the PDL strategies BioID, APEX, and NAT.283
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Figure 1 – Structures of AHA probes used for hNAT labeling.
Next, we were interested in compartmentalized protein labeling by targeting the ectopically 
expressed hNAT1 enzyme to defined subcellular regions. Specific subcellular labeling was 
observed in cells expressing hNAT1 in the nucleus or cytosol upon incubation with AHA probe 1 for five minutes by fluorescence confocal microscopy (Chapter 5). However, we 
detected strong protein labeling by the endogenous enzymes in the lysate and were not able 
to discriminate between this endogenous labeling and labeling by the spatially-restricted 
hNAT1 enzyme.
In order to limit the background labeling by the endogenous hNAT enzymes, we envisioned to 
improve our NAT system by adopting a so-called bump-hole strategy, as described in Chapter 
6.279,280 With this approach, we aimed to introduce substrate orthogonality by developing 
a hNAT1 mutant that recognizes a bulky substrate, which is not bound by the wild type 
enzymes. After examining the crystal structure of hNAT1 and hNAT2, we explored three point 
mutations to enlarge the binding pocket of hNAT1, while preserving the catalytic activity. Wild 
type enzymes and the hNAT1 mutants were able to acetylate 4-aminoazobenzene (4AAB) 
using acetyl coenzyme A (acetyl-CoA) as acetyl source. In contrast to wild type hNAT1, acetylation of 4AAB by the hNAT1 mutants I106A and I106G was inhibited in the presence 
of 2-ethylaniline (2-EA) or 2-isopropylaniline (2-iPA). This indicates that both I106 hNAT1 
mutants have enhanced affinity for 2-EA and 2-iPA compared to wild type hNAT1. Therefore, 
we propose that combining hNAT1 (I106A) or hNAT1 (I106G) with a newly designed 2-ethyl 
or 2-isopropyl substituted AHA probe 1 might be promising for increasing the labeling 
specificity of the hNAT approach.
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7.2 Future perspectives
In this thesis, we have provided the first most important steps towards a new PDL system, 
which is based on a spatially-restricted hNAT1 enzyme. Our NAT strategy holds great promise 
to visualize the proteome at a subcellular level in living cells. In this section, we describe several 
potential improvements and applications of this PDL system. First, we elaborate on a method 
to discriminate between proteins that are labeled by endogenous enzymes versus those that 
are labeled by the localized hNAT1 enzyme. In addition, we propose approaches to further 
optimize the NAT labeling specificity and efficiency. Finally, we describe several alternative 
applications making use of the NAT labeling, such as altering the labeling radius, introducing 
a ligand-directed AHA probe, and labeling alternative biomolecules at a subcellular level.
7.2.1 Bypassing background labeling by the endogenous enzymes
In order to specifically identify proteins labeled by ectopically expressed localized NAT, Stable 
Isotope Labeling by Amino acids in Cell culture (SILAC; Figure 2A) can be utilized to exclude 
proteins that are labeled by the endogenous enzymes.284,285 SILAC is based on culturing cells 
in so-called light or heavy growth medium. Light medium holds normal amino acids, whereas 
heavy medium contains a selection of amino acids labeled with stable heavy isotopes (for 
example arginine labeled with 13C instead of 12C).284,285 Cells cultured for about two weeks 
in heavy medium will incorporate the heavy labeled amino acid into all of the expressed 
proteins.284,285 Tandem mass spectrometry (MS) of the heavy labeled cultures results in an 
increase of 6 Da for each heavy arginine present in the peptides (if heavy arginine is used) 
compared to the light SILAC cultures.284,285
In case of the NAT system, heavy SILAC cultures are transfected with the spatially-restricted 
hNAT1 followed by the protein labeling procedure, whereas the light SILAC cultures are used 
as negative controls (without the localized hNAT1 or without AHA probe). After lysis of both 
cultures, the heavy and light lysates are combined, enriched for the proteins that reacted 
with the activated probe, and analyzed by tandem MS. Proteins labeled by the endogenous 
enzymes are present in both heavy and light cultures, while proteins labeled by the localized 
hNAT1 are enriched in the heavy SILAC culture. 
Instead of using isotopically labeled medium, we can also design isotopically labeled molecules by incorporating 13C or 15N in the AHA probe. Non-transfected cells are incubated 
with the light probe (the regular AHA probe) and cells expressing the localized hNAT1 
enzyme are incubated with the heavy probe. After lysis, the lysates are combined and the 
labeled proteins isolated, followed by tandem MS. Proteins labeled by the endogenous 
enzymes will be labeled by both the light and heavy AHA probe, because these endogenous 
enzymes are present in both cultures (Figure 2B). On the other hand, proteins that are labeled 
by the localized hNAT1 will only be labeled by the heavy AHA probe (Figure 2B). The main 
advantage of the isotopically labeled AHA probe over SILAC is that the AHA probe is directly 
incorporated during protein labeling, whereas incorporation of the heavy amino acids is more 
7
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time consuming (about two weeks). MS data analysis is more challenging using the heavy 
labeled AHA probe due to heterogeneous labeling by the nitrenium ions and the complexity 
of proteins containing multiple labeled amino acids. Determining the exact amino acid(s) that 
react with the nitrenium ions will be of great value for MS data analysis.
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Figure 2 – Schematic representation of NAT labeling combined with SILAC.
A) Cells are incubated with light/heavy medium (containing heavy arginine in this example). After protein labeling, the 
control and experimental sample can be combined and analyzed by tandem MS. B) SILAC can be either performed with 
light medium/probe and heavy medium/probe. As a control, labeling in cells by endogenous enzymes is performed in 
light medium or using a light probe. Nuclear proteins are only labeled in cells overexpressing hNAT1 in the nucleus in 
heavy medium or by a heavy AHA probe, while proteins are labeled by endogenous enzymes in both light and heavy 
samples.
Using either isotopically labeled medium or isotopically labeled AHA probe, the origin of 
each peptide can be determined as a result of the fixed mass difference of peptides treated 
with light or heavy medium/probe. Proteins are labeled only by the endogenous enzymes in 
both heavy and light samples will result in the similar peak intensity. If a protein is labeled 
by the endogenous as well as the localized hNAT1 enzyme, there will be a difference in the 
peak intensity. The relative amount of labeled protein in the heavy sample will be increased 
compared to the light sample, indicating that the proteins are labeled by the localized NAT 
enzyme. 
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7.2.2 Optimizing the NAT PDL system
Implementing the bump-hole strategy
One of the challenges to improve the labeling specificity of the localized hNAT1 enzyme, is to 
overcome the background labeling by the endogenous NAT. To achieve this goal, we described 
in Chapter 6 the use of a bump-hole strategy to develop an orthogonal hNAT mutant-ligand 
pair for labeling. Our results indicated that I106A and I106G hNAT1 mutants have enhanced 
affinity for 2-EA or 2-iPA compared to wild type hNAT1. We therefore anticipate that 
combining the I106A or I106G hNAT1 mutant (Figure 3B and D) with a newly designed 2-ethyl 
or 2-isopropyl substituted AHA probe 1 (Figure 3A) will improve the labeling specificity in 
living cells. 
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Figure 3 – Representation of the substituted AHA probes and hNAT1 mutants I106G, and V93S.
A) Structures of the 2-ethyl, 2-isopropyl, 3-hydroxyl, and 3-ethyl AHA probes. B) Structures of the selected amino acids 
for mutagenesis. C-D) Overlay of part of the substrate binding pocket of hNAT1 (pdb file: 2pqt) with hNAT2 (pdb file: 
2pfr; C), with I106A hNAT1 mutant and with V93S hNAT1 mutant (D). Cys68 of hNAT1 covalent binding to acetanilide 
(Cys68-acetanilide) is shown in green, hNAT1 I106 and V93 in grey, hNAT2 in blue, and mutations in yellow.An alternative is to further study the effect of an additional interacting group at the arylring 
of the AHA probe via the bump-hole strategy. After examining the crystal structure of hNAT1, 
we predicted that mutating the Val93 to a Ser93 in hNAT1 might result in a hydrogen bond 
between an amide at the para position of the AHA probe (as is present in AHA probe 5; Chapter 
3; Figure 3B and E)). However, incubating recombinant hNAT1 with AHA probe 5 did not 
result in protein labeling, likely due to electronically disfavored properties, making this probe 
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not suitable for the NAT PDL strategy (Chapter 3). We hypothesize that substitution of the 
meta position of AHA probe 1 with a hydroxy group (Figure 3A and 3D) might be beneficial for 
binding towards a V93S hNAT1 mutant due to additional hydrogen bonding.
Furthermore, previous studies by others showed that 3-ethylaniline (3-EA) has about two-
fold enhanced affinity for hNAT2 compared to that for hNAT1, due to hydrophobic interactions 
between 3-EA and Phe93 in hNAT2 (Val93 in hNAT1).197 Therefore, a substitution of AHA probe 1 with the ethyl group at the meta position (Figure 3A) combined with a V93F hNAT1 
mutant (Figure 3E) might improve the binding affinity. It has to been seen, however, if the 
labeling efficiencies are also improved by the additional hydroxy or ethyl substituents as these 
meta substituents influence the electronic properties of AHA probes affecting the reactivity of the N-acetoxy ester intermediate.
Exploring alternative NAT enzymes
Up to this point, we have focused on adjusting the specificity of hNAT1 by introducing point 
mutations. However, we did not yet explore the applicability of NAT enzymes expressed in 
other prokaryotes or eukaryotes. In Chapter 5, we showed local labeling by the targeted hNAT1 
enzyme, but we were not able to detect cells expressing the hNAT2 enzyme, likely because 
overexpression of hNAT2 is detrimental for the viability of the cells. Although hNAT2 is not 
suitable for our labeling strategy, other mammalian species also express NAT isoenzymes 
that might be evaluated for proximity-dependent labeling. For example, mouse NAT2 and 
NAT1 (mNAT2 and mNAT1) are the homologues of hNAT1 and hNAT2, respectively.137,138 
Nonetheless, the efficiency by which distinct substrates are converted by mNAT2 and hNAT1 
are substantially different.142,144 According to previous reports, the conversion of aniline (ANL; 
Figure 4A) was almost two-fold less efficient for hNAT1 compared to that for mNAT2, whereas 
a minimal difference was observed between hNAT2 and mNAT1 (Figure 4B).144
In addition, differences in activity between these human and mouse NAT enzymes were also 
measured for the 4-alkoxy anilines. Increased activity for the 4-hexyloxyaniline (HOA; Figure 
4A) was established for mNAT2 compared to hNAT1 or hNAT2 (Figure 4B).138,144 In addition, 
a study performed by Laurieri and coworkers showed that the R127L mutant of mNAT2 
resulted in about four-fold more acetylation of HOA than the wild type mouse and human 
NAT enzymes (Figure 4C).142 The in silico docking of hNAT1 results suggested that the R127L 
mutation generates a larger cavity in the binding pocket of the enzyme (Figure 4D).142 Since 
mNAT2 is the homologue of hNAT1, Laurieri and coworkers hypothesized that the R127L 
mutation also results in a larger binding pocket of mNAT2, and as a consequence this mutant 
is able to bind bulkier 4-alkoxy aniline substrates.142 Spatially-restricting mNAT2 (R127L) in a 
human cell line followed by incubation with AHA probe 1, containing an aliphatic chain, might 
increase the labeling efficiency of the NAT approach.
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Figure	4	–Substrate	specific	activity	profile	of	mNAT2,	hNAT1,	and	hNAT2.
A) Structures of the substrates ANL and HOA. B) Data is derived from Laurieri et al.230 The specific activity for HOA was 
determined by measuring the rate of coenzyme A (CoA) production. Purified mNAT2, hNAT1, or hNAT2 were incubated 
with HOA and acetyl CoA, as described by Kawamura et al.138,144 The specific activities were determined from the linear initial rates of the reaction and all measurements were performed in triplicate. The substrate exhibiting the highest 
specific activity for the enzyme tested was defined as 100 %. The specific activity for HOA relative to the substrate 
exhibiting the highest specific activity is expressed as mean ± standard deviation. C) Crystal structure of Cys68 covalent 
binding to acetanilide (Cys68-acetanilide; green) and Arg 127 (grey) in hNAT1 (pdb file: 2pqt). An overlay of the same 
amino acids is shown, wherein the Arg127 is mutated to Leu (yellow).
Optimization of the NAT PDL via yeast display-based directed evolution
The design of an orthogonal mutant-ligand pair by sequential screening of NAT mutants is 
time consuming and labor intensive. As a solution, a directed evolution setup can be adopted 
to screen at a large scale for a mutant NAT enzyme with high affinity for bulky substrates. 
For example, BioID68 and APEX103 were optimized by employing yeast display-based directed 
evolution, followed by fluorescence-activated cell sorting (FACS) to select mutants with 
improved labeling efficiencies (Chapter 1; Figure 7). First a library of mutants was generated 
by random mutagenesis, which was then displayed at the surface of the yeast cells. Addition 
of the probe resulted in activation by the enzymes followed by labeling of the yeast surface. 
The most intensively labeled cells were selected and isolated by FACS. After several rounds of 
yeast labeling and cell selection, the most active mutants were identified by sequencing the 
corresponding genes and expressed in human cells to compare their labeling efficiency with 
the wild type enzyme. 
We envision that the yeast display-directed evolution method described above, can also be 
adopted to further optimize the NAT enzyme. Expressing a hNAT1 mutant library on the yeast 
cells and incubation with AHA probe 1 will allow the direct selection of a more active variant 
of the hNAT1 enzyme. Alternatively, the use of bulkier AHA probes, for example having 2-alkyl 
or 3-hydroxy groups at the aromatic ring, allows the selection of a mutant enzyme that may 
lead to a novel orthogonal mutant ligand pair. 
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7.2.3 Alternative applications using the NAT enzyme
Tuning the labeling radius of the NAT enzyme
Although we did not examine the labeling radius of the NAT system in this thesis in detail, it 
is interesting to gain information about the reactivity of AHA probes as well as to control the 
labeling radius depending on the biological question. Several factors are important for the 
labeling radius of the hNAT1 enzyme, including the activation rate by hNAT1, the lifetime of 
the acetoxy ester intermediate, and the diffusion rate of the nitrenium ion.
The results described in Chapter 5 indicate that AHA probe 1 is easily distributed throughout 
the cell and is rapidly activated by the nuclear-restricted hNAT1. Previous studies have 
shown that nitrenium ions react close at the diffusion limit (within pico-femtoseconds) 
with nucleophiles residing in DNA, RNA, and proteins.184,185 The labeling radius of APEX is around 20 nm80,103 and that of BioID is around 10-30 nm67,68,118, and in these cases the reactive 
species are estimated to react within microseconds to minutes, respectively. Compared to the 
reactivity and labeling radius of APEX and BioID, we hypothesize that the labeling radius of 
the NAT system using AHA probe 1 will also be in the nanometer range. AHA probes 3 and 5 
will likely have a larger labeling radius as we did not observe protein labeling and therefore 
we assume that these probes are less reactive. 
In Chapter 4, we observed distinct labeling patterns in the protein lysate of cells incubated 
with AHA probes 1, 3, or 5, which indicates that there is a difference in the labeling radius 
of these probes. As mentioned, the stability of the acetoxy ester intermediate of AHA probes 
depends on the substituents at the arylring, which contribute to the resonance structure.188 
Likely, electron-rich groups at the para position of the AHA probe will decrease the stability of the acetoxy ester intermediate and increase the reactivity of the probe resulting in a smaller 
labeling radius. On the contrary, electron-withdrawing groups at the para position of the 
AHA probe will probably increase the stability of the acetoxy ester intermediate leading to a 
larger labeling radius. Gathering information on the reactivity of AHA probes is useful to tune 
the labeling radius by alternating the electron density of the aromatic ring influencing the 
reactivity rate of the activated probe.The labeling radius of the NAT system can be determined by adopting a similar approach as 
used for BioID, which was based on using the nuclear pore complex (NPC) as a molecular 
ruler (Chapter 1; Figure 6).64 The NPC is anchored in the nuclear envelope and in humans 
includes the Y complex consisting of multiple nuclear pore (Nup) proteins.64 To evaluate 
the labeling radius of the BioID system, the BirA* enzyme was genetically fused to several 
of the Nup proteins throughout the human Y complex.64 Depending on the position of the 
BirA* enzyme, a distinct set of NPC constituents was detected within the NPC.64 Subsequently, 
the labeling radius of BioID was defined to ∼10 nm by evaluating the position of the labeled 
proteins within the human Y complex and the size of this complex.64
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The NPC can also be used to measure the labeling radius by fusing hNAT1 to different subunits 
in the NPC and identify isolated labeled proteins by tandem MS. In addition, tandem MS 
will also provide information on the quantity of the labeled proteins. Comparing and cross-
referring the identity and the abundancy of the obtained results with the existing data can 
then be used to estimate the labeling radius of the NAT system.
Ligand-directed	AHA	probe	activation	by	endogenous	NAT	for	target	identification
As an alternative approach for the NAT PDL system, we anticipated that proximity protein 
labeling can also be achieved by targeting the AHA probe towards a protein of interest 
via a directing ligand. In chapter 4 we observed strong labeling around the nucleus when 
using BODIPY AHA probe 7 (structure is shown in Figure 6A). Perinuclear accumulation of 
a BODIPY molecule was also observed in an earlier experiment performed by Cunningham 
and coworkers.268 The nuclear pore complexes in the membrane of the nucleus allow small 
molecules (< 5 kDa) to freely diffuse in and out of the nucleus.268 The BODIPY probe was likely 
aspecifically binding to soluble cytosolic macromolecules, which are too large to diffuse in the 
nucleus.268
It is interesting to see if this observation can be applied for target engagement. In this 
approach, the AHA moiety is conjugated to a small molecule ligand, which binds a target 
protein of interest (POI, Figure 5A). After binding, the AHA functionality is activated by the 
endogenous NAT enzyme, leading to nitrenium ion formation and covalent modification of 
the target protein. In addition, proteins in close proximity of the POI may also be covalently 
modified when ligand dissociation is permitted.
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Figure 5 – Overview of proximity labeling based on localizing the probe activated by the NAT enzyme.
A) Schematic representation. After binding towards the POI, the AHA-ligand probe is activated by the NAT enzyme, 
resulting in labeling of the POI and proximal proteins. B) Design of the AHA-ligand probe.
Identifying protein-protein interactions (PPIs) via the ligand-directed AHA probe that 
is activated by the endogenous NAT enzymes is very promising as the function of the POI 
or interaction proteins are not disrupted by fusion or overexpression of the enzyme. An 
important factor is the proper design of the reacting probe, which we envision to contain 
several functionalities: 1) an AHA moiety for covalent modification of interacting proteins, 
2) a ligand that is recognized by the POI, and 3) a handle to visualize and isolate the labeled 
proteins (Figure 5B). Such hybrid AHA-ligand probe must be recognized by both the NAT 
enzyme as well as the POI. Strong binding of the probe to the POI is required to locate the 
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probe and limit background labeling, though proximal proteins will only be labeled if the 
activated probe can diffuse from the POI or if the spacer is of sufficient length to reach the 
neighbouring protein. Therefore, the reactivity of the AHA probe and ligand binding kinetics 
will be crucial in obtaining a proper PDL labeling. For example, a highly reactive intermediate 
with a labeling radius close to the diffusion limit will possibly only label the POI and not the 
interacting proteins. Tuning of both the spacer length and as well as the labeling radius are 
essential for obtaining a successful ligand-directed AHA probe.
Subcellular RNA labeling by localized NATThe N,O-acetyl transfer reaction by the NAT enzymes was discovered already half a century 
ago. The resulting N-acetoxy arylamine intermediate was hypothesized as source of nitrenium 
ions, which form covalent adducts with guanine in DNA and RNA molecules (described in 
more detail in Chapter 2 – Figure 4).128,174,175 The reaction rate of nitrenium ions with the 
2’-deoxyguanosine was close to or at the diffusion limit (2 x 109 M-1s-1).175,179,180 The majority 
of guanine is forming a C8 adduct upon reaction with the nitrenium ion as shown in Chapter 
2 – Figure 4.190–192 It has been postulated that these adducts are the onset of carcinogenesis. 
Therefore, the potential role of the human NAT enzymes and the reactivity of the nitrenium 
ions in carcinogenesis has been studied in detail.176–178 Since NAT was demonstrated to be able 
to label nucleobases, we hypothesized that the NAT strategy is not limited to labeling proteins, 
but might be used to visualize and identify RNA at a subcellular level. 
RNA is involved in many cellular processes including gene transcription and gene translation. 
The post-transcriptional processing of RNA molecules and their localization is regulated 
by RNA binding proteins (RBPs), which bind to specific structural elements of the RNA 
molecule.286,287 To understand the role of RBPs in the processing steps of specific RNA 
molecules, it is important to identify the interaction site as well as the identity of the interacting 
RNA molecules. Studies to detect these RNA-protein interactions have been developed, such 
as the electrophoretic mobility shift assay (EMSA), RNA immunoprecipitation (RIP), and UV-
induced crosslinking immunoprecipitation (CLIP) (reviewed by Popova et al).288 However, 
identifying RNA molecules recognized by RBPs is still challenging using these techniques.288 
We anticipate that the NAT protein labeling system can also be applied to visualize and 
capture protein interactions with RNA in living cells.
As a first step, we tested the ability of the recombinant hNAT1 and hNAT2 enzymes to label 
RNA molecules using a similar setup as applied for the hNAT1 protein labeling experiments. 
We incubated the purified hNAT enzymes with the fluorescent AHA probe 7 (Figure 6A) and 
isolated total RNA from cells. The analysis by agarose gel electrophoresis showed 28S and 18S 
ribosomal RNA bands, as expected (Figure 6B). Activation of AHA probe 7 resulted in labeling 
of the 28S and 18S ribosomal RNA by both hNAT1 and hNAT2 compared to incubation with AAA probe 8 or without probe (Figure 6B). In addition, a fluorescent smear was observed in 
the top of the agarose gel, which possibly is caused by an artefact of the probe in the sample.
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Figure 6 – RNA labeling by the human NAT enzymes.
A) Structures of probes 7 and 8. B) H
6
-hNAT1 (hNAT1) or GST-hNAT2 (hNAT2) was incubated with probes 7 or 8 in the presence of RNA isolated from cells. In-gel fluorescence of the agarose gel (1.5 %) is shown. As a reference, the agarose 
gel was stained with Ethidium Bromide. The 28S and 18S ribosomal RNA molecules are indicated.
Although further experiments are needed to verify RNA labeling by the hNAT enzymes, we 
hypothesize that this method is useful for RNA labeling in living cells since we detected some 
ribosomal RNA labeling. We envision that in this approach, RNA is labeled at a subcellular 
level using AHA probes in cells expressing the hNAT1 enzyme fused to an RBP. The labeled 
RNA is then isolated and identified by RNA sequencing techniques. This RNA-NAT labeling 
strategy will provide valuable information on the distribution and identity of this class of 
biomolecules. 
7.3 Concluding remarks
In this thesis, we developed a novel PDL approach via activation of AHA probes by a locally 
expressed hNAT1 enzyme. With our chemoenzymatic labeling strategy, we showed fast and 
covalent protein labeling at a subcellular level, while avoiding the use of potentially cell-
disturbing cofactors. The NAT approach complements the existing BioID and APEX techniques, 
because each PDL method has its own advantages and limitations. The best choice to study 
the proteome will depend on the biological question asked. The NAT approach will be more 
suitable for examining the proteome in living cells instead of studying questions in living 
organisms due to the presence of the endogenous enzymes. However, the development of 
an orthogonal NAT-ligand pair as described in this thesis allows for the proximal labeling in 
living organisms. The BirA enzyme used for the BioID system is not endogenously expressed 
in cells and does not require cell-disturbing cofactors, thereby BioID might be preferred for 
in vivo questions in animals. Although the APEX technique requires high levels of hydrogen 
peroxide, this method is applied in living organisms and can be used to visualize protein 
complexes by fluorescent as well as electron microscopy.
The outlook of the NAT approach is promising, we anticipate that this enzymatic NAT labeling 
approach is suitable for a proteomics setup with high spatial and temporal resolution and 
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thereby holds great promise as an approach to unravel fundamental cell biology questions. The system can be further optimized by developing NAT mutants that activate bulkier 
substrates, which are not recognized by the wild type hNAT enzymes, or by developing more 
active NAT enzymes increasing the labeling efficiency. Furthermore, our NAT approach can be applied to examine the proteome in living cells at a subcellular level and has a promising 
potential for studying protein-protein interactions as well as protein interactions with other 
biomolecules.
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7.5 Supplementary Information
RNA isolation
HEK-293T cells (passage number <25) were cultivated in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS), L-glutamine (2 
mM), 100 U/mL penicillin and streptomycin (100 μg/mL) at 37oC under 5% CO2. Cells were 
grown in 10 cm dishes till confluency (2-3 days). After the cells were briefly washed with 1× 
PBS, cells were harvested in 1 mL of 1× PBS and pelleted (2 min, 3,000 rpm). After 1× PBS 
was removed, cells were incubated with 1.5 mL of TRIzol reagent (ThermoFisher Scientific) 
for 5 min on ice. 400 µL of chloroform was added and the cells were incubated for 5 min at 
room temperature. The lysed cells were pelleted (5 min, 10,000 rpm), resulting in two layers, 
including a colourless top layer containing RNA. The top layer was transferred into a clean 
ep and the RNA was precipitated by adding isopropanol (1:1 volume) followed by pelleting 
(30 min, 14,000 rpm, at 4 °C). The supernatant was removed and the RNA pellet was washed 
three times with 500 µL of 70 % ethanol. After the pellet was air dried, the RNA was dissolved 
in MQ and the concentration was determined using the Nanodrop (260/280 ratio, preferably 
around 2.0).
RNA labeling by hNAT enzymes
Recombinant proteins were expressed and purified as described in Chapter 3, Supplementary 
Information. To 5 µL of recombinant H
6
-hNAT1 or GST-hNAT2 (protein concentrations were 
not determined) 5 µg of RNA was added together with 1 µL of RNasin® Plus (Promega). The 
labeling reaction was started by adding 1 µL of DMSO or probe 7 or 8 (0.5 mM in DMSO) in a total reaction volume of 20 µL. The samples were incubated for one hour at 30 °C and to 
the reaction 2.5 µL of 6× RNA loading buffer was added. 2 µg of RNA was loaded on a 1.5 % 
agarose gel without ethidium bromide (EtBr). The labeled RNA was visualized by scanning 
the agarose gel on the Typhoon Trio + (GE Healthcare) at 488 nm (600 PMT). The total RNA 
was visualized afterwards via EtBr staining with 0.5 µg/mL EtBr in 1× PBS for 30-60 min.
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Appendix
Nederlandse samenvatting
Dit hoofdstuk is een vereenvoudigde Nederlandse samenvatting van het onderzoek bestudeerd 
in dit proefschrift. Een gedetailleerde Engelse samenvatting is beschreven in hoofdstuk 7.
Het interne milieu van een organisme is continu onderhevig aan veranderingen in de 
omgeving en wordt in evenwicht gehouden door middel van regelkringen in het organisme 
(homeostase). Het kleinste onderdeel van een organisme, de cel, reguleert alle biochemische 
levensprocessen om het evenwicht in stand te houden. Voor een optimaal functioneren 
van de cel, communiceren cellen onderling en worden vele processen in de cel uitgevoerd 
door complexen bestaande uit verscheidene eiwitten. Het verkrijgen van informatie over 
de identiteit, interacties en de locatie van deze eiwitten is essentieel om de functie van de moleculaire complexen te begrijpen en draagt daarnaast bij aan fundamentele kennis over 
de cel. Een methode om eiwitten nauwkeurig te kunnen identificeren moet voldoen aan 
een aantal eisen: (a) eiwitten voorzien van een label onder fysiologische celcondities om de 
identiteit vast te stellen, (b) een kleine labelingsradius om lokaal in de cel eiwitten te labelen 
en (c) een korte labelingstijd om snelle dynamische veranderingen van eiwitten in de tijd 
te volgen. In dit proefschrift hebben we een strategie ontwikkeld, gebaseerd op bestaande 
technieken, om eiwitten binnen korte tijd op een bepaalde plek in de cel van een label te 
voorzien.
In hoofdstuk 1 geven we een kort overzicht van de meest gebruikte technieken om eiwitten 
te identificeren. Daarnaast introduceren we een nabijheidsafhankelijke labelingsmethode 
(proximity-dependent labeling, PDL) om eiwitten op een lokaal niveau in de cel te voorzien 
van een label. Deze techniek is gebaseerd op een niet-reactief klein chemisch molecuul (probe) 
dat kan worden geactiveerd door een enzym, waardoor de probe reageert met elektronrijke 
aminozuren in eiwitten in de nabijheid van het enzym (Figuur 1). Op deze manier krijgen de 
eiwitten rondom het enzym een label door de actieve probe. De gelabelde eiwitten worden 
vervolgens geïsoleerd en geïdentificeerd met behulp van massaspectrometrie (MS). Hiermee 
kan de identiteit van de eiwitten in de omgeving van het enzym worden bepaald. De afstand 
vanaf het enzym en tijd om de eiwitten van een label te voorzien is onder andere afhankelijk 
van de snelheid waarmee het enzym de probe activeert en de reactiviteit van de actieve probe. 
De locatie van de labeling is afhankelijk van de locatie van het enzym, die kan worden bepaald 
door het enzym op genetisch niveau aan te passen.
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Figuur 1 - Schematische weergave van de PDL-labelingsmethode.
Eiwitten in de omgeving van het enzym worden gelabeld door het activeren van probes 
(eiwitniveau). Door de aanwezigheid van het enzym in de kern, wordt de probe daar geactiveerd 
en worden eiwitten alleen in de kern voorzien van een label (celniveau). Momenteel worden 
de enzymen Biotine Ligase (BirA) en Ascorbaat Peroxidase (APEX) gebruikt voor deze 
PDL-methode. Beide enzymen worden voor verscheidene doeleinden toegepast in cellen. 
Echter, het grootste nadeel van BirA is de relatief lange labelingstijd in tegenstelling tot 
APEX. In het geval van APEX is de activatie van de probe afhankelijk van de aanwezigheid 
van hoge concentraties waterstofperoxide, dat schadelijke effecten kan veroorzaken in de cel. 
Gedetailleerde informatie over BirA en APEX is beschreven in hoofdstuk 1, waarin we ook 
ingaan op de toepassingen van deze systemen. Daarnaast vergelijken we de voor- en nadelen 
van deze twee enzymen en leggen we de nadruk op het belang van de ontwikkeling van een 
nieuw PDL-systeem.
In dit proefschrift onderzoeken wij de mogelijkheid om het enzym arylamine 
N-acetyltransferase (NAT) te gebruiken voor een PDL-strategie om eiwitten snel te kunnen 
labelen (binnen enkele minuten) en het gebruik van schadelijke factoren als waterstofperoxide 
te vermijden. Daarom introduceren we in hoofdstuk 2 het NAT-enzym, dat het molecuul 
N-acetyl-N-hydroxy-arylamine (ook wel arylhydroxamic acid probe, AHA-probe) activeert en 
resulteert in een instabiel intermediair (N-acetoxy-arylamine), dat verder reageert tot een 
reactieve probe (nitreniumion) (Figuur 2). De geactiveerde AHA-probe reageert vervolgens 
met elektronrijke aminozuren in eiwitten. Op deze manier kan het NAT-enzym worden 
gebruikt om eiwitten te voorzien van een label met de AHA-probe.
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Figuur 2 – Reactiemechanisme van de AHA-probe activatie door het NAT enzym.
De activatie van de AHA-probe resulteert in een instabiel intermediair (N-acetoxy-arylamine), dat vervolgens resulteert 
in de activatie van de AHA-probe (nitreniumion). Dit positief geladen ion reageert met elektronrijke substraten. :Nu = 
nucleofiel (elektronrijk molecuul); label = functionele groep voor isolatie van de gelabelde eiwitten;
Voor de ontwikkeling van het PDL-systeem gebruikmakend van het NAT-enzyme, beginnen 
we in hoofdstuk 3 met het ontwerpen en de synthese van AHA-probes, die verschillen in de 
elektronendichtheid van de arylring (elektronrijk en meer elektronarm). Vervolgens testen 
we de activatie van deze probes door het NAT-enzym en volgen we labeling door het enzym in 
de tijd. We laten zien dat het enzym de probes activeert, waarvan de elektronrijke AHA-probe 
het meest intens labelt.
Vervolgens tonen we in hoofdstuk 4 aan dat eiwitten in de buurt van het NAT-enzym worden 
gelabeld. Daarnaast analyseren we de activatie van de AHA-probes in levende cellen. In 
verschillende soorten cellen is eiwitlabeling waargenomen door het toevoegen van de AHA-
probes aan deze cellen. Hierbij nemen we aan dat deze probes worden geactiveerd door de 
NAT-enzymen in de cellen, hoewel het ook mogelijk is dat de AHA-probes worden geactiveerd 
door andere enzymen als NAT.
In hoofdstuk 5 bestuderen we het lokaal labelen van eiwitten in de cel door het NAT-enzym 
te sturen naar gedefinieerde cellulaire gebieden. De locatie van het enzym wordt bepaald 
door genetische tags (plaatsaanwijzingen) aan het enzym te hangen.  We nemen waar dat 
het NAT-enzym inderdaad aanwezig is in de toegewezen regio’s van de cel. Verder detecteren 
we labeling binnen vijf minuten door de elektronrijke AHA-probe alleen in de regio waar het 
NAT-enzym aanwezig is.
Naast labeling door het gelokaliseerde NAT-enzym, hebben we ook achtergrondlabeling 
gemeten in de cellen door de oorspronkelijk aanwezige (NAT-)enzymen. Om deze achtergrond 
te verminderen, testen we in hoofdstuk 6 een strategie om de specificiteit van het NAT-enzym 
aan te passen.
We veronderstellen dat het enzym grotere AHA-probes kan herkennen door het vergroten van 
de ruimte op de plaats waar de probe bindt (bindingsplek). Daarom hebben we het aminozuur 
isoleucine106 in de bindingsplek van het NAT-enzym vervangen door een kleiner aminozuur 
(alanine of glycine). Met behulp van een methode om indirect de affiniteit van het NAT-enzym 
voor de probes te bepalen, hebben we een verhoogde binding van de isoleucine106 mutanten 
activatie
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waargenomen voor grotere, een extra groep bevattende NAT-substraten in vergelijking tot de 
affiniteit van het oorspronkelijke NAT-enzym. We verwachten daarom dat deze NAT-mutanten 
met een hogere affinitieit voor een aangepaste AHA-probe kunnen worden gebruikt voor de 
PDL-techniek om de achtergrondlabeling door de oorspronkelijke enzymen te verminderen.
Tot slot bespreken we in hoofdstuk 7 de bevindingen over onze NAT-PDL-strategie in dit 
proefschrift in de context van de bestaande PDL-methoden. Bovendien worden veelbelovende 
toepassingen voor het labelen met het NAT-enzym beschreven, evenals de uitdagingen om de 
strategie verder te ontwikkelen.
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